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Abstract 
 
Modulation of wound healing is required to inhibit scar formation after trabeculectomy. 
Mitomycin C and 5-fluorouracil (5-FU) are the anti-proliferative drugs currently used in 
the clinic. Their effectiveness is limited due to their toxicity and suboptimal local tissue 
pharmacokinetics caused by rapid clearance within the subconjunctival space. Therefore, 
prolonged release of anti-scarring agents is needed. Ilomastat is a matrix 
metalloproteinase inhibitor that has been shown to moderate favorably the wound 
healing response after surgery. However, due to rapid local tissue clearance, several 
injections are necessary in a clinically relevant animal model.   
 
The thesis describes the development and investigation of implantable ocular tablets for 
wound healing modulation after trabeculectomy. A tablet would be placed in the 
subconjunctival space called a bleb, which is caused by the outflow through the fistula 
made during surgery. While the bleb volume varies, the tablet is thought to dissolve in 
non-sink conditions. Tablet dissolution was evaluated in vitro using a flow chamber that 
mimics the liquid outflow conditions of the bleb. The in vitro release studies suggest 
that tablet dissolution would act to prolong drug release in comparison with injections. 
Tablet dissolution in the subconjunctival space is affected by many factors including the 
physical/chemical properties of the drug and tablet, temperature, the volume and flow 
rate of the dissolution media, and the surface area of the tablet. The efficacy of an 
excipient-free ilomastat tablet was evaluated using a clinically validated rabbit model. 
The tablet dissolution was examined using molecular dynamics simulations to consider 
the molecular interactions of ilomastat and 5-FU undergoing dissolution in non-sink 
conditions. A mathematical model was also developed to describe the dissolution of 
excipient-free tablets in the non-sink conditions with 94% confidence. In conclusion, we 
have established methods to investigate and simulate dissolution of excipientless tablets 
in non-sink conditions within the subconjunctival space.
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1.1. Anatomy of the eye and glaucoma filtration surgery (GFS) 
1.1.1. Glaucoma 
Glaucoma is the second leading cause of blindness in the world (Resnikoff et al. 2004). 
It is the term used for a group of diseases with a characteristic type of optic nerve 
damage with visual field loss. Damage to the optic-nerve can cause irreversible 
blindness (Schuman 2000). It was estimated that more than 60 million people 
worldwide would suffer from glaucoma in 2010; and this population will increase to 
approximately 80 million by 2020 (Quigley & Broman 2006). Hence, the development 
of glaucoma therapies is very important. 
 
As glaucoma is often associated with high intraocular pressure (IOP, usually higher than 
21 mm Hg), one of the aims of treatment is to lower the IOP, which is caused by the 
imbalance in the production and drainage of ocular fluid. The ocular fluid, which is also 
called aqueous humor, is produced by the ciliary body. It flows into the anterior 
chamber through the pupil, and then leaves the eye through the trabecular meshwork 
(shown as the “angle” in Figure 1.1). The blockage of this “angle” obstructs the exit of 
the aqueous outflow and leads to high IOP. Methods of lowering the IOP usually 
include reducing the production or enhancing the outflow of ocular fluid. These will be 
discussed in the following sections.  
 
Figure 1.1. Normal intraocular fluid drainage from the eye. (Image from: 
www.kellyeyecenter.com/whatisglaucoma.htm) 
Chapter I Introduction 
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1.1.2. Treatment of glaucoma  
Treatment of glaucoma usually includes medication and surgery. 
1.1.2.1. Medication 
Medical treatments of glaucoma lower IOP by reducing the production of the aqueous 
or enhancing uveoscleral/trabecular outflow. These medications include topical 
β-adrenergic antagonists (e.g. timolol, betaxolol), carbonic anhydrase inhibitors (e.g. 
dorzolamide, brinzolamide), cholinergics (e.g. pilocarpine), α-adrenergic agonists (e.g. 
brimonidine), prostaglandins (e.g. latanoprost, travoprost), and prostamides  
(bimatoprost) (Noecker 2006). Most of these medications are provided as topical 
eyedrops, with the exception of some carbonic anhydrate inhibitors that are given as 
oral tablets or intravenous injection (acetazolamide) (BNF 2009). Most of the glaucoma 
treatments start with eye drops. Surgery is required when eye drops are not effective 
enough in lowering the IOP.  
1.1.2.2. Surgical procedure 
Laser surgery 
Laser surgery, which is also called laser trabeculoplasty (LTP), is a non-invasive 
technique for lowering IOP that has been used for more than 30 years (Pollack & Patz 
1976;Ticho 1977;Ticho & Zauberman 1976;Wise 1981;Wise & Witter 1979). The aim 
of LTP is to increase aqueous outflow from the trabecular meshwork to improve 
aqueous filtration and to lower the IOP. Originally argon lasers were most commonly 
used. In more recent years krypton, diode, excimer, and Nd:YAG lasers have been 
developed rapidly for LTP (Barkana & Belkin 2007;Wilmsmeyer et al. 2003). In early 
cases of open angle glaucoma, LTP treatment might be able to delay, decrease, or 
replace medical treatments. However, significant tissue disruption and coagulation 
damage caused by LTP can result in a mechanical stretching of the surrounding 
uveoscleral trabecular meshwork and widening of Schlemm‟s canal (Stein & Challa 
2007). Rolim et al found that trabeculoplasty is less effective than trabeculectomy in 
controlling IOP at both six month and two year follow-ups. They also revealed that the 
effectiveness of LTP is less than contemporary medication (prostaglandin analogues, 
topical anhydrase inhibitors and alpha2-agnosts) and surgical techniques (Rolim, 
Paranhos, & Wormald 2007). 
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Filtration surgery 
Glaucoma filtration surgery (GFS) is the most commonly used term in relation to the 
operation called trabeculectomy. It was first described about 50 years ago (Cairns 1968), 
and is still regarded as the “gold standard” for glaucoma surgery (Moura Filho & Sit 
2009). The aim of the surgery is to open a new drainage channel for the outflow of 
aqueous humor through the sclera so that the aqueous humor can be eliminated from the 
conjunctiva (illustrated in Figure 1.2). 
 
Figure 1.2. Mechanism of GFS in human eyes. 
 
GFS in human eyes is further illustrated in Figure 1.3. (Reznick, Noecker, & Lathrop 
2007). During this surgery, a pocket is firstly created under the conjunctiva. Then 
mitomycin C (MMC) or 5-fluorouracil (5-FU) soaked sponges are placed in the 
subconjunctival space for a few minutes. The reasons for using these sponges will be 
discussed later. Then a partial thickness scleral flap is dissected anteriorly into the 
peripheral corneal stroma. A window through the anterior chamber is opened by 
removing portion of sclera, Schlemm‟s canal, and trabecular meshwork. This step is 
called sclerostomy. Following sclerostomy, a small peripheral iridectomy is created to 
avoid iris incarceration in the opening. The scleral flap and the conjunctiva are then 
closed by sutures. Details of the surgery, such as the anesthetic, choice of limbal-based 
or fornix-based conjunctival flaps, and scleral flap shapes, may vary depending on the 
surgeons. After the surgery, visible accumulations of aqueous humor beneath the 
conjunctiva are expected to be observed in the subconjunctival space. This is called a 
bleb. The aqueous humor is excreting from the bleb (Figure 1.4. a). The surgery fails if 
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adequate flow cannot be achieved to maintain the IOP at a level to stop progression of 
glaucoma. 
 
 
Figure 1.3. Illustration of trabeculectomy in human eyes, images are from Reznick et al (Reznick, 
Noecker, & Lathrop 2007). 1. An initial conjunctival dissection is performed to create large 
posterior pocket; 2. Mitomycin C or 5-FU soaked sponges are placed subconjunctivally away 
from the limbal region for about 2-3 minutes; 3. A half-thickness scleral flap is dissected 
anteriorly in the peripheral corneal stroma; 4. After creation of the sclerostony, a small 
peripheral iridectomy is created to prevent iris incarceration in the opening; 5. The scleral flap 
is secured by the sutures, and the knots buried to avoid possible erosion through the 
conjunctiva occurring later; 6. The conjunctiva is closed by sutures to provide tension at the 
limbus and avoid leaks postoperatively. 
 
Despite complications such as hypotony, choroidal effusions, over filtration and 
endophthalmitis following the immediate period of the surgery, the long term success of 
surgery is closely associated with alterations in bleb morphology. Formation of scar 
tissue in the bleb is the main complication which obstructs the outcome of the aqueous 
humor and consequently leads to the failure of the surgery (Figure 1.4. b). Therefore, to 
improve the outcome of the surgery, the wound healing process in the bleb needs to be 
modulated. In order to find a drug that can inhibit scar formation in the bleb, a 
significant amount of research has been carried out. Currently MMC or 5-FU are used 
5 6 4 
3 2 1 
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clinically to stop/reduce the formation of scar tissue (Lama & Fechtner 2003). 
 
  
Figure 1.4. Bleb formation in the human eye after a successful (a) and failed (b) trabeculectomy. 
(Images from P T Khaw, Moorfields Eye Hospital, London) 
 
However, the effectiveness of the current anti-scarring agents is limited due to their 
toxicity and associated side effects. Effectiveness is also severely compromised by the 
quick clearance of the drugs from the bleb area. Tissue pharmacokinetics are suboptimal 
because upon injection into the bleb area, the drug is quickly cleared at the 
subconjunctival space. Research has been carried out in recent decades with the aim of 
developing drugs and formulations that have a longer effect and lower toxicity. The 
effect of new drug candidates or formulations is usually evaluated using animal models 
including primates, rabbits and dogs (summarized in Appendix I). As the wound-healing 
response in rabbits is known to be usually fairly aggressive, it is believed that a rabbit 
model could be equivalent to high-risk eyes in humans, with surgical failure results 
within 1-2 weeks (Grisanti et al. 1999;Miller et al. 1989). Therefore, trabeculectomy on 
rabbits has become a clinically validated in vivo model for evaluating the effects of 
anti-scarring formulations (Khaw et al. 1993).  
 
GFS in a rabbit eye is illustrated in Figure 1.5. Similar to the GFS in the human eyes, a 
conjunctival flap is first created. But instead of sclerostomy, a cannula is inserted 
through the sclera from 2 mm behind the limbus until it becomes visible under the 
cornea. Then the cannula is trimmed and fixed by sutures at the sclera end. Finally, the 
conjunctival incision is closed with sutures. The reasons for using a cannula in this 
a b 
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model are 1) the failure of sclerostomy can occur due to the aggressive healing process 
seen in rabbits and 2) the insertion of a cannula is also a relatively easy and consistent 
technique in comparison to sclerostomy, and is less difficult for in-experienced surgeons. 
In this model, the aqueous humor escapes though the cannula. Similar to GFS in human 
beings，the aqueous humor leaves the eye through the new subconjunctival space (bleb) 
created by the surgery. The morphology of the bleb often changes as healing and 
scarring occur and it can be affected by the effect of the anti-scarring and 
anti-inflammatory agents. A successful bleb in a rabbit eye is shown in Figure 1.6.  
          
Figure 1.5. Illustration of trabeculectomy in a 
rabbit eye. (Image from www.blebs.net/html/ 
introduction.html) 
Figure 1.6. A successful bleb in a rabbit eye 
(circled by red arrows) (Georgoulas 2010) . 
1.2. Wound healing in glaucoma filtration surgery 
1.2.1. Wound healing pathway 
As scar formation is part of the wound healing process, to inhibit the scar formation the 
wound healing pathways need to be understood. Wound healing is a complicated 
process that involves two distinct procedures. One is regeneration, which means the 
restoration of the original tissue structure without any trace of injury. Complete 
regeneration can only be achieved by tissues like the kidney, liver and other glandular 
organs (Benigni, Morigi, & Remuzzi 2010;Michalopoulos & DeFrances 1997). The 
other is replacement, which occurs in most tissue injury, and leads to the replacement of 
damaged cells by the formation of scar tissue at the site of restoration. As with skin, the 
healing process of the conjunctiva involves both replacement and regeneration (Lama & 
Fechtner 2003). 
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Figure 1.7. Flow chart of the wound healing pathway. (Reprinted from The Glaucomas, ed 2, 
1996, with permission of Mosby) (Lama & Fechtner 2003;Tahery & Lee 1989) 
 
The replacement process in wound healing includes several phases: coagulative and 
inflammatory, proliferative, and post- proliferative remodeling. As shown in Figure 1.7., 
each phase is associated with many cellular and humoral factors.  
 
Following hemorrhage and tissue damage caused by injury, clotting factors and 
hormones are released (Lama & Fechtner 2003). The inflammatory phase then begins. 
The vascular permeability is increased by many local hormonal factors including 
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cytokines, growth factors, kinins, prostaglandins, leukotrienes, histamine, and serotonin. 
These factors act as chemo-attracttants to white blood cells (Albert & Jakobiec 2000). 
During this time, inflammatory cells, capillaries, and fibroblasts start to migrate to the 
fibrin-fibronectin matrix built at the injury site (Desjardins, Parrish II, & Folberg 
1986;Dvorak 1986;Goodman, Alvarado, & Stern 1987;Seetner & Morin 1979). Many 
growth factors that stimulate cell migration, the production of matrix, and matrix 
degradation enzymes are produced by the inflammatory cells simultaneously (Cordeiro 
et al. 2000a). In this stage, steroids and non-steroidal anti-inflammatory drugs (NSAIDS) 
are used postoperatively to modulate tissue inflammation at the early stage of wound 
healing (Cordeiro et al. 2000b;Khaw et al. 2001). 
 
In the proliferative phase, fibroblasts play a key role because they are the major 
producer of connective tissue including interstitial collagens, elastin, 
mucopolysaccharides, and glycosaminoglycans. The activity of fibroblasts increases to 
maximum at 3 to 5 days after injury and then starts to decrease afterwards (Albert & 
Jakobiec 2000). Budding and expansion of existing vascular endothelial cells lead to 
angiogenesis. The granulation tissue, which is composed of young fibrovascular 
connective tissue, is formed (Desjardins, Parrish II, & Folberg 1986;Dvorak 1986). The 
wound is finally closed by reepithelialization and contraction of myofibroblasts (Albert 
& Jakobiec 2000). However, the wound closure does not mean the deactivation of 
fibroblasts. In the remodeling phase, fibroblasts fabricate matrix metalloproteinases 
(MMPs), which plays an important role in the process of tissue remodeling and 
contraction (Cordeiro et al. 2000a;Daniels et al. 2003). Hence, anti-fibrotic agents are 
used in the proliferative and post-proliferative phases to inhibit scarring after GFS. 
1.2.2. Clinical drugs for wound healing modulation 
The varied types of cellular and humoral factors involved in the wound healing process 
suggest that there are many different ways to modulate the wound healing response. 
Cordeiro et al summarized the agents that could be used to modulate the wound healing 
process at different phases after GFS (Figure 1.8.) (Cordeiro et al. 2000b). A 
comprehensive list of wound healing modulation targets for GFS has been summarized 
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recently (Khaw P et al. 2009).  
 
Figure 1.8. Targets for wound healing modulation following glaucoma trabeculectomy 
(Cordeiro et al. 2000b). 
 
Although there is a list of wound healing modulation agents, currently there is no 
licensed medicine that is registered to treat fibrosis in the eye. 5-FU (Figure 1.9) and 
mitomycin C (MMC, Figure 1.10) are the most commonly used two drugs after GFS 
(Palanca-Capistrano et al. 2009;Singh et al. 1997;Wollstein et al. 2000;Wudunn et al. 
2002). They are both toxic anti-cancer drugs that administered to inhibit fibroblast 
proliferation, with a narrow therapeutic window. 
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Figure 1.9. Chemical structure of 5-FU. Figure 1.10. Chemical structure of MMC. 
   
5-Flurouracil (5-FU) 
5-FU (2, 4-Dihydroxy-5-fluoropyrimidine, Mw: 130.08 g/mol) is a fluorinated 
pyrimidine analog which act as a thymidylate synthase inhibitor. Its aqueous solubility 
is 11.1 mg/mL (pH 4.0, 22 °C) (Yalkowsky & He 2003). After being converted 
intracellularly, it has three main metabolites: fluorodeoxyuridine monophosphate 
(FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate 
(FUTP). These metabolites inhibit thymidylate synthase and disrupt DNA/RNA 
synthesis in the cells (Longley, Harkin, & Johnston 2003). 
 
Mitomycin C (MMC) 
MMC (Mw: 334.33 g/mol) is an antibiotic agent derived from the soil fungus 
Streptomyes caespitosus by Wakaki in 1958. It is 10 times less soluble than 5-FU (0.912 
mg/mL) (Yalkowsky & He 2003). It blocks DNA synthesis, inhibits cell mitosis, and 
causes cell cycle arrest by producing cross-linking of the DNA molecules between 
adenine and guanine.  
 
Both 5-FU and MMC are anti-proliferative compounds, but 5-FU leads to less direct 
DNA damage than MMC and is more cell cycle specific (Crowston et al. 1998;Falck, 
Skuta, & Klein 1992;Gilman AG, Rall TW, & Nies AS 1990). They are both used 
intraoperatively for GFS in the clinic. Currently sponges soaked with MMC (0.2-0.5 
mg/mL for 2-3 minutes) or 5-FU (50 mg/mL for 5 minutes) were placed in the 
subconjunctival space then removed before the closure of conjunctival flap 
(Palanca-Capistrano et al. 2009;Singh et al. 1997;Wollstein et al. 2000;Wudunn et al. 
2002). Many researchers have compared the effectiveness of these two compounds. For 
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a five minute intraoperative application, it is generally believed that these drugs have 
comparable efficacy (Palanca-Capistrano et al. 2009;Singh et al. 1997;Wollstein et al. 
2000;Wudunn et al. 2002). However, the effectiveness of 5-FU may be more transient 
than MMC (Khaw et al. 1993). But MMC is more toxic than 5-FU as MMC was shown 
to be toxic to vascular endothelial cells (Smith, D'Amore, & Dreyer 1994) and ciliary 
body (Levy et al. 2001;Mietz 1996;Schraermeyer et al. 1999). In addition, it was 
suggested that MMC might led to an over expression of MMPs, thus causing abnormal 
remodeling of the scleral matrix (Hanyu 1999). 
1.2.3. The limitation of current therapeutics 
There are many factors that are related to the success of GFS. Preoperative factors 
(include previous topical therapy, race, age, uveitis, anterior segment neovascularization 
etc) are associated with the outcome of the surgery, and surgical techniques (Jones, 
Clarke, & Khaw 2005), the use of anti-inflammatory agents, fibrinolytics and 
anti-proliferative agents (Atreides, Skuta, & Reynolds 2004) are also important. 
Although highly skilled surgery followed by the application of anti-inflammatory agents 
has increased the success rate of GFS, maintaining the morphology of the bleb is vital 
for the long term halt in the progression of glaucoma. However, the efficacy of the two 
drugs (5-FU and MMC) most often used clinically is limited due to their toxicity, 
narrow therapeutic window, and short retention time.  
 
It was reported that about 80% of trabeculectomies need bleb manipulation after GFS, 
even when a five minute application of MMC or 5-FU was applied intraoperatively 
(King et al. 2007). Almost half of blebs require massage or tissue removal. One third of 
the patients need at least one 5-FU injection and a quarter requires at least one needling 
plus one 5-FU injection. On average, the first intervention for massage, structure 
removal, 5-FU injection and needling plus 5-FU injection were carried out on days 1, 14, 
14 and 43 respectively (King et al. 2007). This indicates that a few minutes application 
of 5-FU or MMC is not sufficient to maintain the long term outcome of GFS. However, 
the improvement offered by the use of these medicines does suggest that more extended 
periods of exposure of the drug to the bleb area may be advantageous. Clearly if this is 
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to be accomplished, it may be necessary to use less toxic drugs with larger therapeutic 
windows. 
 
The need for multiple subconjunctival injections of 5-FU after GFS indicates that the 
residence time of 5-FU or MMC administrated during surgeries short and that the 
pharmacokinetics of subconjunctival injection are suboptimal. It has been reported that 
5-FU reached its peak concentration 30 minutes after subconjunctival injection, and that 
the 5-FU concentration decreased by more than 10 times after one hour (Rootman, Ostry, 
& Gudauskas 1984).  
 
Since the intraoperative plus the post operative applications of 5-FU or MMC do not 
provide ideal long term effects on scar inhibition, new anti-scarring medicines are 
needed to provide longer term residence time in the bleb and to lower the drug toxicity. 
 
1.3. Development of prolonged release drug delivery systems for GFS 
1.3.1. Analysis of the bleb 
A bleb refers to all the structural elements that define an area of subconjunctival 
filtration of aqueous humor. To develop an anti-scarring drug which will be placed in 
the subconjunctival space, it is important to understand the conjunctiva, the bleb, and 
the aqueous humor.  
 
The conjunctiva is a thin, transparent membrane which has a sponge like structure. It is 
usually divided into three layers. The outer epithelium is the first layer, which is a 
permeability barrier. The layer in the middle is substantia propria which contains nerves, 
lymphatics and blood vessels. The inner layer, which attaches to the sclera, is called 
submucosa or Tenon‟s capsule (Sunkara & Kompella 2003). The aqueous in the bleb 
escapes through conjunctival vascular channels, lymphatics, and transconjunctival 
egress (Azuara-Blanco & Katz 1998).  
 
Bleb morphology indicates the function of the bleb. It is associated with the surgical 
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complications and changes considerably after GFS. The preferred appearance is with 
moderate elevation, paucity of vessels, large surface area, the absence of a distinct 
demarcation between filtering and non-filtering areas, and the presence of conjunctival 
microcysts (Filippopoulos et al. 2009;Picht & Grehn 1998). The morphology and 
function of the bleb as well as the aqueous pathway can be investigated in vivo using 
confocal microscopy (Amar et al. 2008;Guthoff et al. 2006;Labbe et al. 2005). In 
histology, clear intraepithelial spaces between morphologically normal epithelial cells 
and clear spaces within loose subepithelial connective tissue, which are referred to as 
microcysts, were observed in functional blebs, and loosely arranged connective tissue 
was observed by confocal microscopy. In contrast, non-functioning blebs showed fewer 
intraepithelial microcysts and denser subepithelial connective tissue. Observations from 
confocal microscopy have shown that successful blebs in the early postoperative stage 
have some features including a trabecular connective tissue pattern, a high density of 
stromal cystic spaces, numerous stromal round cells, and small vessel diameters 
(Guthoff et al. 2006). 
 
The estimated bleb volume can vary. New techniques, such as 3-D optical coherence 
tomography (OCT), have been used to evaluate the bleb volume. However, some of the 
results do not seem to be accurate enough. Kawasaki et al have reported that the bleb 
volume evaluated by OCT is approximately 6.27 mm
3 
(Kawasaki et al. 2009). As this 
volume is similar to the volume of some of the inserts listed in Appendix I, it is believed 
that the bleb volume is larger than the results reported above. Theelen et al haves 
reported a more reasonable bleb volume which is approximately 50-100 μl (Theelen et 
al. 2007). The average temperature of bleb in good and poor controlled IOP eyes are 
35.4 and 35.8 °C respectively (Kawasaki et al. 2009). 
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Table 1.1 Inorganic and organic substances of the anterior aqueous humor in humans and 
rabbits. (Kaufman P.L. & Alm A. 2003) 
Substances Human Rabbit PBS  
Inorganic 
 substances 
Bicarbonate (µmol/mL) 20.2 27.7-33.6  
Chloride (µmol/mL) 131.0 105.1-105.77 4.15 
Oxygen (mm Hg) 53 30-55  
Phosphate (µmol/mL) 0.62 0.86-0.89 9.57 
Calcium (µmol/mL)  1.7  
Potassium (µmol/mL)  5.1-5.2 4.15 
Magnesium (µmol/mL)  0.8  
Hydrogen ion (pH)  7.6  
Sodium (µmol/mL)  143-146 153.2 
Organic 
 substances 
Ascorbate (µmol/mL) 1.06 0.96  
Citrate (µmol/mL) 0.12 0.38-0.46  
Glucose (µmol/mL) 2.8 4.9-6.9  
Hyaluronate (µg/mL) 1.1   
Lactate (µmol/mL) 4.5 9.3-12.1  
Protein (mg/100ml) 23.7 25.9  
Creatinine (µmol/mL)  0.11  
Urea (µmol/mL)  6.3-7.0  
 
The aqueous humor is composed of many organic and inorganic substances 
(summarized in Table 1.1). It also contains more than 10 different amino acids 
(Kaufman P.L. & Alm A. 2003). From Table 1.1 it can be seen that aqueous humor of 
rabbits is similar to that of humans. However, compared to the human or rabbit aqueous 
humor, PBS has higher concentration of ions. An OXOID PBS tablet contains NaCl 
(8.0g/L), KCl (0.2g/L), Na2HPO4 (1.14g/L), and KH2PO4 (0.2 g/L). These ions 
therefore lead to the high ion strength of PBS (0.165). Therefore, theoretically PBS is 
not an ideal buffer for the in vitro investigation of the formulation. But in the literature, 
it is the most frequently used buffer in the in vitro studies of ocular drugs (See Appendix 
I). This is because PBS is easy to be made and stable in room/body temperature. The 
rabbit aqueous contain more types of organic and inorganic substances than humans 
aqueous. Aqueous humor has a pH of 7.6 (Maren 1973). In normal human eyes, the 
average flow rate of aqueous humor is between 2.2-3.1 μL/min (McLaren 2009). The 
aqueous flow decreases with the age by approximately 4% per decade of life (Brubaker, 
Nagataki, & Townsend 1981;Toris et al. 2002). The aqueous appears to have the highest 
flow rate in the morning and decreases to almost half of the rate during sleep (Koskela 
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& Brubaker 1991;Reiss et al. 1984). But it does not vary much during the day time. It is 
also known that the aqueous flow appears to be independent of transient changes in 
intraocular pressure but it can be suppressed by some pharmacological agents. In 
abnormal eyes with different intraocular pressure, the aqueous flow rate does not seem 
to be affected significantly (McLaren 2009). 
1.3.2. Ocular drug delivery 
To develop a prolonged release anti-fibrotic drug for GFS, ocular drug delivery systems 
must be understood. Drug transportation in the eye is fairly restricted because the eye is 
well protected by several membrane barriers including the cornea, conjunctiva, 
iris-ciliary body, lens epithelium, and retina. Hence, ocular drug delivery is a big 
challenge in pharmaceutical science.  
 
An ideal ocular drug delivery system should be able to deliver the drug to the targeted 
site with a defined range of therapeutic concentration without causing permanent tissue 
damage. Additionally, the residential time of the drug needs to be maintained for a 
certain period to achieve its pharmacological effects without causing any severe 
toxic/side effects. Ocular drugs can be delivered by topical administration (eye drops, 
ointments, contact lenses, and some ocular devices), systemic administration, 
periocular/intraocular injections, and ocular inserts. Topical administration is the most 
straightforward and convenient way of ocular drug delivery. However, it is well known 
that the majority of the drug delivered by this way is eliminated through nasolacrimal 
drainage. Drugs delivered systemically barely reach the eye due to the presence of 
blood-retinal barrier. Additionally, there can be undesirable systemic side effects.  
 
Ocular drug delivery usually targets either the anterior segment (the cornea, iris, ciliary 
body, and lens) or the posterior segment (the vitreous humor, retina, choroid, and optic 
nerve) of the eye. For the targeted sites like subconjunctival space or the vitreous body, 
injections or inserts are the most direct approach for delivering the drug. But the local 
drug pharmacokinetics in these two parts of the eye are different. Due to the gel like 
structure of the vitreous body, the diffusion and movement of the drug molecules are 
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restricted. While in the subconjunctival space, the flow of the aqueous humor promotes 
the release and diffusion of the drug. Therefore, the half lives of the intravitreally 
delivered drugs are usually longer (hours or days) than the subconjunctival injections. 
Delivery of 5-FU by subconjunctival injections is not ideal because 1) the drug is 
delivered in a small volume (100 μl) with high concentration (50 mg/mL) which can 
lead to severe toxicity effects to the eye and 2) the drug residence time is short. 
Therefore, a prolonged release anti-scarring drug is highly desirable. The drug is ideally 
delivered as a semi-solid/solid insert with excellent biocompatibility which can be 
placed in the subconjunctival space. However, a recent review on ocular drug delivery 
systems has shown that most of the clinically used ocular inserts are designed either for 
the conjunctival sac or for the vitreous cavity. Few of them are designed specifically for 
subconjunctival space (Kearns & Williams 2009).  
1.3.3. Development of prolonged release drug delivery systems for anti-scarring 
agents post GFS 
Many research groups have tried to develop prolonged release anti-scarring agents that 
can be placed in the subconjunctival space (summarized in Appendix I). These drugs 
were incorporated in different drug carriers include liposomes, collagen sponges, matrix 
disks/pellets containing various polymers and injectable microspheres or semi-solid 
materials. The duration of the drug release time varies from days to months. However, 
most of these studies were at the preclinical stage with exception of Surodex (Chang et 
al. 1999;Kimura & Ogura 2001;Seah et al. 2005;Tan et al. 1999). 
 
Polymers that have been frequently used include polyanhydride, poly (ortho ester) 
(POE), poly (lactic acid) (PLA), poly (glycolic acid) (PGA), and their copolymers 
(PLGA). Polyanhydride and POE usually undergo a surface erosion process when 
releasing the drugs. PLA, PGA, and PLGA are the polymers that release the drug 
through bulk erosion (Kimura & Ogura 2001). These polymers are used in many local 
administrated dosage forms including viscous solutions, particle systems, and 
semi-solid/solid dosage forms. They can improve the therapeutic efficacy by controlling 
drug release, prolonging drug retention, reducing the dosage frequency and hence 
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reducing the transient overdose, enhancing drug bioavailability, and reducing the 
systemic side effects.  
 
Polyanhydrides with different molecular weight are synthesized by different methods. 
One of the typical high molecular weight polyanhydride is synthesized using bis 
(carboxyphenoxy) propane and sebacic acid (PCPP-SA) (Rabowsky et al. 1996). The 
ratio of the two monomers is highly related to the breakdown of the polymer. The 
hydrolysis and metabolism of PCPP-SA are shown in Figure 1.11. Since the breakdown 
products of PCPP-SA are acids, it can be seen that polyanhydride degradation can be 
slower in acidic medium. Bioerodible disks which are made of polyanhydride (diameter 
3 mm thickness 1 mm) containing daunorubicin for GFS were developed by Rabowsky 
et al (Rabowsky et al. 1996). They found that by day 13 around 90% of control blebs 
failed, and in comparison only 20% of daunorubicin treated blebs failed. However, 
conjunctival erosions were observed in some of the daunorubicin treated eyes. 
 
Figure 1.11. The hydrolysis of poly[bis(p-carboxyphenoxy) propane:sebacic acid](PCPP-SA) 
and its metabolism. 
 
Poly (ortho esters) (POE) have been extensively examined for ocular use. Much work 
has been done with these polymers for the delivery of 5-FU. They have been studied for 
more than 30 years. Currently POE has four different families (POE I, II, III, and IV, 
Chapter I Introduction 
40 
 50
 
Figure 1.12.). Their development, synthesis, characterization, and application were 
summarized in detail by Heller et al (Heller et al. 2000;Heller et al. 2002;Heller 2005). 
The mechanism of the breakdown of POE is different in each of these families. POE III 
and IV have shown excellent controlled release of 5-FU and good biocompatibility in 
subconjunctival, intravitreal, intracameral, and suprachoroidal injections (Heller 2005). 
Injectable POE containing anti-proliferative agents have been developed by Gurny et al 
(Bernatchez et al. 1994;Einmahl et al. 2003;Einmahl et al. 2001;Heller et al. 
2000;Heller et al. 2002;Merkli et al. 1994;Polak et al. 2008;Zignani et al. 1997;Zignani 
et al. 1998;Zignani et al. 2000a;Zignani et al. 2000b). It was found that the polymer was 
able to release the drug for 2-7 days in vitro. In the in vivo studies, the polymer was not 
able to be identified 10 days after surgery. Although the polymers appeared 
biocompatible in their early studies (Bernatchez et al. 1994), hyperemia and chemosis 
triggered by POE alone were observed for 3 days post surgery (Zignani et al. 2000a). 
 
Figure 1.12. Poly (ortho ester) families (Heller 2005) . 
 
PLA and PLGA are also the most popular biodegradable polymers that have been 
examined in controlled release in recent years. PGA is usually not used in controlled 
drug release systems due to its high sensitivity to hydrolysis. The mechanism of 
breakdown of PLGA is shown in Figure 1.13. Lactic and glycolic acids are the 
degradation products of PLA and PLGA. They are metabolized to carbon dioxide and 
water via Kreb‟s cycle. Cui et al developed subconjunctival PLA disks (diameter 3 mm 
thickness 1 mm) containing 5-FU microspheres for GFS. The implantation of the disks 
resulted in bleb survival for more than 30 days without any toxic reaction in the 
conjunctival biopsy. 5-FU was found to have been released for at least 91 days (Cui et al. 
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2008). However, there have been reports showing the toxic effects of PLA/PLGA 
nanoparticles to the ocular tissue, including tissue inflammation, corneal opacities and 
epithelial erosion, and transient hyphema etc. (Chang et al. 1999;Gould et al. 
1994;Huhtala et al. 2009;Kimura et al. 1992;Kimura & Ogura 2001;Seah et al. 
2005;Tan et al. 1999). In addition to their toxicity, we are not using PLA/PLGA here 
because they are very expensive materials.  
O CH CO
R
H2O
OH CH2
R
COOH
R=CH3 or H
CO2+H2O
n
Kreb's cycle
 
Figure 1.13. Mechanism of breakdown of PLGA in an aqueous humor. 
 
It is shown in Appendix I that more than 70% of cited studies were conducted with 
cytotoxic agents such as 5-FU, and that all the drug carriers contain polymers. Most of 
the dosage forms led to mild inflammation. Some of them induced other complications 
such as hyphema, hyperemia, conjunctivitis and corneal edemas/opacities. There are 
some papers which claimed that no significant irritation or toxicity were observed, but 
the histology results were not provided (Chiang et al. 2001;Zignani et al. 2000a). In 
addition, only a few reports have mentioned the termination of the formulations, which 
is important because some of the papers have reported the encapsulation of the 
formulations (Cui et al. 2008;Tilleul et al. 1997). Although many in vitro release studies 
have demonstrated the long term release of the drugs, it is not well known whether the 
release of the drug will be stopped or slowed due to the formation of the capsule or the 
physical change of the formulations. It is also not clear whether the formation of a 
capsule can lead to wound closure in a bleb.  
 
The prolonged release drugs summarized in Appendix I improved the outcome of GFS 
in animal models, but few of them have been through clinical trials because the 
intraoperative application of MMC has been found to have long efficacy in scarring 
inhibition. However, it was confirmed that MMC led to some complications after GFS 
such as avascular and atrophic blebs, postoperative hypotony, and pathologic changes of 
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the ciliary epithelium, which did not recover over time (Falck, Skuta, & Klein 
1992;Mietz et al. 1994;Mietz et al. 1996;Mietz 1996). Due to the complications caused 
by either the drug or the polymers, the anti-scarring medicines reported previously were 
not ideal. New drug candidates with low toxicity and long term effect in scar inhibition 
are needed. 
1.3.4. Non-sink conditions and ocular drug delivery 
Non-sink condition and the bleb 
Before in vivo studies, the release profiles of drugs need to be evaluated in vitro. Orally 
taken tablets are usually evaluated in sink conditions using rotating paddle methods 
(Aulton 1998). Due to the significant difference of the volume between the 
gastric-intestinal fluid and aqueous humor, a drug that is placed locally in the bleb may 
demonstrate a completely different release profile as a function of its dissolution rate 
when compared to orally administered tablets. Hence, we could not evaluate the release 
of drugs in the bleb using the same method as the one used for orally taken tablets. A 
sustained release formulation in the bleb needs to be evaluated in non-sink conditions.  
 
To evaluate the localized release of a drug placed in the bleb, it is important to 
understand how non-sink conditions of flowing aqueous in the bleb environment can be 
exploited. To understand sink and non-sink conditions, one should first understand the 
dissolution process. The simplest process of solid dissolution described by 
Noyes–Whitney is shown in Figure 1.4. (Aulton 1998). Cs is the saturated concentration 
on the surface of the solid. C is the concentration of the bulk solution. The relationship 
between the diffusion rate of solid molecules or ions through a static diffusion layer 
(dm/dt), transformation area (A), and concentration gradient (ΔC) is shown in Equation 
1.1. D is known as the diffusion coefficient with the unit of m
2
/s and h is the thickness of 
the boundary layer.  
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Figure 1.14. Diagram of the boundary layers and concentration change surrounding a 
dissolving particle. 
 
  
  
 
        
 
 1.1.  
 
  
  
 
    
 
 1.2.  
If the solute passes from the dissolution medium into the bulk at a higher rate than it 
passes into the boundary layer (which means the solute is diluted immediately to a very 
low concentration), Equation 1.1 can be approximated by Equation 1.2. Similarly, if the 
volume of the dissolution medium is large enough (C≤Cs/10), (Cs-C) can be 
approximated to Cs. Either of these two conditions can be defined as „sink conditions‟. 
In contrast, if C＞Cs/10, then this is described as a „non-sink‟ condition. Partitioning of 
the solute between the solid and dissolved state can occur. Non-sink conditions are 
useful for characterizing the release profile of drugs that are applied topically and are 
diffused or transported into local tissues.  
 
Complete dissolution or release of an active ingredient by partitioning requires that once 
the partitioned volume becomes concentrated in the solute there is a mechanism for 
dilution of the solute. When a semi-solid or solid dosage form is placed in the bleb, it 
starts to release free drug molecules due to the presence of aqueous humor. Due to the 
small volume of the bleb (50-200 μL), the free drug molecules cannot be diluted quickly 
and consequently start accumulating on the surface of the formulation. When more drug 
molecules are released, the drug solution becomes concentrated; meanwhile, partition 
between the solid and dissolved state occurs. Although the turnover of aqueous humor 
(2 μL/min) contributes to the dilution of the drug solution in the bleb, complete 
Concentration of 
solute 
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dissolution or release of the drug cannot be achieved instantly due to insufficient 
dilution (the rate of dilution is 1-4% per minute only). Hence, for a solid or semisolid 
dosage form, the concentration gradient between the drug surface and the bleb is 
significant. Therefore, a sustained release formulation in the bleb can be described as 
non-sink conditions. 
 
Considerations for investigating drug release in non-sink conditions 
1) Bleb volume and aqueous flow 
Equation 1.1 suggests that the dissolution of a drug is related to the diffusion coefficient 
of the drug (D), the transformation area (A), the thickness of the boundary layer (h), and 
the gradient concentration of the drug (Cs-C). For localized drugs placed in the bleb, D 
and h are related to the dissolution/release of the drug, which is dependent on the drug 
and the formulation. For a given formulation, D and h are considered constant. Then the 
transformation area (A) and the gradient concentration (Cs-C) become the key factors 
that affect the drug release rate. Since the formulations were to be placed in the bleb 
with a small volume, it is assumed that drug saturation would occur in the bleb. 
However, this has not been confirmed because the presence of the aqueous flow may 
affect the drug concentration. Hence, we believed that, in the non-sink condition of the 
bleb, the surface area of the formulation, the bleb volume and the aqueous flow rate can 
greatly affect the release of the drugs. However, how these factors can affect drug 
release in quantity can be hardly found in the literature. 
2) Physical properties of the dosage form 
Since there is a turnover of aqueous humor in the bleb, drugs that exist in solid or semi 
solid states are expected to be exposed to moisture at body temperature. This may lead 
to the change of the physical properties of the drugs and/or the drug carriers and 
consequently lead to the change of drug release profile. Hence, to understand the 
long-term release of the drug, the physical properties of the dosage forms need to be 
investigated before implantation.  
3) Investigation using an in vitro model 
When developing a prolonged release formulation, it is important to investigate whether 
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the local drug concentration is in the therapeutic window. Before conducting in vivo 
studies, evaluation of the drug release profiles is required. Hence, an in vitro model that 
simulates the bleb would be very helpful in screening the dosage forms as well as in 
predicting the local drug concentration and drug residential time. Most of the in vitro 
release profiles in the studies listed in Appendix I were obtained by placing the 
formulations in a small closed tube containing 1-2 mL dissolution media, which does 
not simulate the bleb because 1) there is no flow in the tube, and 2) the volume of the 
dissolution media is much larger than the real bleb in vivo. Gurny et al designed special 
thermo stated cells to investigate the drug release profile. They placed the polymers 
loaded with the drug into the cells into which PBS was ciceluated at the rate of 8-10 
mL/h (equal to 133-167 μL/min). These cells did simulate the flow in the bleb, but the 
volume of the cells was not mentioned. In addition, the flow rate was more than 60 
times higher than the real condition (Merkli et al. 1994;Zignani et al. 2000a).  
4) Correlation between in vitro and in vivo 
Although all the dosage forms were usually investigated using in vitro and in vivo 
models, few studies correlated the in vitro and in vivo models. This suggests that the 
release studies of the in vitro models could not properly predict the in vivo release 
because the in vitro models did not simulate the bleb very well. Wang et al developed a 
subconjunctival implant which released 5-FU for more than 8 days (Wang et al. 1996). 
In this paper, the in vitro and in vivo studies showed a good correlation. However, the 
implants were placed directly into the subconjunctival space without performing GFS in 
the rabbit eyes; the in vitro studies were conducted in 10 mL of PBS with samples (2 
mL) taken at pre-determined time point. Both the in vivo and in vitro studies did not 
fully simulate the bleb after GFS due to the lack of constant liquid turnover. Therefore, 
after improving the in vitro model, further studies are needed to correlate the in vivo and 
in vitro models. 
5) Formation of capsules in the bleb 
It is understood that even a good in vitro model cannot fully represent the in vivo 
conditions. With exception of the two factors (bleb volume and aqueous flow rate) 
mentioned above, another key point is that the dissolution media usually used (PBS) in 
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the in vitro model is not identical to aqueous humor. The differences between aqueous 
humor and PBS are shown in Table 1.1. It can be seen that PBS has neither inorganic 
substances nor protein or amino acids. Since these substances and fibroblasts are absent, 
one of the results that cannot be predicted by the in vitro model is the encapsulation of 
the formulation. It has been known that foreign body reaction (FBR) is a common 
wound  healing response following any implantation of a medical device (Anderson, 
Rodriguez, & Chang 2008). With no exception, a formulation will also be susceptible to 
be encapsulated after being placed in the bleb.  
 
A few studies have mentioned encapsulation of dosage forms (Cui et al. 2008;Gould et 
al. 1994). They suggested that a drug that exists as a solid or semi solid form could 
possibly be encapsulated if it stays in the bleb for a long time. But most of the in vivo 
studies did not mention or predict the termination of the dosage forms. It is unclear 
whether capsule formation can affect the drug release and hence reduce the anti-scarring 
effect in long term. Although a good in vitro model is helpful in predicting the 
termination of the dosage forms, the release profiles in the in vivo conditions may be 
altered due to the capsule formation. Hence, further studies on capsule formation are 
needed.  
1.4. Matrix metalloproteinase (MMP) inhibitors  
Since most of the anti-scarring agents studied previously were cytotoxic drugs, many 
studies were conducted with new drug candidates with low toxicity. One group of 
agents is matrix metalloproteinase (MMP) inhibitors (Atreides, Skuta, & Reynolds 
2004;Wong et al. 2002). MMPs are a family of proteolytic enzymes that are tightly 
regulated and capable of degrading components of the extracellular matrix (ECM). They 
play an important role in mediating proteolytic activities during the tissue repairing 
process. In the inflammatory phase, large amounts of MMP-9 are secreted by the 
leakage plasma components. During the subsequent migration of neutrophils, 
lymphocytes, and macrophages, MMP-9 stored in macrophages and neutrophils 
granules is released. In the proliferative phase, MMP-1, 3 and 9 have all been shown to 
be over-expressed at the wound healing edge. In the post-proliferative phase, which is 
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also called the remodeling phase, the migration of fibroblasts through the surrounding 
ECM and wound bed are facilitated by MMPs. In addition, fibroblast–mediated 
collagen contraction, which leads to wound closure, is associated with increased 
production of MMPs (Wong et al. 2002). Therefore, MMP inhibitors can potentially be 
used to interrupt the wound healing process. 
 
Figure 1.15. MMPs and inflammatory cytokines influence the outcome at each step of the 
wound healing event. PDGF, platelet derived growth factor; TGF-beta, transforming growth 
factor beta; PGF, fibroblast growth factor; EGF, epidermal growth factor; IFN-γ, interferon 
gamma; VEGF, vascular endothelial growth factor. (Figure adapted from Occleston NL and 
Khaw P. T) (Wong et al. 2002). 
 
Ilomastat (N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan 
methylamide, Mw: 388.5, alternative name is Galardin or GM6001) is a MMP inhibitor 
that has been evaluated on a rabbit model of GFS (Wong, Mead, & Khaw 2005) (Figure 
1.16.). Ilomastat is a broad-spectrum MMP inhibitor which inhibits MMP 1, 2, 3, 8 & 9. 
It has been found to be active in a number of inflammation and cell invasion animal 
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models. Its inhibitory effectiveness on corneal ulceration has been studied in clinical 
trials (Fini et al. 1991;Galardy et al. 1994). It has been later found that ilomastat was 
able to inhibit post operative scarring in vitro and in vivo (Daniels et al. 2003;Wong, 
Mead, & Khaw 2003). Additionally, it was established that post-subconjunctival 
injections of ilomastat (0.1 mL of 100 μM) has a similar effect to intraoperative MMC 
(0.2 mg/mL) in long term scar inhibition. The results showed that, 21 days after surgery, 
all the blebs in the control group had failed but no bleb failures were observed on 
ilomastat or MMC groups. Some MMC and ilomastat treated blebs survived (57% and 
29% respectively) till the end of the study (60 days post surgery). In the histology 
studies, ilomastat treated tissue appeared normal while MMC resulted in 
subconjunctival hypocellularity (Wong, Mead, & Khaw 2005). The histology results 
indicate that ilomastat is less toxic than MMC. However, it is noticed that the 
subconjunctival injections were given daily for the first 9 days post surgery, followed by 
twice weekly injections for 2 weeks and weekly injections for a further 2 weeks. The 
need of multi-injections suggests that the pharmacokinetics of ilomastat is suboptimal 
due to rapid clearance of the drug solution. This problem could be resolved if ilomastat 
were to be incorporated in a slow released solid or semi-solid dosage form. Hence, the 
development of prolonged release formulations for ilomastat becomes important in 
future studies. 
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Figure 1.16. Chemical structure of ilomastat 
 
1.5. Hypotheses and aims 
From the literature and current clinical practice, we understand that scar inhibition plays 
an important role in determining the success of GFS in halting the progression of 
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glaucoma. The anti-cancer drugs 5-FU and MMC are unlicensed for ocular use, but are 
commonly used in clinical practice; currently there is no licensed medicine. The 
effectiveness of 5-FU and MMC is limited due to their narrow therapeutic window, 
severe side effects and suboptimal pharmacokinetics. Hence, there are two broad 
clinical needs: (1) a need for less toxic agents to inhibit the scaring after GFS and (2) a 
need to increase the local bleb tissue exposure of the drug beyond that which is possible 
by subconjunctival injection. One MMP inhibitor, ilomastat, has a potential to work as a 
good anti-scarring agent due to its low toxicity compared to 5-FU and MMC. However, 
its residence time in the bleb needs to be prolonged. Due to the small volume of the 
subconjunctival space and the existence of the aqueous flow, a formulation that is 
placed in the bleb will potentially clear more quickly than in the back of the eye. But 
due to the small volume, prolonged residence time may be possible. Therefore, drug 
release profiles in the bleb need to be studied specifically. We hypothesize that 1) the 
long term inhibition of scarring with low toxicity can be accomplished by placing a 
prolonged release formulation in the bleb, 2) the release profiles of the formulation can 
be evaluated in vitro using a flow chamber that mimics the bleb, 3) the efficacy of the 
formulation can be evaluated in a clinically validated rabbit model, and 4) the 
dissolution of the formulation in non-sink conditions can be simulated computationally.  
 
Therefore, we aim to fabricate and develop a prolonged release formulation that is less 
toxic than the currently used therapeutics. This formulation is preferred to be a small 
implantable tissue tablet. Before placing the tablet in the bleb, its release profile will be 
evaluated using a flow chamber. Following the in vitro studies, the effectiveness of the 
tablet will be evaluated in vivo using a clinical validated rabbit model. In addition, the 
dissolution of the tablet and the release rate of the drug in non-sink conditions will be 
simulated using molecular dynamics simulation as well as a computational 
mathematical model. 
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2.1. Introduction  
As mentioned in the introduction (1.2.3), the need for bleb maintenances (massage, 
needling, and 5-FU subconjunctival injections) after GFS indicates that the long term 
efficacies of 5-FU or MMC are not sufficient for long term scar inhibition. Bleb 
needling augmented along with 5-FU has been confirmed as a safe and effective way of 
rescuing failing blebs (Broadway et al. 2004). As summarised in Appendix I, in the last 
two decades much work has been done to prolong the drug residential time by 
incorporating these drugs into polymers. However, the efficacy has not been ideal due to 
the side effect caused by the drug carrier. Therefore, we decided to examine how to 
prolong the residential time of 5-FU using polymers that are clinically used in 
commercial products..   
 
Polymers used in commercial ophthalmic products, such as polyvinylalcohol (PVA), 
polyvinylpyrrolidone (PVP) (K 29/30/32/90), dextran, hydroxypropylmethylcellulose, 
hydroxyethylcellulose, methylcellulose, polyacrylic acid, sodium hyaluronate, and 
sodium alginate (U.S. Food and Drug Administration), play an important role in the 
ophthalmic formulations as their viscosity can prolong the drug residential time and 
increase the mucoadhesion. We have chosen two polymers as carriers for 5-FU: 
hyaluronic acid (HA, Figure 2.1) and PVP (Figure 2.2.). According to the criteria of 
FDA, PVP K 29/30/32/90 has been used in the ophthalmic formulations. Here we 
choose K30 as it was widely used in both ophthalmic solutions and suspensions. 
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Figure 2.1. Chemical structure of hyaluronic acid. 
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Figure 2.2. Chemical structure of polyvinylpyrrolidone (PVP). 
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HA is a polysaccharide composed of disaccharide units linked by glycosidic bonds (Kim 
et al. 2003). It is a natural product of mammals and human beings, and is one of the most 
important components of the vitreous body. HA has been registered as an intra-articular 
and intra-ocular medicine. It has many advantages over other commonly available 
polymers including a high molecular weight, high viscosity, as well as non-toxic, 
non-inflammatory, and non-antigenic properties. In addition, it does not cause a foreign 
body response (Reinmuller 2003). It is also effective in atraumatic manoeuvres, for 
controlling and keeping tissues separated. Furthermore, it has been found that HA is able 
to form a large coiled, porous meshwork which can entrap drug molecules (Hascall & 
Laurent 2007). Accordingly, HA could be used as a vehicle for anti-proliferative drugs in 
the treatment of GFS.  
 
Healon® is a marketed ocular HA product. It is a steam-sterilized solution of sodium 
hyaluronate 5000 dissolved in a physiological buffer (pH 7.0-7.5). There are three 
different Healon® products available, all with different concentrations of sodium 
hyaluronate: Healon® (10mg/mL), Healon® GV (14 mg/mL), and Healon® 5 (23 
mg/mL). They all have a fairly similar osmolality and pH to aqueous humour, but more 
than 20,000 times the viscosity. Although highly viscous (viscosity: 3,000,000 mPas), 
Healon® is easy to inject because the viscosity decreases considerably when ejected 
through a cannula, whereas the viscosity is restored immediately after injection 
(Pharmacia 2007). As a result, Healon® GV has been widely used in clinic including in 
trabeculectomy (Goa & Benfield 1994). In our study, HA was used as a vehicle for the 
delivery of anti-scarring agents due to its very high molecular weight and high viscosity. 
In the preliminary studies we used Healon®, but in the tablet fabrication we used 
different source of HA (purchased from Sigma). It is understood that the HA contained 
in Healon® might be different from the ones purchased from Sigma but we believe they 
are similar as they both were extracted from rooster combs. We decided to purchase 
some HA instead of freeze drying Healon® because 1) Healon® is relatively expensive, 
and 2) we do not want to include any salt in the tablet since Healon® is a HA solution in 
a biological buffer. 
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Although HA has a very good biocompatibility, it is relatively expensive compared to 
many other polymers. PVP is a nonionic, water soluble polymer which is widely used in 
pharmaceutical products. It is used as an excipient in artificial tears. Its rheology does 
not change significantly when mixed with artificial tears (Hartmann & Keipert 2000). 
Hence, it is hoped that PVP can prolong the residential time of 5-FU by increasing the 
viscosity of the aqueous humor in the bleb and delaying the diffusion and elimination of 
the drug. Therefore, we decided to use PVP and HA to prolong the residence time of 
5-FU. 
2.2. Materials and methods 
2.2.1. Materials and instrumentation 
5-fluorouracil (5-FU), hyaluronic acid sodium salt from human umbilical cord (Cat No. 
H1876), PBS (phosphate buffered saline) tablets (OXOID), sodium hydroxide (NaOH) 
and triethanolamine (TEA) were purchased from Sigma-Aldrich (UK). 
Polyvinylpyrrolidone (PVP, Mw approx 44,000) was purchased from BDH. Healon® 
(10mg/mL), Healon® GV (14 mg/mL), and Healon® 5 (23 mg/mL) was made by 
Pharmacia (Switzerland). The Discovery® HS F5 HPLC column (15 cm×4.6 mm, 5 
μm) was purchased from Sigma-Aldrich (UK). The syringe pump (PHD2000 model) 
was manufactured by Harvard Apparatus. The multi-channel peristaltic pump was 
manufactured by ISMATEC (Switzerland). The tubing used on the peristaltic pump 
(inner diameter 0.25mm, color code: orange/blue) was purchased from ISMATEC. The 
manual hydraulic press was manufactured by Specac Orpingham (UK). The punches 
and dies used for tablet compression were manufactured by iHolland Ltd (UK). The 
Turbula® T2C / T2F Heavy-Duty Shaker-Mixer was manufactured by the Willy A. 
Bachofen (WAB) company (German company manufacturing these units in 
Switzerland). The flow chambers were made by Mr. John Frost in the workshop of the 
London School of Pharmacy. The Pyris 1 differential scanning calorimetry (DSC) 
instrument was purchased from PerkinElmer Ltd. The high performance DSC was 
purchased from TA instruments. 
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2.2.2. Preparation of phosphate buffer at pH 7.6 
Phosphate buffer pH 7.6 was made from PBS tablets. Ten tablets were dissolved in 1 L 
of deionized water (NaCl 8.0 g/L, KCl 0.2 g/L, Na2HPO4 1.15 g/L, KH2PO4 0.2 g/L ), 
the pH of the solution was then adjusted to 7.6 by 0.1 M NaOH. The solution was 
filtered using a 0.22 μM syringe filter (purchased from Millipore) to remove bacteria 
before use. 
2.2.3. Preparation of 5-FU powder suspended in HA gel 
Healon® GV (50 mg) was firstly injected into the flow chamber. Then 5-FU (6 mg) was 
deposited on the Healon® GV. Another addition of Healon® GV (50 mg) was injected 
into the chamber on top of 5-FU. This was followed by a gently stirring of the viscous 
suspension using a glass stick for approximately 15 seconds. 
2.2.4. Preparation of tablets 
2.2.4.1. Preparation of 5-FU HA tablets 
5-FU (45 mg) and HA (9 mg or 45 mg, 5-FU: HA=5:1 or 5:5, W/W) were dissolved in 
10 mL deionized water and stirred overnight. The solutions were then lyophilized for 48 
hours. The freeze dried solid mixture was compressed into tablets under the pressure of 
5 bars. Each tablet was 3 mm in diameter. Tablet weight and thickness varied according 
to the different ratios of excipients (Table 2.1). 
2.2.4.2. Preparation of 5-FU PVP tablets 
Direct blended 5-FU PVP tablets 
5-FU (3 g) and PVP (3 g) were put in a 50 mL amber glass jar and then mixed by 
Turbula® heavy-duty shaker-mixer for 30 minutes. The solid mixture was then 
compressed into tablets directly using a pressure of 5 bars. Tablet weight and thickness 
is illustrated inTable 2.1. 
Freeze dried blended 5-FU PVP tablets 
5-FU (100 mg) and PVP (100 mg) were dissolved in 10 mL deionized water and the 
solution stirred overnight at room temperature. The solution was then lyophilized for 48 
hours. After lyophilization, the mixture was compressed into tablets using a pressure of 
5 bars. Tablet weight and thickness is illustrated inTable 2.1. 
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Table 2.1 Weight and thickness of the 5-FU HA and 5- FU PVP tablets. 
Tablets Weight (mg) Thickness (mm) 
5-FU HA (5:5, W/W) 10.1 ± 0.2 (n=3) 1.31 ± 0.02 (n=3) 
5-FU HA (5:1, W/W) 6.1 ± 0.2 (n=3) 0.78 ± 0.02 (n=3) 
5-FU PVP (1:1, freeze dried blended) 11.1 ± 0.6 (n=3) 1.16± 0.06 (n=3) 
5-FU PVP (1:1, direct blended) 11.4 ± 1.3 (n=3) 1.24 ± 0.12 (n=3) 
 
2.2.4.3. Tablet fabrication by compression 
The lower punch was firstly put into the die. The drug or mixture of drug and polymer 
were weighed using a small weighting boat and gently placed into the space between the 
lower punch and the die. The upper punch was placed on the die. The tip of the upper 
punch was pushed down until it was in contact with the drug or the mixture. The 
assembled punch and die sets were placed in the manual hydraulic press. A pressure (5- 
14 bar) was applied for 10 seconds. Finally, both the upper and lower punches were 
removed, and the tablet ejector inserted into the die to gently push the tablet out. The 
diameter of the tablets was 3 mm. Tablets with or without excipients were compressed 
using the same punch and die sets. 
2.2.4.4. Preparation of excipient-free 5-FU tablets 
The 5-FU tablet was compressed using the method described in 2.2.4.3. 5-FU was 
compressed into tablets directly using a pressure of 14 bar. The excipient-free 5-FU 
tablets weighed approximately 5.1 ± 0.4 mg (n=12). The thickness of the tablets was 
approximately 0.55 ± 0.06 mm (n=12). 
2.2.5. Use of a flow chamber to obtain release profiles: evaluation of the release 
profiles of the formulations 
After the formulated tablets were placed inside, the flow chambers were sealed and 
connected to a syringe pump or a multi-channel ISMATEC dispensing pump. Each 
chamber contained one formulation only. Then the PBS solution was pumped into the 
chamber at a flow rate of 100, 50, 20 (provided by syringe pump) or 2 (provided by 
multi-channel pump) µL/min. The accuracy of the flow was validated by evaluating the 
volume of the collected liquid using pipette (volume collected = flow rate (volume/time) 
× time). The fluid that flowed out of the chamber was collected at predetermined time 
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points and analyzed by HPLC. Each sample was injected 3 times. The amount of drug 
released at each time point was calculated by multiplying the volume and the 
concentration of the outgoing fluid (Figure 2.1, Table 2.2). 
2.2.6. HPLC instrumentation and conditions 
The HPLC methods were developed with the guide and discussion with Dr. Hardyal 
Gill at London School of Pharmacy. HPLC analysis was performed on an Agilent 
Technology 1200 series system consisting of a separation module for solvent and 
sample delivery, a UV detector and chemstation software for data acquisition and 
analysis. The UV wave length was set at 260 nm following the HPLC methods for 5-FU 
in the literature(Chu et al. 2003;Gamelin et al. 1997). Since 5-FU is a polar compound, a 
15cm  4.6mm I. D., 5µm particle size Discovery® HS F5 HPLC column was used for 
compound separation. The mobile phase was 20mM ammonium acetate buffer with 0.6% 
TEA (pH 5.0). 5-FU was eluted at a flow rate of 1.0 mL/min. The chromatography was 
performed at 40°C. The injection volume for each sample was 10μl.  
2.2.7. Testing tablet content uniformity 
Each tablet (5-FU HA and 5-FU PVP) was put in 10 mL of de-ionized water and then 
stirred until the tablet was completely dissolved. The solution was injected in to the 
HPLC column to analyze the concentration of 5-FU. Each sample was injected three 
times. The amount of 5-FU contained in the tablet was calculated by multiplying the 
5-FU concentration with the volume of the water (10 mL) that was used to dissolve the 
tablet. 
2.2.8. Examination of the biological effects of an excipient-free 5-FU tablet on 
Human Tenon’s Fibroblasts 
Culturing and counting of the cells 
Human Tenon‟s Fibroblasts (HTFs) were grown to confluency in a T75 Flask (Fisher, 
UK) containing 12 mL of fibroblast growth media (FGM) with 10% FBS (fetal bovine 
serum, Sigma, UK), 100 U/mL Penicillin/Streptomycin and 2mM L-Glutamine (both 
Invitrogen, UK). Flasks were incubated at 37 °C in 5% humidified CO2. The culture 
medium was replaced every 3 days until confluency was reached. Cells were used 
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between passage 2 and 8. 
 
Cells were removed from the flask via trypsinisation. To accomplish this the media was 
aspirated from the flask and the flask was then washed with 5-10 mL of PBS 
(Invitrogen, UK). The PBS was then aspirated and 2 mL of 1X Trypsin solution 
(Invitrogen, UK) added. The flask was then placed in an incubator for 2 minutes, after 
which it was checked for complete HTF detachment using phase-contrast microscopy 
(Leica) and a x4 objective lens. FGM (5 mL) was then added to the flask and the base 
washed several times before all liquid was transferred to a 15 mL falcon tube (Fisher, 
UK) and centrifuged at 1000 RPM for 5 minutes. The cell pellet was then re-suspended 
in 1 mL of FGM before being counted. 
 
Cell counting was undertaken using Trypan Blue (Invitrogen, UK) whereby 20 µL of 
cell suspension was mixed in a 1:1 ratio with Trypan Blue. Cells were then plated onto a 
Neubauer plate (10 µL). The number of cells was calculated by taking an average from 
4, 4 × 4 squares. Cells that were colored blue were not included in total cell number 
count, as the blue indicated a ruptured membrane and therefore a dead or dying cell. 
 
5-FU treatment I  
HTFs were plated into 6 well plates at a concentration of 1×105 cells per well. Cells 
were allowed to attach to the plates for 24 hours prior to 5-FU treatment. Then 5-FU (6 
mg/mL, 2 mL per plate) was added to each of the wells for 8 hours. Following treatment 
the wells were washed three times with PBS (200 μl per well). Afterwards, HTFs were 
removed, counted and seeded into 96 well plates at a concentration of 2×104 cells per 
well. Cell viability and proliferation were investigated 0, 24, 48, 72 hours after being 
plated in the 96 well plates. 
 
5-FU treatment II 
HTFs were plated into the wells of 96 well plates at a concentration of 2×104 cells per 
well. Cells were allowed to attach to the plates for 24 hours prior to the 5-FU treatment. 
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Then 5-FU (6 mg/mL, 200 μl per plate) was added to each of the wells for 8 hours. 
Following the treatment the wells were washed for three times using PBS (200 μl per 
well). Cell viability and proliferation were investigated 0, 24, 48, 72 hours after 
treatment. 
 
Measuring cell viability and proliferation 
Cell viability and proliferation was measured using MTT (3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyl tetrazolium bromide; Sigma; 5 mg/mL stock in PBS), following previously 
published procedures. The assay is dependent on the production of purple formazan 
crystals from a methyl tetrazolium salt in the mitochondria of active cells. 
 
At the predetermined time points, MTT solution (10 µL) was added to each well and 
incubated for 4 hours at 37 °C. Following the incubation the solution was carefully 
removed. The wells were carefully washed once with PBS, taking care not to disturb the 
formazan crystals at the bottom of each well. The crystals were then dissolved in a 
mixture of DMSO and ethanol (50:50, 200 µL per well). The plates were placed on a 
rocker for 10 minutes to ensure all the crystals had dissolved. The absorbance of the 
colored solution was then measured using a Tecan Safire spectrophotometer (test 
wavelength: 570 nm; reference wavelength 630 nm). The spectrophotometer was 
operated using the XFluor 4 software and results were extracted as an Excel formatted 
spreadsheet. To take a back ground for each condition, media was added to a well 
without cells before being washed and 200 µL of DMSO/ethanol added. This 
background reading was accounted for and used in calculation of the results. Cell 
viability/proliferation was then calculated through the reading and the use of statistical 
tests. 
2.2.9. DSC measurements of the tablets 
The DSC samples were all weighed using a METLER TOLEDO XS105 balance (d = 
0.01 mg). The DSC measurements of the 5-FU PVP tablets and 5-FU excipient-free 
tablets were made with a Pyris 1 DSC (PerkinElmer Ltd.). Samples (2–5 mg) were 
sealed in non-hermetic aluminum pans and measured with a nitrogen purge gas (25 
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m/min). Samples were firstly heated from 25 to 120 °C at a rate of 100 °C min
−1
, then 
held at 120 °C for 3 minutes to remove the moisture. Finally the samples were quenched 
at -10 °C and heated to 300 °C at a rate of 100 °C/min.  
 
The 5-FU HA tablets were measured with a high heating and cooling DSC (TA 
instruments) with nitrogen purge gas (25 mL min
-1
). Samples (approximately 0.1 mg) 
were sealed in non-hermetic aluminum pans. They were firstly heated from 25 to 
120 °C at 500 °C /min, then held at 120 °C for 3 minutes to remove the moisture. 
Following this step the samples were quenched to -50 °C and heated to 300 °C at a 
heating rate of 500 °C /min. In all the DSC experiments, an empty pan was used as a 
reference and the instrument was calibrated for temperature and enthalpy with indium 
(melting point 156 ◦C and H = 28.4 J/g). 
2.3. Results and discussion 
2.3.1. Designing the in vitro model 
When developing a new formulation, the release of the drug usually needs to be 
evaluated using some in vitro models before conducting the in vivo studies. Although it 
is appreciated that an in vitro model can never perfectly predict in vivo conditions, it is 
still expected to be able to provide some useful information. As mentioned in Chapter 1, 
the bleb forms a non-sink condition for the formulations, but few studies have paid 
much attention to the importance of the in vitro model. As a result, the in vitro and in 
vivo studies were not correlated well. Therefore, we developed an in vitro model 
mimicking the bleb. It is hoped that the experimental data obtained using this model 
correlates well with in vivo studies in the future. 
 
Since the volume of the bleb has been estimated at approximately 50-100 μl (Theelen et 
al. 2007), we designed two types of flow chambers with different volumes. One with a 
volume of 50 μl, which is the minimum volume used for most of the formulations 
studied previously (Appendix I). Theoretically the other volume should be around 100 
μl but we made it 200 μl. By enlarging the volume we are able to more fully investigate 
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how the chamber volume affects drug release. Ideally the liquid in the flow chamber 
would be similar to the aqueous humor. However, it was mentioned in Chapter 1 that the 
aqueous humor is composed of many different organic/inorganic substances as well as 
amino acids; so it is difficult to make a solution that is exactly the same as the aqueous 
humor because proteins and amino acids are unstable. PBS with a pH that is similar to 
aqueous humor was usually used in the in vitro release studies in the literature (). It is 
appreciated that PBS is not the buffer that is most similar to aqueous humor because its 
ion strength is much stronger than aqueous humor; BSS or Kreb‟s buffer for example 
are more similar to aqueous humor. But the flow in the chamber did not seem to be 
constant when using BSS or Kreb‟s buffer because of the presence of the carbon dioxide 
bubbles generated from the bicarbonate. Therefore, PBS was used as the dissolution 
media in our preliminary study.  
 
It is also understood that a drug released into the aqueous humor will be eliminated 
from the capillaries and lymphatics in the conjunctiva (Azuara-Blanco & Katz 1998). 
Hence, ideally a piece of conjunctiva should be placed on the top of the chamber to stop 
the undissolved drug particles coming out of the chamber. But this is difficult because 1) 
the presence of conjunctival stops the flow as it causes high back pressure in the 
chamber and 2) the thickness of the conjunctiva varies in different parts of the eye or 
among individual animals. Therefore, a sponge was placed on the inner top of the flow 
chamber to prevent the drug particles from being flush out before they had chance to 
dissolve. However, a few types of sponges were tested but they all led to failing of the 
experiment again due to the back pressure brought by the sponge. Therefore, it was 
decided that the drug solution would be collected directly without placing a piece of 
tissue. Although this flow chamber does not mimic the bleb perfectly, we believe that 
the approximation from the in vitro model will give us some trends and information 
with regard to the retention of the formulation as well as the drug release profile. 
 
It has been predicted that tablets placed in a flow-through cell may have different 
release behavior caused by the varied liquid flow (Kakhi 2009). Although in our case 
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the flow rate of aqueous humor is as low as about 2 μL/min, the release rate of the drug 
may vary on the formulation because the boundary layer will be disturbed by the liquid 
flow. In the in vivo condition, this problem may also exist as the volume and shape of 
the blebs are varied among the individuals. To obtain consistent results from the flow 
chamber, we try to avoid dead spaces as much as possible. Hence, the flow chamber 
was made in round shape. We also make sure that 1) the formulation is placed 
constantly right at the same place of the chamber (usually the center) 2) the fluid 
entrance was designed to be near the bottom of the chamber, and the fluid exit at the top 
of the chamber as far away from the entrance as possible (Figure 2.3, Figure 2.4, & 
Figure 2.5). In addition, tubing with a small inner diameter (0.92 mm) was used as the 
out-going channel. This tubing was also designed to be as short as possible to ensure it 
does not significantly enlarge the volume of the chamber. The volume of the outgoing 
tubing was approximately 10% of the chamber volume. To mimic the temperature of the 
eye, the chambers were placed in a 37 °C oil bath. By collecting the liquid that flows 
out of the chamber and determining the concentration of the drug at different time 
points, the amount of the drug that flows out of the chamber can be evaluated (Figure 
2.3). The calculation of accumulate drug that flows out of the chamber is demonstrated 
in Table 2.2. It is understood that the flow chamber is not perfect in predicting the in 
vivo conditions, but we believed that this in vitro model is able to give us some trends. 
By testing the formulations in the flow chamber, we are able to make sure that 1) the 
retention of the formulation in the bleb is prolonged, 2) the formulation and drug is 
stable before the drug release is completed, and 3) the release profile of the drug can be 
estimated approximately.  
        
Figure 2.3. Design of the in vitro model for the release studies of the drug formulation. 
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Figure 2.4. A flow chamber that simulates the bleb. Arrows in the figure illustrate the flow of 
the liquid. 
 
a                                    b 
Figure 2.5 The dimensions of the 200 μL (a) and 50 μL (b) flow chamber. 
 
Table 2.2 Calculation of the accumulate drug that flows out of the chamber. 
Time 
point 
Volume of the 
liquid 
collected 
Drug 
concentration 
The amount of drug that 
came out of the chamber 
Accumulation of the drug 
that came out of the chamber 
(%) 
0 0 0 0 0 
t1 Flow rate × t1 A a×t1 a×t1/m0* 
t2 
Flow rate 
×(t2-t1) 
B a×t1+b×( t2-t1) [a×t1+b×( t2-t1)]/ m0* 
… … … … … 
tn 
Flow 
rate×(tn-tn-1) 
X a×t1+b×( t2-t1)+…+x×(tn-tn-1) 
[a×t1+b×( t2-t1)+…+x×(tn-tn-1)]/ 
m0* 
*m: total amount of the drug contained in the formulation. 
2.3.2. Preliminary studies: 5-FU solution mixed with Healon® 
It is understood that the pharmacokinetics of 5-FU are not sufficient when it is delivered 
as a solution. Hence, it was suggested that the elimination of 5-FU could be delayed if the 
viscosity of the solution was increased. In order to see whether the presence of polymer 
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could prolong the release of 5-FU, a preliminary study was conducted in the 50 μL 
chamber with HA (Shen.Y. 2004;Wong et al. 2006). Different concentrations of HA 
(Healon® 10 mg/mL, Healon® GV 14 mg/mL) and 50 mg/mL 5-FU solution (1:1 W/W) 
were injected into the flow chamber and then manually mixed by stirring. In the 
preliminary studies, the flow of PBS was initially provided by a syringe pump. As the 
syringe pump could not provide any accurate flow rate that is less than 20 μL/min, 
studies were conducted using the flow rate of 20 μL/min. Since our aim is to see 
whether the polymer viscosity can prolong the drug retention time, it is believed that the 
5-FU retention time in the bleb will definitely be prolonged if it can be prolonged at a 
flow rate in vitro that is 10 times higher than the human average aqueous flow rate (2 
μL/min). 
 
The results show that, at a flow rate of 20 μL/min, 5-FU solution was eliminated 
completely within one hour (60 minutes). But 5-FU was slowly released for more than 3 
hours (180 minutes) when mixed with HA solutions (Figure 2.6.). Complete release of 
5-FU was not shown in this figure because the experiment was not conducted till the 
time when all the 5-FU was released. It is believed that, due to the high viscosity of HA, 
complete release of 5-FU will need another few hours. This suggests that 5-FU release 
was prolonged at least two fold by Healon® due to the high viscosity of HA.  
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Figure 2.6. 5-FU concentrations released from Healon®  mixed with the 5-FU solution (50 
mg/mL) at ambient temperature and a flow rate of 20 μL/min (n=3, error bars indicates 
standard deviation) (Wong et al. 2006). ◇5-FU solution only ▽Healon®  (10mg/mL HA) with 
5-FU solution △Healon®  GV (14 mg/mL HA) with 5-FU solution. Data suggest that the 
residence time of 5-FU was prolonged when the 5-FU solution was mixed with Healon® . 
2.3.3. 5-FU powder mixed with Healon® 
The above study has shown that the release of 5-FU can be slowed down when mixed 
with HA solution because the presence of HA increases the viscosity of the solution 
inside the chamber. But the water contained in the 5-FU solution could still decrease the 
HA viscosity. Therefore, to avoid the dilution of HA caused by the water contained in 
the 5-FU solution and to obtain a longer drug residential time, 5-FU powder was simply 
mixed to the most concentrated HA solution (Healon® GV). Using this method, it is 
believed that the release of 5-FU will be more prolonged because 5-FU would need to 
dissolve in the HA solution and then eliminated slowly by diffusion. Meanwhile, to 
understand whether the 5-FU release rate will be affected by different flow rates, the 
release of 5-FU was evaluated using different flow rates (20, 50, and 100 μL/min). The 
results indicate that the 5-FU release rate was decreased with a decreasing of the flow 
rate (Figure 2.7). When the flow rate was 100 μL/min, 5-FU was completely released 
after 5 hours. Meanwhile, about 80% of 5-FU was released when the flow rate was set at 
20 μL/min. These studies further confirmed that HA is able to prolong the release of 
5-FU. However, it is understood that the results of this study may show significant 
variability due to the difficulties of reproducibly formulating the 5-FU powder which 
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suspended in Healon®. Results will also be affected by factors such as stirring 
techniques, particle size, and polymorph of 5-FU. The release profiles of 5-FU with 
different particle size can be vary because the particle size is associated with the surface 
area which greatly affects the dissolution rate of a material, whilst the particle size of 
the 5-FU powder can vary from different manufacturer or even in different batch from 
the same manufacturer. As different crystal forms of 5-FU may have very different 
dissolution rate, the polymorph of 5-FU also needs to be defined. Hence, further studies 
on 5-FU HA suspensions were not conduct since this is only a preliminary study. 
 
 
Figure 2.7. Release profiles of Healon®  GV mixed with 5-FU powder under different flow rate 
in the 200 μl chamber at ambient temperature (n=3, error bars indicates standard deviation). 
◇ 100 µL/min, □ 50 µL/min △ 20µL/min. Data suggest that the residence time of 5-FU 
will be reduced when the flow rate increases. 
2.3.4. Fabrication of a mini tablet 
Since it was established that HA was able to prolong the release of 5-FU, it was 
considered that the release of 5-FU could be further prolonged if the drug was 
incorporated into the polymer and then compressed into a tablet. Hence, we decided to 
make 5-FU tablets using HA as an excipient. Based on findings from previous studies 
(Chapter 1), it was felt that a mini tablet with 3 mm diameter and maximum 1 mm 
thickness is suitable for the bleb. To make these mini tablets, a punch and die set was 
designed (Figure 2.8.). As the diameter of the punch is only 3 mm, one of the most 
important issues in this design is that the punches must be well protected from bending 
and damage under high pressure. Therefore, we had several discussions with Mr. J frost 
from the workshop at the School of Pharmacy and specialists in tablet compression 
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from iHolland Ltd. In accord with these discussions, the upper and lower punches were 
designed to be as short as possible to minimize the risk of distortion on compression. 
They were attached to a strong base with a large surface area with radian so that the 
pressure could be applied evenly during tablet compression. The tools were designed so 
that a 0.2 mm safety gap is maintained between the upper and lower punch. This is to 
ensure that they do not collide during compression if there is insufficient material to fill 
the die space. Due to the absence of lubricants, the tablets were sometimes found to 
stick to the die after compression. A tablet ejector was therefore made to push the tablet 
out (Figure 2.8.).  
 
Figure 2.8. The punches and die used for compressing tablets. 
2.3.5. 5-FU HA tablets 
Having carefully designed the punch and die sets, we started to make tablets. We first 
used HA as the excipient for the 5-FU tablet. It is hoped that 5-FU could be well 
dispersed in the polymer, and that the residence time of 5-FU would be prolonged due 
to the viscosity of the polymer. To make reproducible tablets, it was important to ensure 
that the polymer and drug are well mixed. In other words, a good content uniformity 
was required before testing the tablet release profiles. As the HA purchased from Sigma 
was fleecy, its compressibility was poor. In addition, it was not possible to mix 5-FU 
powder directly with the fleecy HA. Therefore, to obtain a good content uniformity, HA 
was dissolved in 5-FU solution. The solution was then lyophilized to get a proper 
mixture of 5-FU and HA. This mixture appeared to have a better compressibility than 
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HA, so the 5-FU HA tablets were made from this lyophilized mixture.  
 
To simulate flow of the aqueous humor, a peristaltic dispensing pump was purchased to 
ensure that the flow rate was set as the average flow rate of human aqueous humor (2 
μL/min) (McLaren 2009). To gain some understanding on how the release rate could be 
affected by different proportion of HA, two types of tablets containing the same amount 
of 5-FU but different amounts of HA (50% and 16.7%, W/W) were fabricated and 
evaluated using the in vitro model. 
 
Figure 2.9. Release profiles of 5-FU HA tablets in the 200 μl chamber at ambient temperature 
(n=3, error bars indicates standard deviation). ◇ represents 5-FU: HA = 5:5 (W/W), □
represents 5-FU: HA=5:1 (W/W). Data suggest that with the decreasing of the proportion of HA 
the release rate of 5-FU as well as the 5-FU concentration in the flow chamber will be 
decreased. 
 
The accumulate release (in %) of the tablets in 8 hours is shown in Figure 2.9. A lag time 
of tablet dissolution was observed in both tablets, led by the water absorption process of 
the tablet. After 8 hours, approximately 80% of 5-FU was released from the tablets 
containing 50% HA; meanwhile, less 5-FU (70%) was released from the other type of 
tablets which contained 16.7% HA. The peak concentration of 5-FU, which appears at 
around 3-4 hours, was around 6-7 mg/mL. The 5-FU concentration was found to be 
nearly zero after 24 hours (data not shown). This indicates that with the same flow rate (2 
μL/min), tablets containing the higher proportion of HA (50%) released 5-FU more 
quickly. 
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2.3.6. 5-FU PVP tablets 
Although HA did prolong 5-FU release, the price of HA is relatively high. Other water 
soluble polymers that are used in the commercial ophthalmic products could also be 
good excipients for a prolonged release 5-FU tablet. PVP is a good candidate because 1) 
it is frequently used as a tablet binder 2) it is water soluble and 3) its solution is viscous. 
Hence, PVP was also mixed with 5-FU and compressed into tablets. As PVP is a powder, 
it could be directly blended with the 5-FU powder. 5-FU and PVP mixture could also be 
obtained by freeze drying their aqueous solution. Therefore, 5-FU and PVP were 
dissolved in water and then lyophilized. The 5-FU PVP tablets were made from the 
lyophilized mixture. The release profiles of the different type of 5-FU PVP tablets were 
investigated using our in vitro model. 
 
The release profiles of 5-FU PVP tablets blended using different methods were 
compared. The results show that PVP prolonged the release of 5-FU for more than 8 
hours (Figure 2.10.). After 8 hours, 75% of 5-FU was released from freeze dried 
blended tablets; meanwhile, only about 50% of 5-FU was released from the directly 
blended tablets. This suggests that 5-FU is released more quickly if it was freeze dried 
blended with PVP, probably because lyophilization leads to the formation of amorphous 
5-FU, which dissolves faster than the 5-FU crystals. 
 
Although the 5-FU tablets containing HA and PVP did prolong the release of 5-FU in 
comparison with the 5-FU solution, all the tablets released 100% of the 5-FU within 24 
hours, even when the proportion of the polymers was increased. Although the highly 
viscous polymer solution obstructed the diffusion of 5-FU solutions in the flow chamber, 
the wettability and dissolution rate of 5-FU was enhanced by the hydrophilicity of PVP 
and HA. It was also believed that the residence time of 5-FU would not be significantly 
prolonged unless the compression force of the tablet is increased considerably. A high 
compression force may delay the hydration time of the tablets; as once the tablet is fully 
hydrated, the release profiles cannot be significantly changed. However, we did not try 
any higher compression force because we are not sure whether the punch and die sets 
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will be damaged if a high pressure (more than 30 bar) is applied.   
 
Figure 2.10. Release profiles of 5-FU PVP (1:1 W/W) tablets in the 200 μl chamber at ambient 
temperature (n=3, error bars indicates standard deviation). □ Direct blended ◇Freeze dried 
blended. Data suggest that with the decreasing of the proportion of PVP the release rate of 
5-FU as well as the 5-FU concentration in the flow chamber will be decreased. 
2.3.7. Excipient-free 5-FU tablets 
Excipient-free 5-FU tablets in different chamber volumes 
When analyzing the release profiles of the 5-FU tablets with PVP and HA, it was found 
that tablets containing larger amounts of polymer demonstrated a faster release rate than 
the ones containing smaller amounts of polymer. Although both HA and PVP prolonged 
the release of 5-FU due to their viscosity, they also improved the 5-FU dissolution 
process because their hydrophilicity and potential wettability brought more contacts 
between water and the dispersed 5-FU. So it was considered that the release of 5-FU 
might be slower without the presence of hydrophilic polymers. Thus, excipient-free 5-FU 
tablets were also fabricated and evaluated. Fabrication of excipient-free tablets means 
that the tablets contain only the solely pure drug. This brings us some unique 
advantages include 1) batch to batch difference caused by the excipients can be avoided 
2) reworking and recovery of the drug material is possible when problems occur. 
However, batch to batch difference induced by inconsistencies associated with the drug 
such as polymorph and the water content of the material should always be considered 
and investigated.  
 
The evaluations were conducted in both the 200 and 50 μl chambers at a flow rate of 2 
μL/min. As with the tablets tested before, the 5-FU excipient-free tablets also 
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disappeared overnight. But they exhibited the slowest release rate compared to all the 
previous studied tablets. In the 200 μl chamber, less than 50% of 5-FU was released 
after 8 hours. After 24 hours, the 5-FU concentration in the chamber was still around 1.6 
mg/mL. The release profiles appeared almost as first order. In the 50 μl chamber, it was 
found that the release of 5-FU was significantly accelerated (Figure 2.13.). This is 
because the fresh PBS around the surface of the tablets was replaced more frequently 
when the tablet was placed in a relatively small chamber (Figure 2.11). As a result, the 
boundary layer at the tablet surface becomes thinner in the small chamber due to the 
relatively faster diffusion of the 5-FU solution.  
 
Tablets placed at different positions inside the 200 μl chamber 
Based on results that the tablets dissolved faster when placed in a smaller chamber, it was 
suggested that the direction of the liquid may also have an effect on the tablet release. It 
was therefore considered that the tablet release behavior might change if the tablet is 
placed at different positions in the chamber. Hence, the same 5-FU tablets were evaluated 
again by placing them at different positions in the 200 μl flow chamber (centre, side, near 
the outgoing tube or in going tube, Figure 2.12). The release profiles are shown in Figure 
2.13. However, it is difficult to tell by eyes whether there is any difference between the 
release profiles of the tablets placed in different positions. Hence, a two way 
between-groups analysis of variance was conducted to explore the impact of position 
(centre, side, in going and outgoing Figure 2.13) and time on the levels of drug release. 
Subjects were divided in to 9 groups according to the different time points (Group 1: 1 
hour, Group 2: 2 hours, …, Group 9: 9 hours). The results show that there is a statistically 
significant change with time (F (8, 68) =62.86, P < .0005). Also there was a statistically 
significant main effect for position (F (3, 68) =7.21, P < .0005). But the release profile of 
the group in the center did not differ significantly from the groups on either side or by 
the out-going tube (F (2, 50) =2.52, P = .091). The group by the in-going tube was 
significantly different from all the other three groups. These results indicate that 5-FU is 
released more quickly when the tablet is placed near the in going tube in the chamber. On 
reflection, these results suggest that, when placing the tablet in vivo, a faster drug 
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release of the drug might be achieved if the tablet is placed near the exit of the aqueous 
humor.  
      
Figure 2.11. The same tablet (3 mm diameter, 0.5 mm thickness) placed in 200 μl (a) and 50 μl 
(b) chamber.  
 
Figure 2.12. Illustration of 5-FU tablets placed in different position in the flow chamber. a. near 
the in going tube; b. near the out going tube; c, the side of the chamber; d, the centre of the 
chamber. 
 
Figure 2.13. Release profiles of excipient-free 5-FU tablets at ambient temperature (n=3, error 
bars indicates standard deviation). ◇ Tablets in the 50 µL chamber □ Tablets at the centre 
of the 200 µL chamber △ Tablets placed in the 200 µL chamber close to the in going tube  
Tablets placed in the 200µL chamber close to the out going tube  Tablets at the side of the 
200 µL chamber. Data suggest that 1) the release rate of 5-FU and the 5-FU concentration will 
be increased when the tablet is placed in the 50 µL chamber and 2) in the 200 µL chamber the 
release rate of 5-FU will be higher when the tablet is near the in going tube. 
 
The excipient-free 5-FU tablets released at different temperatures 
As a real bleb in the body is not at ambient temperature, there was a need to find out 
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whether temperature significantly affected tablet release. Hence, tablet release studies 
were conducted again in the 200 μl chamber at 37°C. It was found that the 5-FU release 
rate became double at 37°C than at ambient temperature (Figure 2.14.). This is because 
5-FU dissolved faster when the temperature was increased. However, a saturated 
concentration of 5-FU (11.1 mg/mL) was still not observed even when the release study 
was conducted at a higher temperature. Assuming a complete mix of 5-FU and PBS 
exists in the flow chamber, this suggests that the 5-FU dissolution, not the drug 
solubility, is the rate limiting step for the release of the drug. Hence, the release profiles 
of the 5-FU tablets cannot be calculated directly using its intrinsic solubility.  
 
Figure 2.14. Comparison of 5-FU release profiles at different temperature in 200 μl chamber 
(n=3, error bars indicates standard deviation).  Ambient temperature ○37 °C. Data suggest 
that the release rate of 5-FU and the 5-FU concentration will become significantly higher at 
37 °C than at ambient temperature. 
2.3.8. The biological effect of the excipient-free 5-FU tablets 
Our studies highlight the difficulties in prolonging the release of 5-FU using hydrophilic 
polymers. Although there have been many reports of successful sustained release of 
5-FU for GFS using hydrophobic polymers, side effects caused by the drug carriers 
were frequently reported (Appendix I). An excipient-free 5-FU tablet will not cause 
excipient mediated side effects but the toxicity of the excipient-free 5-FU tablets 
remains unclear.  
 
Khaw et al. found that HTFs were “growth arrested” after 1 day of treatment with high 
concentrations (0.1 and 1 mg/mL) of 5-FU (Khaw et al. 1992;Khaw 1995). When the 
HTFs were constantly treated with 1 mg/mL 5-FU for 3 days, the whole population of 
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the cells died gradually in a 30 day period. However, our results suggest a potential 
different way of the 5-FU treatment. In our in vitro release studies at 37 °C, the 
concentration of 5-FU were determined from the solutions that flushed out of the 
chamber. It was found that the 5-FU concentration increased to 6 mg/mL after 3 hours 
and then decreased gradually to 2.5 and 0 mg/mL at 8 and 24 hours respectively. This 
means an excipient-free 5-FU tablet is different from all the formulations reported in the 
literature because the fibroblasts will be exposed to a range of 5-FU concentrations that 
are all less than 25 mg/mL (0- 6 mg/mL), for a period which is longer than 5 minutes 
but less than 24 hours. Since Khaw et al found that HTFs were still alive after 1 day 
treatment of 1 mg/mL 5-FU, it is possible that HTFs will be alive and “growth arrested” 
after exposure to an excipient-free 5-FU tablet in the flow chamber. Therefore, it would 
be interesting to see how HTFs behave in a flow chamber which mimics the bleb. 
However, growing cells in a flow chamber was not practical for a number of reasons. 
One of the biggest obstacles is the maintaining of the humidified 37 °C CO2 which is 
required for the cell growth. To maximize the possible toxicity of the excipient-free 
5-FU tablets, further biological studies on HTFs were conducted using the peak 
concentration (6 mg/mL) of 5-FU observed in the in vitro release study. Hence, we 
decided to treat the HTFs with 6 mg/mL 5-FU for 8 hours. These biological studies 
were mainly conducted in collaboration with our colleagues (Mr. Daniel Paull). 
2.3.8.1. 5-FU treatment I 
The HTFs were seeded in 6 well plates and then treated with 5-FU for 8 hours. After 
that, the cells were removed from the plate. The number of the live cells was examined 
using Trypan blue (a stain that selectively colors dead cells). Most of the cells were 
found alive after 8 hours of treatment with 6 mg/mL of 5-FU. To examine the 
proliferation of the treated cells, the cells were re-seeded into the 96 well plates. Cell 
viability and proliferation was measured using the MTT assay. Proliferation of HTFs 
was still observed within 24 hours post treatment, but significant differences in cell 
number was found between the control group and treated group after 3 days (Figure 
2.15.). The cell number of the treated group was half that of the control group. This 
indicates that 8 hours treatment with 6 mg/mL of 5-FU will inhibit the proliferation of 
HTFs. 
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Figure 2.15. HTFs viability and proliferation after 8 hours of 5-FU treatment in the 6 well plate. 
* P<0.0001. Data suggest that proliferation of HTFs was still observed within 24 hours post 
treatment but cell number decreased significantly compared to control group. 
 
2.3.8.2. 5-FU treatment II 
To confirm the above findings and to understand whether the 5-FU treatment have 
killed some of the HTFs, we plated the cells in the 96 well plates directly. Cell viability 
and proliferation were measured directly using the MTT assay. It was found that, 
although approximately 25% of HTFs were killed by the 5-FU treatment, cell 
proliferation were still able to occur after 5-FU was removed. Three days post 5-FU 
treatment, the cell number of the treated group was significantly lower than that of the 
control group (Figure 2.16).  
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Figure 2.16. HTFs viability and proliferation before and after 5-FU treatment in the 96 well 
plates. *P<0.0001. Data suggest that proliferation of HTFs was still observed within 24 hours 
post treatment but cell number decreased significantly compared to control group. 
 
2.3.8.3. Cell morphology before and after the 5-FU treatment  
The morphology and proliferation of the HTFs were also observed under a microscope. 
The density of the cells was found reduced slightly after the 8 hour 5-FU treatment 
(Figure 2.17. A & B). Cell proliferation was observed in both control and treated group 
after the 5-FU treatment. But proliferation in the treated group was not as confluent as 
the control group (Figure 2.17. C & D). 
 
The above studies reveals that an 8 hour treatment of high concentrated 5-FU (6 mg/mL) 
is able to inhibit the proliferation of HTFs for at least 3 days. Investigation into its long 
term effect on cell proliferation and inhibitory effect on the collagen gel contraction are 
currently being conducted by our colleagues. Although an 8 hour treatment at a 
concentration of 6 mg/mL does not exactly equal the release of an excipient-free 5-FU 
tablet, the preliminary studies above provided us with some positive indications. They 
suggest that an excipient-free 5-FU tablet is possibly as effective as a 5 minute 
application of 25 mg/mL 5-FU in inhibiting the proliferation of HTFs.  
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▲ Before 5-FU treatment ▲ Immediately after 5-FU treatment 
  
▲ Control group after 3 days ▲ Treated group 3 days after treatment 
Figure 2.17. Morphology of HTFs before and after an 8 hour 5-FU treatment. It suggests that 
the number of the cells decreased slightly after 5-FU treatment. Cell proliferation was observed 
72 hours after 5-FU treatment, but the proliferation in the treated group is not as confluent as 
the control group. 
 
2.3.9. Preliminary characterizations of the 5-FU tablets 
Since our results have shown that the polymers can affect the 5-FU release rate, we then 
investigate the interactions between the drug and polymers. It is hoped that by 
evaluating the tablet physical properties, the release mechanism of the tablet can be 
understood. To study the physical properties of the tablets, one of the most commonly 
used methods is differential scanning calorimetry (DSC). Hence, DSC analysis was 
conducted on the 5-FU PVP, 5-FU HA, and the 5-FU excipient-free tablets.  
5-FU excipient-free tablets 
The analysis was conducted firstly on excipient-free 5-FU tablets to see if there are any 
polymorphic transitions induced by compression. Figure 2.18 shows that 5-FU powder 
has a sharp melting peak with an onset temperature of 283°C. This agrees with the 
C 
A 
D 
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melting point of 5-FU reported in the Merck Index. But the excipient-free 5-FU tablet 
has the same onset temperature of melting with a few melting peaks overlaid. These 
peaks could indicate degradation of 5-FU since the decompositions of 5-FU above 
280 °C have been well confirmed (Liu et al. 2008;Singh et al. 2009). In addition, the 
initial temperature cycling and annealing at 120 °C could have lead to conversion of 
less stable polymorphs back into the most stable polymorph. Although there is only one 
crystal structure of 5-FU reported in the literature (Fallon III 1973;Hulme, Price, & 
Tocher 2005), it is unknown whether these peaks can be attributed to the formation of 
different polymorphs of the 5-FU crystals, since new polymorph of 5-FU have recently 
been predicted by computers using molecular dynamics simulations (Hamad et al. 
2006;Hulme, Price, & Tocher 2005;Karamertzanis et al. 2008). Therefore, to fully 
understand the formation of 5-FU polymorph after compression, our studies are far from 
enough. But we did not continue this investigation because it is unsure whether the 
5-FU tablets will be applied in vivo.  
 
Figure 2.18. DSC curves of the 5-FU powder (solid line) and 5-FU excipient-free tablet (broken 
line) in a nitrogen atmosphere, flow rate 25 mL/min, heating rate 100℃/min. Data indicates 
the degradation of 5-FU at its melting point. 
 
5-FU PVP tablets 
From Figure 2.18 it can be seen that the 5-FU powder purchased from the provider was 
crystallized. Figure 2.19 shows the interactions between 5-FU and PVP. It can be seen 
that freeze dried 5-FU shows two melting peaks (283 and 304 °C). This could be caused 
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by the degradation of 5-FU. When PVP alone was analyzed using the same heating rate, 
a fairly weak glass transition was observed at 167 °C (Figure 2.20 A), which is close to 
the reported Tg of PVP (160 °C) in literature (Turner & Schwartz 1985).  
 
When 5-FU was mixed directly with PVP, both melting of 5-FU (at 283 °C, Figure 2.19) 
and a weak Tg of PVP (at 167 °C, Figure 2.20 B) were observed. However, the freeze 
dried blended 5-FU PVP tablet did not show any melting peak around 283 °C; whilst a 
glass transition and a melting/degradation peak were clearly observed at 152 and 260 °C 
respectively (pointed by red arrows in Figure 2.19). Since the Tg of PVP appears fairly 
weak in our results, it is felt that the Tg of PVP could not be well determined using this 
heating rate. However, the DSC curve of freeze dried 5-FU PVP tablets shows different 
from the direct blended ones. This suggests that 5-FU and PVP might become 
amorphous clusters after lyophilization. Further investigation needs to be conducted.  
But currently this has not been done since we are not planning to use these tablets in 
vivo.  
 
Figure 2.19. DSC curves of 5-FU powder, freeze dried 5-FU, directly blended 5-FU&PVP (1:1)， 
freeze dried PVP, and the 5-FU PVP tablet (freeze dry blended, 1:1) in a nitrogen atmosphere, 
flow rate 25 mL/min, heating rate 100℃/min. Data suggest that 5-FU became amorphous after 
being mixed with PVP by lyophilization. 
Tg at 152 °C 
Melting and degradation at 260°C 
Tg at 160 °C (enlarged below) 
Tg at 160 °C (enlarged below) 
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Figure 2.20 Glass transition of PVP alone (A) and 5-FU PVP directly blended tablets (B). 
 
5-FU HA tablets 
In a manner similar to the 5-FU PVP tablets, the 5-FU HA tablets were also analyzed. 
However, identification of the glass transition of HA was fairly difficult using either 
normal DSC, or the high heating and cooling rate DSC because HA has very high 
molecular weight (Mw > 1,000,000). Some of the curves seem to suggest that HA was 
in semi-crystallized state, but the results were not reproducible. The glass transition of 
solid HA can hardly be found in the literature as most of the thermal analysis was 
conducted on HA hydrogels. The DSC curves of HA show that degradation starts 
around 250 °C. When 5-FU and HA were physically mixed without lyophilization, the 
5-FU melting peak over laid that of the HA degradation (Figure 2.21).  
 
On the DSC curve of freeze dry blended 5-FU and HA (1:1, W/W, ), a small sharp 
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melting peak with an onset temperature of 281 °C was observed, which is similar to 
pure 5-FU (283 °C). This suggests that a small fraction of 5-FU was crystallized after 
lyophilization with HA. The peaks before the 5-FU melting peak could be attributed to 
the glass transition of the amorphous 5-FU HA clusters and degradation of HA. To 
interpret these peaks, further studies need to be conducted. But as with the 
excipient-free 5-FU tablets, it was felt that tablet dissolution would not be significantly 
affected as the 5-FU HA tablets would absorb water immediately after being placed in 
the bleb. This water absorption process actually made the tablet become a HA gel 
containing 5-FU. The release of 5-FU then mainly depends on the diffusion of the 5-FU 
solution within the flow chamber. 
 
Figure 2.21. DSC curves of 5-FU powder, freeze dry blended 5-FU & HA (1:1), directly blended 
5-FU & HA (1:1), and HA in a nitrogen atmosphere, flow rate 25 mL/min, heating rate 500℃
/min. Data suggest that part of 5-FU was in crystal forms after being mixed with HA by 
lyophilization. 
 
The DSC analysis of the 5-FU tablets showed that 1) the 5-FU powder was crystallized 
and 2) that 5-FU tends to become amorphous after being lyophilized with PVP or HA. 
This is one possible explanation for the observed higher release rate seen with the freeze 
dried blended 5–FU PVP tablets compared to the direct blended ones. It also suggests 
that the hydrophilic polymers accelerated 5-FU release by enlarging its surface area and 
enhancing its wettability.  
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2.4. Conclusions 
We have developed an in vitro model with a flow chamber, which can mimic the bleb. 
Also, a punch and die set that can compress small tablets with 3 mm diameter was 
designed and fabricated. From the in vitro experiments conducted using the flow 
chamber, we understand that  
1) Polymers with high viscosity can prolong the residential time of 5-FU, but 
hydrophilic polymers can also accelerate the 5-FU dissolution; 
2) The release rate of 5-FU can be enhanced when the flow rate is increased; 
3) At the same flow rate, the release rate of 5-FU can be enhanced when the volume of 
the flow chamber is decreased; 
4) The release rate of 5-FU can be affected by the position of the tablet. The tablet 
demonstrates the highest release rate when it is near the entrance of the liquid flow; 
5) An excipient-free 5-FU tablet is possibly as effective as a 5 minute application of 25 
mg/mL 5-FU on inhibiting the proliferation of HTFs. 
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3. Chapter III Prolonged release of ilomastat  
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3.1. Introduction  
The excipient-free 5-FU tablets were able to prolong drug release in the flow chamber 
for more than 8 hours at 37 °C. But they had not been studied in vivo, as it had not been 
confirmed whether they are able to inhibit fibroblast proliferation for longer than 
subconjunctival injections. From the preliminary studies on the excipient-free 5-FU 
tablets, we learned that 1) it is possible to make a small tablet without excipients that 
could potentially be placed in the subconjunctival space and 2) the release profiles of an 
excipient-free tablet in a non-sink condition in the bleb are mainly correlated to the 
solubility and dissolution rate of the drug. Since it has been established in pre-clinical 
studies that post-operative subconjunctival injections of ilomastat were more effective 
and less toxic than intraoperative MMC (Wong, Mead, & Khaw 2005), it was thought 
that ilomastat could possibly be fabricated into a tablet which is similar to the 5-FU 
tablet. Since ilomastat is a poorly water-soluble compound, we considered using some 
hydrophobic materials as the tablet excipients. However, the hydrophobic excipients 
used in the literature usually cause unintended inflammatory effects. Since it is possible 
to make an excipient-free 5-FU tablet, before seeking for new excipients it is worth 
trying to compress ilomastat into an excipient-free tablet directly. If an excipient-free 
ilomastat tablet can be fabricated successfully, we then do not need to worry about the 
side effects brought by the excipients. Since the dissolution rate of 5-FU has been found 
to be the rate-limiting step of the release of the drug, it suggests that, when placed under 
the same conditions (50-200 μl volume with liquid turnover at a flow rate of 2 μL/min), 
an ilomastat tablet could provide a longer release than 5-FU because ilomastat has much 
lower aqueous solubility (0.039 mg/mL,(Millipore 2010)) than 5-FU (11.1 mg/mL, 
(Yalkowsky & He 2003)). Therefore, we started to make the excipient-free ilomastat 
tablets.  
3.2. Materials and methods 
3.2.1. Materials 
Ilomastat was supplied by Europa Bioproducts, Cambridgeshire, UK. Acetonitrile 
(ACN) was purchased from Sigma-Aldrich (UK). The Discovery® HS C18 HPLC 
column (15 cm×4.6 mm, 5 μm) was purchased from Sigma-Aldrich (UK). The guard 
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column (C18 4×3.0 mm) was purchased from Phenomenex. 
3.2.2. Preparation of ilomastat tablets 
The ilomastat tablets were made by direct compression using method described in 
2.2.4.3. The weight of the ilomastat tablets was 4.1 mg, 4.8 mg (preliminary in vitro 
study), and 2.1-2.3 mg (in vivo studies). Their thicknesses were 0.54, 0.64, and 0.33 mm 
respectively. 
3.2.3. Evaluation of the release profiles of ilomastat tablets 
The release of ilomastat was evaluated using the method described in 2.2.5. The PBS 
flow rate was set to 2 or 4 µL/min.  
3.2.4. Application of the tablets in vivo 
3.2.4.1. Glaucoma filtration surgery in rabbits 
All experiments conformed to the ARVO Statement for the Use of Animals in 
Ophthalmic and Visual Research (ARVO Animal Policy). To anaesthetize the rabbits, 
Ketamine (50 mg/kg) and Xylazine (10 mg/kg) were given by intramuscular injections. 
Initially, a partial thickness 8-0 silk corneal traction suture (Ethicon) was used at the 12 
o‟clock position to gain access to the superior conjunctiva. A fornix based conjunctival 
flap was then raised and blunt dissection of subconjunctival area was performed. 
Following this, a partial thickness scleral tunnel was created with an MVR blade starting 
2 mm behind the limbus and continuing until the blade was visible in the anterior chamber. 
Then a 22G/25 mm Veflon in a cannula was passed through the scleral tunnel until the 
cannula needle was visible in the clear cornea. During this process the cannula needle 
entered the anterior chamber, was advanced to the mid puppilary area and then withdrawn. 
The cannula was trimmed and bevelled at its scleral end so that it protruded 1 mm from 
the insertion point. The tube was fixed to the scleral surface using a 10-0 nylon suture on 
a B/V 100/4. The conjunctival incision was closed with two interrupted sutures as well as 
with a central mattress type 10-0 nylon suture on a B/V 100/4 needle to form a water-tight 
closure. One drop of Atropine Sulphate 1% (Martindale Pharmaceuticals, Romford, UK) 
and Betnesol N ointment was administrated at the end of the surgery (Wong, Mead, & 
Khaw 2005;Wong, Mead, & Khaw 2003). 
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3.2.4.2. Preliminary in vivo study 
Experimental design 
A random, one block study design was performed, with four rabbits undergoing GFS to 
the left eye. Animals were observed for a period of 30 days. The experiment was 
performed as a randomised, blind, controlled study with masked observers. Each 
observer was used to assess clinical data. 
Animals 
Four female New Zealand White (NZW) Rabbits (Harlan UK Ltd; 2-2.2 kg, 12 - 14 
weeks old) were used. Animals were housed in the BRU Unit of the UCL Institute of 
Ophthalmology and were allowed an acclimatization period of 7 days, as is normally 
required. 
Treatment regimen 
Animals were randomly assigned to two selected groups, as shown in Table 3.1. Rabbits 
underwent GFS (described in section 3.2.4.1) in the left eye, and the right eye was used as 
control. Animals in Group A received an ilomastat excipient-free tablet and Group B an 
ethylcellulose tablet, which is the control. Ethylcellulose is an excipient that does not 
swell or dissolve in aqueous solution and hence we expected the size of the ethylcellulose 
tablet to remain unchanged during the 30-days of the in vivo experiment. This control 
tablet was the same size as the ilomastat tablet in order to establish if the effect of 
ilomastat itself and not just the placement of an external body (tablet) kept the bleb area 
functioning.  
 
The ilomastat and ethylcellulose tablets were placed subconjunctivally just before 
conjunctival closure at the end of GFS. Tablets were placed only in the left eyes (one 
tablet per eye).  
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Table 3.1 Description of the groups for a preliminary in vivo study in which the anti-scarring effect 
of an excipient-free ilomastat tablet was tested. 
Group Treatment 
Tablet 
characteristics 
Left eye Right eye Study end 
A (3 rabbits) 
Ilomastat 
tablets 
Weight: 2.1-2.3 mg 
Diameter: 3 mm 
Thickness: 0.4 mm 
Place one tablet in 
the left eye during 
GFS 
No 
treatment 
Day 30-all rabbit 
eyes to histology 
B (1 rabbit) 
Ethylcellulose 
tablet 
Weight: 1.5 mg 
Diameter: 3mm 
Thickness: 0.4 mm 
 
3.2.4.3. Second in vivo study 
Experimental design 
A randomized, prospective, masked-observer study with 24 female NZW rabbits was 
conducted to evaluate the potential therapeutic effect of these tablets. The 24 rabbits 
were divided into three different treatment groups (8 rabbits in each group) as shown in 
Table 3.2, the ilomastat tablet treatment group, the positive control group treated with 
sponges with 0.2 mg/mL MMC and the negative control group treated with sponges 
with sterile water. Rabbits underwent GFS (described in section 3.2.4.1) in the left eye 
and the right eye was used as control. As in the previous in vivo study, the rabbits (24 
Female NZW Rabbits) were bought from the same provider (Harlan UK Ltd) and were 
of similar size and weight (2-2.2 kg, 12 - 14 weeks old). 
 
Endpoints, clinical examination, measurement of IOP and study termination are 
described in section 3.2.4.4,3.2.4.5, and 3.2.4.6. 
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Table 3.2 Description of the groups for a second (randomized, blind, control) study in vivo 
study in which the anti-scarring effect of ilomastat tablet were tested. 
Group # 
 
Treatment 
Tablet/ sponge 
characteristics 
Left Eye Right Eye Study End 
A 
(8 rabbits) 
Ilomastat tablet Weight: 2.1-2.3 
mg 
Diameter: 3mm 
Thickness: 0.4 mm 
Placement of one pellet in the 
subconjunctival area of the left 
eye at the end of the GFS just 
before conjunctiva closure 
No treatment 
On day 30 all rabbit 
eyes to histology 
B  
(8 rabbits) 
0.2 mg/mL MMC 
sponges for 3 
minutes 
Sponges removed 
after 3 minutes 
Placement of the sponge in the  
subconjunctival area of the the 
left eye d at the end of the GFS 
just before conjunctiva closure 
C  
(8 rabbits) 
Sponges with 
sterile water for 3 
minutes 
Sponges removed 
after 3 minutes 
Placement of the sponge in the  
subconjunctival area of the the 
left eye d at the end of the GFS 
just before conjunctiva closure 
 
Aqueous, vitreous and blood samples 
At the end of the in vivo study and prior to the killing of the rabbits, samples of aqueous 
humor and cardiac blood were taken from each rabbit. Blood was obtained from the 
heart of the rabbits by cardiac puncture. The bloods were placed in lithium heparin 
polypropylene tubes and spun using centrifuge at 4000 rpm for 10 minutes. The plasma 
was collected and was placed in 15 mL polypropylene tubes. The amount of ilomastat 
contained in the samples was determined by HPLC (method described in 3.2.7.1).  
 
3.2.4.4. Endpoints and clinical examination 
Clinical assessments of the following parameters were undertaken every 2-3 days from 
day 0 to day 30: 
 Bleb size (width, height and length) using callipers,  
 Bleb capacity (width × height × length),  
 Bleb vascularity (very hyperaemic = 3, hyperaemic = 2 , normal vascularity = 1, 
avascular = 0) 
 Bleb location (top, nasal, temporal),  
 Anterior chamber inflammation (0 = quiet, 1 = many cells, 2 = fibrin,  
3 = hypopyon), 
 Anterior chamber depth (deep, swallow or flat), 
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 Corneal epitheliopathy (0 = nil,  1 = <25 %,  2 = 50 %,  3 = 75 %, 5 = up to 
100%). 
3.2.4.5. Measurement of IOP 
Measurements of intraocular pressure in both eyes were carried out using a Mentor 
tonopen. IOP was measured after the topical administration of 0.5 % Proxymetacaine 
HCl a local anesthetic. The tonopen was lowered perpendicularly onto the corneal surface 
and a recording made. Five recordings per eye were made per time point and all the 
readings, were documented and the mean calculated. 
3.2.4.6. Termination of the in vivo study 
All animals were sacrificed on day 30 of the experiment. This was carried out using a 
lethal intracardial injection of pentobarbitone (4 mL), administered under general 
anesthetic. 
3.2.5. Thermal and surface analysis of tablets 
3.2.5.1. DSC measurements of ilomastat tablets 
Preparation of the ilomastat tablets 
An ilomastat tablet was placed in the flow chamber with PBS (flow rate 2 μL/min) at 
37 °C. After 48 hours, the tablet was taken out and washed three times with 200 μl 
de-ionized water. The tablet was then dried in a 37 °C oven overnight. The control tablet 
was not incubated in the flow chamber. The tablets were crushed gently using motor and 
pestle before analysis. 
DSC measurements 
Due to the limited amount of samples, DSC measurements of the ilomastat tablets were 
conducted on a high heating and cooling (RHC) DSC (mentioned in 2.2.9) because the 
amount of sample required for RHC DSC is small. The DSC samples were all weighed 
using a METLER TOLEDO XS105 balance (d = 0.01 mg). Samples (approximately 0.1 
mg) were sealed in non-hermetic aluminium pans and heated from 25 to 300 °C at 
500 °C min
−1
 with a nitrogen purge gas. In all the DSC experiments, an empty pan was 
used as a reference and the temperature and enthalpy of the instruments calibrated with 
indium. 
3.2.5.2. Surface analysis of the ilomastat tablets 
All the surface analyses were conducted by Prof. Xinyong Chen, Dr. David Scurr, and 
Chapter III Prolonged release of ilomastat 
89 
 50
 
Prof. Clive Roberts at Laboratory of Biophysics and Surface Analysis, School of 
Pharmacy, The University of Nottingham. 
Preparation of the ilomastat tablets 
 Ilomastat tablets for AFM and nanoLTA 
An ilomastat tablet was placed in the flow chamber with PBS (flow rate 2 μL/min) at 
37 °C. After 24 hours, the tablet was taken out and washed three times with 200 μl 
de-ionized water. Then the tablet was dried in a 37 °C oven overnight. The control tablet 
was not incubated in fluid. 
 Ilomastat tablets for XPS and Tof-SIMS 
An ilomastat tablet was incubated in the 200 μl flow chamber for 9 hours at 37 °C. 
Simulated aqueous fluid (Hanks buffer containing CaCl2, 10% serum and 0.5% NaN3) 
was pumped into the flow chamber at a flow rate of 2 μL/min. The tablets were then 
taken out and washed three times with 200 μl de-ionized water. Then the tablets were 
dried in a 37 °C oven overnight. The control tablet was not incubated in fluid. 
Atomic force microscopy (AFM) and nano-TA localized thermal analysis (nanoLTA) 
Atomic force microscopy (AFM) and Nano local thermal analysis (nanoLTA) were used 
to determine topographic, adhesive, stiffness and thermal changes of the tablet both 
before and after incubation in the flow chamber.  
 
A Veeco MultiMode AFM with a NanoScope V controller in HarmoniX mode using 
HMX probes (k = 4 N/m) was used for AFM imaging. The same MultiMode AFM with 
an Anasys Instruments nano-TA attachment using AN2-200 thermal probes were used 
for nanoLTA. The same probes were used for tapping mode (TM) imaging to identify 
areas with relatively high or low phase contrast and for the nanoLTA measurement after 
area of interest were located.  
XPS and TOF-SIMS analysis 
XPS (X-Ray Photoelectron Spectroscopy) spectra were recorded using a Kratos Axis 
Ultra spectrometer employing a monochromated Al K X-ray source (h = 1486.6 eV), 
hybrid (magnetic / electrostatic) optics, hemispherical analyzer and a multi-channel plate 
and delay line detector (DLD) with a collection angle of 30º and a take off angle of 90º.  
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X-ray gun power was set to 100 W. All spectra were recorded using an aperture slot of 
300  700 microns with a pass energy of 80 eV for survey scans and 20 eV for 
high-resolution core level scans. All XPS spectra were recorded using the Kratos VISION 
II software; data files were translated to VAMAS format and processed using the CASA 
XPS
TM
 software package (Version 2.3.2 and later). During experiments charge 
compensation was used (Kratos AXIS Nova charge neutralization system: a coaxial low 
energy electron source within the field of the magnetic lens)) and samples were earthed 
via the stage using a standard BNC connector. Binding energies were charge corrected by 
setting the C 1s aliphatic carbon signal from adventitious carbon contamination to 285 
eV. 
 
Secondary ion mass spectrometric analysis was carried out using a SIMS IV 
time-of-flight instrument (ION-TOF GmbH., Münster, Germany) equipped with a 
Bismuth liquid metal ion gun and a single-stage reflectron analyser. Typical operating 
conditions utilised a primary ion energy of 25 kV and a pulsed target current of 
approximately 1.0 pA. Low energy electrons (20 eV) were used to compensate for the 
surface charging caused by the positive primary ion beam on insulating surfaces. 
 
3.2.6. Preparation of ocular tissue for ilomastat extraction 
Ocular tissues (cornea, bleb conjunctiva, sclera under the bleb, iris, and vitreous body) 
were dissected from rabbit eyes and soaked in ilomastat solutions (100 μM). The tissues 
were freeze-dried and then digested in Collagenase D (1.0 mL, 2mg/mL) for up to 48 
hours. The liquid was then analyzed for ilomastat concentrations using the HPLC method 
described in 3.2.7.2. The same method was then used to detect levels of Ilomastat 
following the creation of an artificial bleb in an ex-vivo model. A tablet was placed under 
an artificial bleb and a flow (2 µL/min) passed through the subconjunctival space using a 
pump. Eyes were maintained for either 4 or 24 hours before tissue digestion and ilomastat 
detection. 
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3.2.7. HPLC instrumentation and conditions 
The HPLC methods were developed with the guide and discussion with Dr. Hardyal 
Gill at London School of Pharmacy. HPLC analysis was performed on an Agilent 
Technology 1200 series system consisting of a separation module for solvent and 
sample delivery, a UV detector and Chemstation software for data acquisition and 
analysis. The UV wave length was set at 280 nm according to the maximum absorption 
of ilomastat shown on the UV scan. Both C8 and C18 column were tested. It was found 
that the C18 column demonstrated better retention and separation than the other. 
Therefore, a Discovery® HS C18 HPLC column (15cm  4.6mm I. D., 5µm particle 
size) was used with a guard column for compound separation. 
3.2.7.1. HPLC method for in vitro release of ilomastat tablets 
The mobile phase was 20 mM ammonium acetate buffer with 0.1% TEA (pH 5):ACN 
(75:25). Samples were eluted at a flow rate of 1.0 mL/min. The injection volume was 10 
μl. Chromatography was performed at 40°C. The retention time of ilomastat was found 
to be 6.5 minute. 
3.2.7.2. HPLC method for detection of ilomastat in ocular tissues 
The mobile phase was 20mM ammonium acetate buffer with 0.1% TEA (pH 5):ACN 
(75:15). Samples were eluted at a flow rate of 1.2 mL/min. The injection volume was 
100 μl. Chromatography was performed at 40°C. The retention time of ilomastat was 
found to be 25.6 minute. 
 
3.3. Results and discussion 
3.3.1. In vitro release profiles of ilomastat tablets 
Since there is no excipient in the ilomastat tablets, we need to find out whether 
ilomastat can be compressed into tablets that are robust enough for handing and 
transportation. So a number of different pressures (1, 2, 4, 5 bar) were tested during 
tablet compression. It was found that at least 5 bar was required to fabricate an ilomastat 
tablet which can keep its integrity during handling and transportation. According to the 
regulatory in industry, friability of the ilomastat tablets compressed under this pressure 
needs to be investigated. But it was felt that this should be investigated after the efficacy 
and dose of the tablets are confirmed due to the limit availability of ilomastat. Therefore, 
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we needed to decide how much drug the tablet should contain. Previous studies on 5-FU 
showed that a 5 mg excipient-free 5-FU tablet could stay in the flow chamber for 
approximately 8 hours at 37 °C. However, during the release studies on the 5-FU tablets, 
the concentration of the drug was not constant; it changes along with the time as a result 
of the changing of tablet surface area and the presence of aqueous flow. Similarly, the 
concentration of ilomastat is expected to change if a saturation of ilomastat cannot be 
observed. Therefore, the dissolution of a 5 mg ilomastat tablet could not simply be 
predicted using its intrinsic solubility alone because it is unknown whether saturation of 
ilomastat will occur in the flow chamber. To understand the dissolution profiles of the 
ilomastat tablets, we investigated the ilomastat tablets using the same in vitro model that 
was used for the 5-FU tablets. 
 
The release profiles of the ilomastat tablets were evaluated at different flow rate (2 and 
4 μL/min, Figure 3.1.) and at different temperatures (ambient temperature and 37 °C, 
Figure 3.2.) using the flow chambers. It was observed that the tablet kept its integrity 
during the in vitro dissolution experiments. Although the experiments were not repeated 
three times due to the limited availability of ilomastat, Figure 3.1. shows that the 
ilomastat tablets dissolved much slower than 5-FU tablets. After one month at ambient 
temperature, approximately 70% of the ilomastat was released under a flow rate of 4 μl; 
whilst only about 46% of ilomastat was released when the flow rate was 2 μl. During 
this period, the ilomastat concentration was kept at 60-100 μM with the low flow rate (2 
μL/min); but when the flow rate was doubled (4 μL/min) the ilomastat concentration 
dropped below 20 μM after 20 days. This is probably because the surface area of the 
tablet decreased more quickly when the flow rate was increased. Hence, the results 
suggest that the dissolution rate of the ilomastat tablets increased with an increase in the 
flow rate. Meanwhile, the ilomastat concentration seemed to decrease more rapidly with 
an increase in flow rate, which is probably the result of a fast diffusion of the drug 
solution at a high flow rate of the dissolution media. 
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Figure 3.1. Release profile of ilomastat (ILO) tablets in 200 μl chamber in ambient temperature 
at different flow rate.  2μL/min □ 4 μL/min. Data suggest that the release rate of ilomastat 
would be enhanced when the flow rate is increased. 
 
The dissolution of the ilomastat tablet was significantly increased at 37 °C. More than 
40% of the ilomastat was released from the tablet after 2 days at 37 °C compared to less 
than 10% of the ilomastat at ambient temperature (Figure 3.2.). Due to the limited 
availability of ilomastat, evaluation of the ilomastat tablet at 37 °C was conducted for 2 
days only because we wanted to use the remaining tablet for thermal analysis. The 
concentration of ilomastat in the flow chamber reached around 200 μM at 37 °C, which 
is twice as high as the one at ambient temperature. However, this concentration is still 
far below the saturated concentration of ilomastat in pH 7.4 PBS at 37 °C (574.1 μM, Dr. 
Hala Fadda), which again confirmed that the dissolution rate of ilomastat, not the 
solubility, is the rate limiting step for the dissolution of the ilomastat tablet. 
 
Figure 3.2. Comparison of ilomastat (ILO) release profiles in 200 μl chamber at 2 μL/min in 
ambient temperature () and 37 °C (□). Data suggest that the release rate of ilomastat will be 
increased with the increasing of temperature. 
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Unlike the 5-FU tablet which disappeared in the flow chamber after 8 hours, the 
ilomastat tablet still remained in the flow chamber after 48 hours. Although the above 
studies were not done in triplicate due to the limited availability of ilomastat, it still 
suggests that the residence time of an ilomastat tablet is significantly longer than the 
5-FU tablets. This is encouraging because we believed that when the ilomastat tablet is 
placed in the bleb its anti-proliferative effect would possibly last for at least 2 days, 
which is longer than an intraoperatively used sponge or subconjunctival injections. 
However, before the in vivo studies, we needed to find out whether the ilomastat tablet 
is as effective as the ilomastat solution at scar inhibition. To confirm this, we needed to 
ensure that 1) there is no degradation of ilomastat during the tablet incubation period 
and 2) the ilomastat concentration in the flow chamber is in the therapeutic window.  
 
It has been established that ilomastat degrades in aqueous solutions at a ratio of 1% per 
month at 4 °C. At 37 °C, the degradation increases to 1% per day (Millipore 2010). 
Since the tablet will be exposed to an aqueous environment at the body temperature for 
a long period of time, it is possible that ilomastat could start to degrade within the bleb 
before it joins in the blood/lymphatic circulation. Therefore, the degradation of 
ilomastat was investigated using HPLC. To ensure that the degradation product does not 
have the same retention time as ilomastat, fully degraded ilomastat solution was injected 
into the HPLC. No peak could be seen at 6.5 minute (the retention time of ilomastat). 
This suggests that the degradation product will not produce a peak on the HPLC that 
overlays with ilomastat. Hence, we can evaluate the degradation of ilomastat by 
observing the presence of extra peaks on the HPLC chromatograms. When we evaluated 
the ilomastat solution collected from the 37 °C flow chamber at different time point by 
HPLC, no extra peaks were observed in comparison to the ilomastat powder. This 
suggests that the ilomastat released at 37 °C did not degrade in the flow chamber. In the 
in vitro study at ambient temperature, after 30 days the remaining ilomastat tablet was 
dissolved in pH 7.6 PBS and injected into the HPLC. No extra peaks were observed 
either. This suggests that the ilomastat solid which was exposed to moisture for 30 days 
did not degrade. Hence, it was confirmed that no chemical decomposition of ilomastat 
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had occurred in the flow chamber. This provides us with a positive indication that 
ilomastat will probably be stable when the tablet is placed in the bleb. 
3.3.2. Sterilization of the ilomastat tablets 
Before the ilomastat tablets could be implanted in a bleb, they had to be sterilized. Since 
no data has been published on the degradation of ilomastat following sterilization, we 
needed to confirm whether the sterilization process could cause any degradation of 
ilomastat. Following the guidelines of European and the US pharmacopoeias, the 
ilomastat tablets were irradiated by either gamma radiation (28.8 kGys) or electronic 
beams (28.0-29 kGys) and then dissolved in pH 7.6 solutions. The degradation of 
ilomastat was evaluated by injecting the solutions into the HPLC. As shown in Figure 
3.3., a new peak was observed at 7.4 minute on the irradiated ilomastat, which 
represents the degradation products of ilomastat. These peaks account for a 0.55% 
(gamma radiation) and 0.47% (electronic beams) degradation of the ilomastat in the 
tablets respectively, which is less than 1% of degradation after irradiation. These results 
meet the criteria of the American and European Pharmacopoeia (less than 1% 
degradation). 
 
Figure 3.3. HPLC chromatograms of the non-irradiated (blue), gamma radiation (red) and 
electronic beams (green) irradiated ilomastat. The degradation peak appears at 7.4 min. Data 
suggest that gamma or electronic beam radiation can cause a small amount of ilomastat 
degradation. 
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It was then necessary to establish whether a sterilized ilomastat tablet is able to inhibit 
the Human Tenon‟s Fibroblasts (HTF) populated collagen I gel contraction for more 
than 7 days. Thus, the inhibitory contraction of non-irradiated ilomastat and ilomastat 
released from irradiated tablets were compared (by Dr. Stylianos Georgoulas). The 
results showed that the efficacy on HTF gel contraction of the irradiated tablet is similar 
to the non-irradiated ilomastat powder (Figure 3.4., provided by Dr. Stylianos 
Georgoulas), thus confirming that the sterilized ilomastat tablet is as effective as the 
non-irradiated ilomastat. So the in vivo studies of the ilomastat tablets could be 
conducted.  
 Control 
Non- 
irradiated 
ilomastat 
Irradiated 
ilomastat 
Day 2 
   
Day 4 
   
Day 7 
   
Figure 3.4. HTF populated collagen I gels treated with normal media without ilomastat 
(negative control), media in which non-irradiated ilomastat powder was dissolved without 
DMSO (positive control) and media in which irradiated ilomastat tablet was dissolved without 
DMSO. The concentration of ilomastat in the positive control and the media in which the 
ilomastat tablet was dissolved was tested with HPLC and was adjusted to be at the same level 
(65 μΜ). The results indicate that the efficacy on HTF gel contraction of the irradiated tablet is 
similar to the non-irradiated ilomastat powder.  
3.3.3. In vivo release of ilomastat tablets 
3.3.3.1. Preliminary in vivo experiment 
To evaluate the anti-scarring effect of the ilomastat tablet, the tablets needed to be 
placed in the bleb. Since the in vivo studies require filtration surgeries on the rabbit eye, 
the studies was conducted in collaboration with a clinician (Dr. Stylianos Georgoulas). 
All the surgeries were performed by Dr. Georgoulas. A preliminary in vivo experiment 
was conducted on four rabbits. To establish that the formation of the bleb is not a result 
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of spacer effect caused by the tablet, an ethylcellulose tablet which has the same size as 
the ilomastat tablet was designed as a control. Since ethylcellulose is insoluble, inactive 
and does not swell in the bleb, we were able to compare the effect of the ilomastat 
tablets and the inert tablet on the morphology of the bleb. The other three rabbits were 
all treated with the ilomastat tablets (weight approximately 2.3 mg each). Unlike the 
clinically used sponges which are removed after a few minutes, all the tablets were left 
in the subconjunctival space before the closure of the conjunctiva. After the surgery, the 
bleb treated with ethylcellulose tablet failed on day 10 (Figure 3.5); while the ilomastat 
tablet treated blebs were still functional after 30 days (Figure 3.6). These results indicate 
it is the drug (ilomastat) and not the tablet itself that is responsible for scar inhibition in 
the bleb.  
 
Figure 3.5. Appearance of a bleb in which an ethylcellulose tablet has been inserted after 
glaucoma filtration surgery. The bleb failed on day 10. This image shows the conjunctiva 
surrounding the tablet and the tip of the tube, possibly stopping aqueous outflow from the 
tube.   
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Figure 3.6. Appearance after 30 days of the bleb in which an ilomastat tablet was placed after 
glaucoma filtration surgery. The bleb remained elevated and functional throughout the 
experiment and it indicated that the ilomastat tablet may be effective in vivo in the inhibition of 
scarring. 
 
3.3.3.2. Second in vivo study 
Effect of ilomastat tablets on bleb function and morphology 
Having confirmed that the survival of the bleb was not due to the presence of a tablet 
but due to the anti-scarring effect of ilomastat, a second in vivo study was conducted to 
further investigate the anti-scarring effect of the ilomastat tablet. In this study, the 
ilomastat tablets were compared with both negative (water sponge for 3 minutes) and 
positive (MMC 0.2 mg/mL sponge for 3 minute) controls. It was observed that blebs 
treated with the ilomastat tablets (Figure 3.9) appeared larger than the MMC treated 
blebs (Figure 3.8). In addition, all the ilomastat tablet treated blebs remained functional 
for 30 days. The bleb survival curve is shown in Figure 3.10. It indicates that the scar 
inhibition effect of ilomastat tablets was significantly better than the MMC treatment 
currently used in the clinic.  
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Figure 3.7. Representative failed bleb from the water sponge negative control group. The bleb 
is shown to be flat and to block the tip of the tube due to the development of scarring, possibly 
inhibiting the aqueous outflow through the tube. 
 
 
Figure 3.8. Representative functional bleb from the positive control group (MMC 0.2 mg/mL) 
sponge for 3 minutes). Two out of eight blebs treated with MMC remained functional 
throughout the experiment. 
Chapter III Prolonged release of ilomastat 
100 
 50
 
 
Figure 3.9. Representative functional bleb from the ilomastat tablet group. The bleb area of all 
rabbits treated with the ilomastat tablet remained functional and significantly elevated 
throughout the experiment. This outcome was significantly superior not only compared to the 
negative control (water sponge) but also compared to the positive control (MMC). 
 
Figure 3.10. Bleb survival in the ilomastat tablet group was found to be significantly superior to 
the sterile water group (P<0.001) and the MMC group (P<0.01) (n=8) (Georgoulas S.D. et al. 
2008). 
 
Effect of ilomastat tablets on intraocular pressure (IOP) 
As IOP is one of the most important indexes in halting the progression of glaucoma, the 
effect of ilomastat tablets on the IOP was also evaluated (Figure 3.11). A normal IOP 
was observed in all the rabbit eyes treated with the ilomastat tablets. The mean IOP of 
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the ilomastat treated eyes was found to be significantly lower than the negative control 
group on day 7, 16, 20, 23 and 27. In comparison with the positive control group, the 
IOP was significantly lower on days 20 and 23. No hypotony was observed in the 
ilomastat tablet treated eyes. In contrast, hypotony was observed in MMC treatment 
group on day 3.   
 
Figure 3.11. Ilomastat tablet significantly reduced IOP compared to positive and negative 
controls (Georgoulas S.D. et al. 2008). 
 
The IOP was measured with a Mentor tonopen. The tonopen is based on the principle 
that the IOP can be gauged by the pressure necessary to flatten the central area of the 
cornea. The accuracy of the IOP based on this principle is influenced by corneal 
biochemical properties such as its thickness and rigidity. Hence, as shown in Figure 3.11, 
fluctuation of the measurements does occur because 1) there is variation in individual 
rabbit corneas, and 2) the outflow of aqueous humor, which is directly associated with 
the IOP, is affected by the varying bleb dimensions as well as the level of scarring in the 
subconjunctival space. Newer tonometry devices, including the dynamic contour 
tonometry and the Ocular Response Analyzer®, which take into account the 
biomechanical properties of the cornea, have been designed to measure the IOP more 
consistently (Stamper 2011). However, a Mentor tonopen was the best technique we had 
when the animal studies were conducted. Nonetheless, this technique has been proven 
to be useful in both animal and human being studies, and has been clinically validated 
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(Mollan et al. 2008;Rahman, Cannon, & Sadiq 2010). 
Detection of ilomastat in the aqueous humor, vitreous body and blood serum of the 
rabbits treated with the ilomastat tablet 
Since ilomastat may cause adverse effects (musculoskeletal syndrome) when 
administrated systemically at a dose of 50-100 mg/kg body weight (Dormn et al. 
2010;Fingleton 2007;Li et al. 2002;Millipore 2010), it is important to examine its local 
and systemic toxicity. Using the HPLC method described in 3.2.7.1, no ilomastat was 
detected in the blood serum or the aqueous humor that was obtained at day 30 from the 
rabbit eyes treated with the ilomastat tablets. However, since the sensitivity of this 
method is low (approximately 5 μM, see the calibration curve in Table 3.3), it is 
possible that ilomastat exists in the blood at a concentration lower than 5 μM. As the 
typical dose of ilomastat in animals is 50-100 mg/kg body weight (Millipore 2010), it is 
believed that the systemic toxicity of the ilomastat tablet is fairly low because our tablet 
contains less than 5 mg of ilomastat. 
Table 3.3 Calibration curve of ilomastat using the HPLC method described in 3.2.7.1 (n=3, 
R2=0.9999). Data indicates that the lowest ilomastat concentration that can be detected using 
this HPLC method is approximately 3-5 μM. 
Concentration (μM) Average Peak Area 
250 712.8±1.17 
100 281.5±0.52 
125 357.4±0.21 
62.5 178±0.26 
50 143.7±0.40 
31.25 87.87±0.2 
12.5 35.4±0.1 
6.25 21.7±0.06 
3.125 8.533±0.12 
3.3.4. Thermal and surface analysis of ilomastat tablets 
3.3.4.1. Thermal analysis of tablets 
Since the ilomastat tablets will stay in the bleb for days, the tablets were immersed in 
35 °C aqueous humor for a long time. As the physical properties of ilomastat have not 
been studied before, the morphology of ilomastat is unknown. It is also unknown 
whether its morphology will change on long exposure to aqueous humor. Change in 
drug morphology (such as crystal forms) may affect tablet release profiles. Therefore, it 
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is necessary to determine the physical properties of the tablets. Due to the limited 
availability of ilomastat, we only evaluated two tablets use high heating and cooling rate 
DSC. One was the control tablet; and the other the tablet that was in the flow chamber 
for 48 hours. 
 
Figure 3.12 shows the DSC curves of the ilomastat tablet before and after being 
incubated in pH 7.6 PBS for 48 hours. In this figure, ilomastat demonstrates crystalline 
form with no detectable amorphous content. However, the initial temperature cycling 
and annealing at 120 °C could have lead to conversion of less stable polymorphs back 
into the most stable polymorph. Therefore, further investigation was conducted by our 
colleague (Dr. Hala Fada) using thermal activity monitor. It was later confirmed that 
there is no quantifiable amorphous content in the ilomastat tablet (data not shown). The 
tablets demonstrated a similar melting with an onset temperature of 217.7 °C (before) 
and 216.5 °C (after) respectively. The melting peak is not a sharp single peak, which 
suggests that the overlaying peaks could come from the degradation of ilomastat. It is 
known that using high heating rate in DSC experiments can improve the detection 
sensitivity of different transitions; but the peaks could still not be resolved at a high 
heating rate (500 °C/min). The color change of the material at the end of the DSC 
experiments confirmed the degradation of ilomastat while melting. An endothermic 
peak with a low heat capacity change was observed around 130 °C in both tablets. This 
peak was reversible (existed in the same position on repeated heating and cooling). The 
evidence suggests it is an enantiotropic solid-solid transition, which was further 
confirmed by performing X-ray on an ilomastat tablet heated to 150 °C (data not shown, 
experiments conducted by Dr. Hala Fadda).  
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Figure 3.12. DSC curves of the excipient-free ilomastat tablets before (solid line) and after 
(broken line) aqueous incubation. The DSC experiments were conducted in a nitrogen 
atmosphere, flow rate 25 mL/min, heating rate 500℃/min. Data suggest possible formation of 
ilomastat polymorphs after tablet incubation. 
 
Therefore, further investigations were conducted by our colleague (Dr. Hala Fadda). It 
was found that different batches of ilomastat from the same supplier demonstrated 
different crystal forms on an X-ray powder diffractogram (Figure 3.13). The moisture 
uptake of the ilomastat tablets was investigated by dynamic vapour sorption (DVS). The 
results show that the moisture uptake of the ilomastat tablets was 4.7% at 90% relative 
humidity (RH), but all moisture absorbed was displaced at 0% RH (Figure 3.14). The 
X-ray showed changes in the crystal habit of ilomastat on immediate exposure to a 
moist environment (Figure 3.15). This can have implications on the solubility and 
dissolution of the drug. However since these changes arise immediately on wetting, the 
dissolution characteristics of the tablet will not change during the course of incubation 
in the bleb (Fadda et al. 2010). 
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Figure 3.13. X-ray powder diffractogram of ilomastat tablets prepared from different batches 
obtained from the same supplier (Fadda et al. 2010). Data suggest existence of new ilomastat 
polymorphs from different batches of ilomastat provided by the same supplier.  
 
Figure 3.14. Water uptake of the ilomastat tablet as studied by dynamic vapour sorption 
(Fadda et al. 2010). Data suggest that the moisture uptake of the ilomastat tablets was 4.7% at 
90% relative humidity (RH), but all moisture absorbed was displaced at 0% RH. 
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Figure 3.15. X-ray powder diffractogram illustrating changes in the crystal form of ilomastat on 
exposure to high humidity levels. (Arrows indicate where the changes are observed) (Fadda et 
al. 2010). 
  
3.3.4.2. Atomic force microscopy (AFM) and nano-TA localized thermal 
analysis (nanoLTA) of ilomastat tablets  
Although it has been established that changes in the physical properties of the ilomastat 
tablets did not significantly affect the in vitro tablet releases profiles, it is still unknown 
whether the in vivo environment will affect the release and efficacy of the tablets. One 
of the probable responses from the in vivo conditions is the encapsulation of the tablet, 
which has been described in the literature (Chapter 1). In our second in vivo study, the 
tablets could still be observed on day 30 after surgery; but it was unknown whether the 
tablets were encapsulated. The encapsulation of the ilomastat tablet in a functional bleb 
was later found in another in vivo study. The remaining tablet was removed from the 
bleb and dissolved (Figure 3.16). The amount of ilomastat left in the tablet was 
determined by HPLC.The results showed that 57.7% ilomastat had dissolved in the bleb 
over 30 days, which suggests that tablet dissolution in the bleb is slower than in the flow 
chamber. This indicates that, once encapsulated, tablet dissolution slows down. But this 
does not mean the tablet will not completely dissolve. Another in vivo study was 
conducted with excipient-free lenalidomide tablets which have a similar size to the 
ilomastat tablets (by Dr. Ashkan Khalili). These tablets were found to dissolve in the 
bleb within 3 weeks. To fully understand the dissolution of the ilomastat tablet, we need 
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to understand the encapsulation. Although clinically the small ilomastat tablet 
encapsulation is less disruptive than the usual fibrosis or the fibrosis around an implant, 
but it is not known when the encapsulation started. It is also unclear whether the 
formation of the capsule will slow down or stopped the release of ilomastat. We 
therefore do want to ensure that the tablet will be resorbed completely. 
 
Figure 3.16. An ilomastat tablet was encapsulated on day 30 after implantation (image 
provided by Dr. Sumit Dhingra). 
 
It has been established that the encapsulation is caused by foreign body reactions (FBR), 
which are the end stage response of the inflammatory and wound healing responses 
following implantation (Anderson, Rodriguez, & Chang 2008). The FBR is carried out 
by macrophages and foreign body giant cells. It is believed that the biomaterial surface 
plays an important role in modulating the BFR in the early stages of implantation 
(Anderson, Rodriguez, & Chang 2008). Protein adsorption is considered to be one of 
the key events in FBR because the types, levels, and surfaced conformations of the 
adsorbed proteins are critical determinants of tissue reactions to the implants (Wilson et 
al. 2005). Since it has been described that implants are covered (Wilson et al. 2005), the 
ilomastat tablet was supposed to be covered by similar materials due to the trauma of 
the surgery. However, as the tablet was placed in an environment with aqueous turnover 
which can cause the displacement of the cells and proteins, investigation of the surface 
of the remaining tablet will provide us some information on the initial signals of 
encapsulation. But our previous studies using the flow chamber could not predict the 
formation of capsule as all the studies were conducted using PBS with the absence of all 
the other substances (e.g. fibroblasts, proteins and amino acids (Table 1.2)) existing in 
aqueous humor. Therefore, we incubated the ilomastat tablets at 37 °C with simulated 
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aqueous fluid (see 3.2.5.2) being pumped into the chamber at a flow rate of 2 μL/min. It 
is hoped that during this incubation the deposition of proteins and salts on the surface of 
the ilomastat tablets will simulate the in vivo conditions. The effect of the simulated 
aqueous fluid on the surface physical properties of the tablets will then be determined. 
 
Atomic force microscopy (AFM), which is also called scanning force microscopy, is 
one of the most advanced tools for imaging, measuring, and manipulating materials 
(Giessibl 2003). Its resolution is demonstrated on nano scale, which is more than 1000 
times better than the optical diffraction limit. AFM is able to “feel” the specimen 
surface with a mechanical probe, which is a conducting cantilever with a sharp tip 
(Giessibl 2003). Information about the material surface is gathered from the forces 
between the tip and the sample. The forces measured could be mechanical contact 
forces, van der Waals forces, chemical bonding, and electronic forces etc. Depending on 
the application, different modes can be operated in an AFM, including static (contact) 
modes and dynamic (non-contact) modes. In the static mode operation, the feedback 
signal comes from the static tip deflection; whist in the dynamic mode, the cantilever is 
externally oscillated (Garcia & Perez 2002).  
 
When an AFM is attached to a thermal probe, it is able to perform local thermal analysis 
on the material surface on a nano scale, which is called nano localized thermal analysis 
(nanoLTA). In pharmaceutical science, AFM and nanoLTA are used in the investigation 
of drug crystal growth, particle characterization, and tablet granules/ coatings in solid 
dosageforms. It is hoped that this technique will be able to help us to observe the 
surface of the ilomastat tablets and to investigate the change in the surface physical 
properties of tablets after being in contact with the aqueous fluid. Of interest is the 
accumulation of both salt and protein on the surface of the tablet following incubation 
with simulated aqueous fluid. Ultimately we aim to understand the deposition behaviour 
of proteins in an effort to understand how the tablets may interact with tissue and cells 
in vivo.  
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Optical microscope images 
The ilomastat tablets‟ surface was observed firstly by the AFM. Optical microscope 
images were captured using the basic CCD camera attached to the AFM. In all the 
images, the AFM cantilever might not be properly focused as the samples need to be 
focused on. A relatively “clean” surface was observed for the control ilomastat tablet 
which had not been in the flow chamber (Figure 3.17 A). The observed parallel lines are 
probably caused by the compression punch. These lines were not observed on the 
incubated ilomastat tablet (Figure 3.17 B). This change is caused by the dissolution of 
the ilomastat on the tablet surface.  
 
 
Figure 3.17. AFM optical images of the ilomastat tablets before (A) and after (B) being in the 
flow chamber. The control tablet appears more “clean” than the incubated tablet.  
 
Other surface quantitative “images” 
HarmoniX is a new AFM mode that provides true nanoscale quantitative material 
property mapping of adhesion, stiffness, dissipation, peak force, and average force for a 
wide range of materials. Unlike the previous AFM techniques, HarmoniX is able to 
acquire both the high-resolution imaging and high-resolution, quantitative material 
property maps simultaneously (Veeco 2010). In HarmoniX AFM, as well as Height and 
Phase images as in normal tapping mode, a number of quantitative “images” relating to 
surface mechanical properties or tip-sample interactions, such as surface Young‟s 
Modulus (stiffness), peak force, average force, adhesion, energy dissipation, can be 
simultaneously obtained. For clarification, only the most representative adhesion and 
stiffness images are presented together with the corresponding height and phase images 
A
 
 A 
B 
Chapter III Prolonged release of ilomastat 
110 
 50
 
in Figure 3.18. More adhesion is observed in the control tablet (22 nN) as compared to 
the incubated tablet (5.3 nN) both of which are highlighted with a red square. The surface 
of the control tablet shows greater stiffness, 6 GPa as opposed to 0.8 Gpa. Surface 
component-related phase separation was obviously observed in the incubated ilomastat 
tablet. The “adhesion” image shows that the surface areas showing “brighter” phase data 
possess higher adhesion to the silicon based AFM tip. These surface areas are also 
slightly “harder” than the other areas, as shown in the corresponding “stiffness” image. 
 
In the HarmoniX images of the control tablet shown in Figure 3.18, the contrast in the 
phase, adhesion, and stiffness images are just topography-related artefacts. „True‟ phase 
contrast was clearly observed in another tapping mode image (Figure 3.19). This may 
indicate a fairly inhomogeneous surface.
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Figure 3.19. Tapping mode AFM images of the control ilomastat tablet. This indicates an 
inhomogeneous surface on the control tablet. 
 
nanoLTA results 
NanoLTA results of the ilomastat tablets are shown in Figure 3.20. For both ilomastat 
tablets (before and after being incubated), a sharp dropping down consistent with a 
melting event was observed in the ranges of about 150-190 °C and 130-160 °C, 
respectively. Since the nano-TA thermal probe can perform normal tapping mode AFM 
imaging, it was used to investigate if there was any difference in the observed thermal 
transition temperature (Tx) between the surface areas with bright and dark phases (the 
phase images obtained by the nano-TA probe are not shown, but they are very similar to 
those shown in Figure 3.20). There seemed to be no significant correlation with the 
phase difference compared with the relatively large variation of Tx itself from repeated 
nanoLTA measurements.  
 
It was observed during tapping mode that imaging of the nano-TA measurements made in 
the high-phase areas was usually unstable. Once the scan size of the tapping mode 
imaging was reduced and limited to the high-phase area, the phase signal usually shifted 
down very quickly. Therefore, special attention was paid to avoid excessive heavy 
tapping (and hence applied force) on the high-phase areas before the nanoLTA was 
conducted. This quick change in the high-phase areas during tapping imaging may mainly 
result from 1) a change in the tip status because of adsorption of material from the surface 
or 2) that the material with the high-phase feature may be a loosely attached thin layer, 
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which was swept off by the nano-TA probe during TM imaging. If the latter reason is true, 
it may explain why the high-phase area has the similar Tx to the low-phase area. 
 
 
 
 
Figure 3.20. The effect of incubation on the thermal properties of the tablets using NanoLTA 
(localized thermal analysis) measurements with AFM. Differences in the transition 
temperature (Tx) were determined. The lower Tx observed following incubation suggests a 
softening of the tablets. The complexity of melting curve with the incubated tablet may be as a 
result of deposition of salts on the tablet surface. 
 
Difference in the mechanical properties and Tx were observed for both ilomastat tablets, 
in addition to differences in their optical image. This indicates that they are different 
materials, at least in terms of their surfaces. This may correlate with changes in the 
crystal form of ilomastat after exposure to high humidity levels (Figure 3.15). The 
surface of the control tablet is generally harder, more adhesive (to the silicon tip) and 
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has a higher Tx. 
3.3.4.3. XPS and TOF-SIMS (time-of-flight secondary ion mass spectrometry) 
of ilomastat tablet (ions mapping) 
In addition to AFM, X-ray photoelectron spectroscopy (XPS) and time of flight 
secondary ion mass spectrometry (Tof-SIMS) are other surface analysis techniques that 
can be used to analyze the surface chemistry of a material. XPS quantitatively measures 
the elemental composition, empirical formula, chemical state and electronic state within 
a material. Tof-SIMS provides information about the chemical structure, including 
elements, functional groups, polymer constitutes, molecules, with very high sensitivity. 
It is hoped that these techniques will help us to further investigate the differences 
between the ilomastat tablet before and after being incubated in a simulated aqueous 
fluid. Specifically, the presence of proteins, which are associated with the possibility of 
capsule formation, can be identified by sulphur. 
 
Atomic composition of the ilomastat tablet surface (Ca. 8 nm) 
Surface analysis using X-ray photoelectron spectroscopy (XPS) reveals an accumulation 
of sodium, sulphur and increased composition of calcium on the tablet surface (Table 
3.4). Figure 3.21 shows the distribution of the different positive ions deposited on the 
tablet surface. It was found that the ion intensities of Na
+
, K
+
, and CHS
+
 on the tablet 
surface increased 3.7, 1.3, and 4.1 times after incubation. This data in combination with 
Table 3.4 suggests that the accumulation of both salts (e.g. sodium and calcium) and 
protein (sulphur) within 8 nm of the tablet surface.  
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Table 3.4. Atomic composition (%) of ilomastat tablets surface before and after incubation in a 
simulated aqueous fluid. Data suggest the significant increasing of Na+, K+, and CHS+ on the 
tablet surface after incubation.  
Element Control ilomastat tablet Incubated tablet 
Chlorine 2p 0.28 0.53 
Carbon 1s 74.06 71.09 
Nitrogen 1s 12.9 13.28 
Oxygen 1s 12.19 14.63 
Sodium 1s 0.00 0.09 
Calcium 2p 0.01 0.04 
Sulphur 2p 0.00 0.12 
Silicon 2p 0.55 0.23 
 
 
Figure 3.21. Distribution of different positive ions on the tablet surface. Data shows an 
accumulation of sodium (Na+) potassium (K+) and sulphur (CHS+) on the tablet surface 
following incubation in the rig with simulated aqueous fluid (9 hours). This in turn suggests 
the accumulation of both protein and salts on tablet surface. Ion intensities (TC) are given in 
the bottom. Higher values depict higher intensities. This data complement the XPS data shown 
in Table 3.4. 
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Figure 3.22. Distribution of ions associated with amino acids on the surface of the tablets. The 
normalized intensities (TC) suggest an increase in the deposition of all ions with the exception 
of C8H7N+ which is believed to be a fragment of ilomastat.  
 
Figure 3.22 shows the distribution of ions associated with amino acids (including 
isoleucine, phenylalanine, proline, arginine, and histidine) on the surface of the tablets 
(Wagner et al. 2002;Wald et al. 2010). An increase in the deposition of all ions with the 
exception of C8H7N
+
 (a fragment of ilomastat) was observed. This data in combination 
with the ToF-SIMS and XPS data suggest that, even with a liquid turnover, the ilomastat 
tablets accumulate protein on their surface following incubation with serum containing 
proteins. This will have implications for the release rate of ilomastat from tissue tablets 
that will come into contact with proteins. More importantly, this indicates that capsule 
formation is possible within the bleb. 
 
3.3.5. Determination of the accumulation of ilomastat in rabbit ocular tissue 
Previous studies have demonstrated that using HPLC, ilomastat with a concentration that 
is higher than 5 μM could not be found in blood serum or the aqueous humor of the 
rabbits after 30 days of exposure to an ilomastat tablet (Georgoulas 2010). However, as 
the ilomastat tablet will be placed in the subconjunctival space, accumulation of 
ilomastat in ocular tissue is possible. It has been reported in literature that drugs 
delivered locally can accumulate within tissues close to the site of delivery (Wang et al. 
1996). Since the toxicity of ilomastat with regards to ocular tissue remains unclear, 
understanding both the tissue distribution and accumulation of ilomastat within the eye 
will provide us valuable information for future toxicity studies.  
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Most studies analyzing the bio-distribution of drugs commonly involve the use of one of 
two markers either: (1) use of a fluorescent probe or (2) radiolabelling. In devising a 
method for the analysis of the bio-distribution of ilomastat in ocular tissues, both methods 
were fully investigated. 
 
Use of a Fluorescent Probe 
Ilomastat itself does not have any absorption on fluorescence spectroscopy. As 
previously documented, ilomastat is a relatively small molecule with a molecular weight 
of 388.5 g/mol. A number of commercially available fluorophores were investigated for 
conjugation with ilomastat, but even the smallest of the probes available (members of the 
Couramin family) had molecular weight of around 300. Using a probe of this size would 
almost double the size of ilomastat and likely impact the function of the drug. 
 
Much smaller in size than the types of fluorophore previously discussed, quantum dots 
(QDs) are rapidly becoming a favored tool for both in vitro and in vivo imaging of cellular 
targets, cells themselves and drugs (Gao et al. 2005;Hild, Breunig, & Goepferich 
2008;Orlov et al. 2008;Smith et al. 2008). The use of fluorophore and QDs with drug 
molecules (particularly protein antibodies) is becoming widespread (Agarwal et al. 
2008;Frasco & Chaniotakis 2010;Furrer & Gurny 2010;Lu 2010). However, conjugation 
of either fluorophore or QD to a small molecule without affecting its efficacy is still an 
obstacle that needs to be overcome.  
 
Use of Radiolabelling 
Radiolabelling has long been used to determine drug distribution in vivo, particularly in 
ocular tissues as well as drugs currently used during GFS (Jarus et al. 1985;Rootman, 
Ostry, & Gudauskas 1984). To radiolabel a drug, two options are available: either creation 
of the drug using a radiolabelled molecule (such as carbon-14) or the substitution of a 
radiolabelled molecule (such as tritium) to modify a pre-existing compound. The 
development of a radiolabelled compound from the start using a radiolabelled molecule is 
very expensive and often prohibitive to many investigators. We therefore set out to 
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develop a method using HPLC to determine the distribution of ilomastat in ocular tissues.  
 
Using HPLC for drug detection in ocular samples is not a novel concept, but previous 
studies have focused primarily on fluid samples such as the aqueous humor and blood 
serum, although some studies have looked at ocular tissues (Hollo et al. 2006). We sought 
a method that 1) would provide a high sensitivity for ilomastat detection 2) would not 
compromise the integrity of ilomastat, and 3) is reproducible. 
 
Increasing the Sensitivity of HPLC 
Using the previously described HPLC method for ilomastat (see 3.2.7.1) may not be 
sensitive enough for the purpose of drug detection in tissue. Therefore, we tried to 
improve the sensitivity of the HPLC method, which means the lowest ilomastat 
concentration which can be detected using HPLC. Firstly, the injection volume was 
increased from 10 µL to 100 µL so that the amount of ilomastat in one injection could 
be increased. Following this change in injection volume, the flow rate was increased to 
1.2 mL/min to minimize any broadening of the peak that would occur had the initial 
flow rate been used. Following these small, yet important changes, the sensitivity of 
ilomastat detection using HPLC was increased from 5 µM (Table 3.3) to 100 nM (Table 
3.5). 
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Table 3.5. Calibration curve of ilomastat using the HPLC method described in 3.2.7.2 
(R2=0.9999). Data suggest that the sensitivity of this HPLC method is approximately 100 nM. 
Concentration (nM) Average Peak Area 
100000 2757 
50000 1375 
25000 681.2 
12500 338.7 
6250 163.4 
3125 80.83 
1562.5 39.83 
781.25 18.57 
390.625 10.07 
195.3125 3.9 
97.65625 2.7 
 
Tissue digestion 
To determine the ilomastat tissue concentration using a HPLC method, several 
confirmatory conditions during the digestion step were required. Firstly the ocular tissue 
had to be well digested, with all tissue (including fibrous regions) digested as fully as 
possible. Secondly, it needed to be confirmed that the digestion reagents did not cause a 
decomposition of ilomastat. Thirdly, it needed to be confirmed that the digestion reagents 
(including the tissue itself and digestion reagents) did not lead to the creation of peaks 
that overlay with ilomastat on the HPLC curve. This would be confirmed by HPLC (data 
shown below). 
 
During method development several chemicals and enzymes were tried at different 
temperatures. Mechanical methods were also examined. A summary of those used are 
presented below in Table 3.6. Although some of the methods, including Trizol and 
proteinase K, provided good homogenization of the tissue, the reagents led to the 
decomposition of ilomastat. The only method which provided both good tissue 
digestions without destroying ilomastat was through the use of collagenase D. 
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Table 3.6 The methods used to digest the ocular tissues. It suggests that the only method which 
provided good tissue digestions without interfering with ilomastat was through the use of 
collagenase D. 
Mechanism of 
Homogenization 
Extra Products 
Used 
Positive Results Negative results 
Acid/Base 
  
Degradation of ilomastat 
Laemelli Buffer 
 
Relatively Inexpensive 
Little to no degradation 
without some mechanical 
input 
Mortar and Pestle 
Homogenize 
directly 
 
 
 
Inconsistent 
homogenization 
Loss of Sample 
Laemelli Buffer 
Liquid Nitrogen 
Homogenizer 
Various sized 
probes  
Loss of tissue in the probe 
With Laemelli 
Buffer  
Poor homogenization in 
Laemelli Buffer 
With TRIZOL 
Good homogenization in 
Trizol 
Degradation of ilomastat 
due to TRIZOL 
Centrifuge Beads 
Various speeds in 
PBS 
Rapid Tissue degradation Sclera not homogenized 
Various speeds in 
Laemelli Buffer 
Rapid Tissue degradation Sclera not homogenized 
TRIZOL 
 
Excellent tissue degradation, 
particularly with mechanical 
input 
Degradation of ilomastat 
Proteinase K 
56 
o
C 
Excellent tissue degradation 
after 24 hours 
Degradation of ilomastat 
37 
o
C, 300 RPM 
 
Poor tissue degradation 
after 48 hours 
Collagenase D 37 
o
C, 300 RPM 
Excellent tissue digestion 
after max. 48 hours  
 
 
 
 
Internal standard 
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During the extraction process, an internal standard, that is similar to the standard analyte, 
is normally used to correct the loss of the analyte during sample preparation prior to 
detection. An internal standard must have several properties similar to that of the target 
analyte including its molecular weight and structure. A number of databases were 
searched to find a compound that would act as an internal standard for ilomastat, 
including PubChem, ChemSpider and SciFinder. It was found that Leu-Trp 
(Sigma-Aldrich, UK) was the only commercially available compound that had a similar 
molecular weight and structure to that of ilomastat (Figure 3.23.). The solubility of 
Leu-Trp was unknown. Leu-Trp was later found to be soluble not in water or the HPLC 
mobile phase but in DMSO. Using DMSO to dissolve Leu-Trp and then mixing it with 
ilomastat, it was found that the ilomastat peak overlaid with one of the impurities in 
Leu-Trp when a gradient elution was used (Figure 3.24.). Alternative gradient methods 
were tried but the peaks could not be separated. The overlaying peaks were not observed 
when an isocratic flow (3.2.7.2) was used (Figure 3.25.). 
 
 
NH
H
N
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Figure 3.23. Chemical structure of LEU-TRP (a) and ilomastat (b). 
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Figure 3.24. One of the impurities of Leu-Trp overlays with ilomastat peak when using a 
gradient method. 
 
Figure 3.25. HPLC chromatograms of the ilomastat (blue) and ilomastat solution containing 
LEU-TRP (red) using the isocratic method. It can be seen that ilomastat peak is separated from 
the from the Leu-Trp impurity. 
 
3.3.5.1. Tissue soaked in ilomastat solution 
Following on the initial experiments that confirmed that Leu-Trp did not overlay with 
ilomastat on the HPLC chromatograms, we next set out to determine if ilomastat could be 
detected in tissue. Before conducting any in vivo studies, we firstly examined whether 
the accumulation of ilomastat can occur in dissected ocular tissue. Using rabbit eyes 
obtained from an abattoir (Woldsway Farm), the eyes were dissected and different 
Leu-Trp 
Ilomastat
mastat 
Leu-Trp 
Ilomastat
mastat 
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sections of ocular the tissues (cornea, conjunctiva, sclera, muscles, iris, and vitreous 
body) obtained. The tissues were weighed and placed and incubated in a 100 µM 
ilomastat solution (ilomastat dissolved in DMEM 1X (Invitrogen, UK)) overnight at 
room temperature. After 24 hours of soaking, each piece of the tissues was washed 
briefly using 1 mL 1X PBS (Invitrogen, UK) in an eppendorf tube. Tissues were then 
placed in 15 mL falcon tubes (Fisher, UK) followed by the addition of 1ml of 
Collagenase D (2 mg/mL in PBS containing MgCl2) (Roche, UK). The tubes were then 
placed in a 37 °C shaking incubator, shaking at 300 RPM. Samples were checked every 
6-12 hours and after 48 hours digestion of all tissues was complete. Samples were passed 
through a 29 gauge needle following digestion to further disrupt any small fragments. 
 
The samples were then centrifuged at 13000 RPM for 5 minutes and the supernatant 
passed through a 0.22 (or 0.45) µM filter before being run on the HPLC. It was found that 
ilomastat could be detected in most of the tissues with the exception of the lens, and that 
no overlay peaks from the tissue and ilomastat were observed. However, as the amount 
of water contained in the tissues could not be quantified as the total volume of the 
sample was unknown. We therefore could not calculate the concentration of ilomastat 
accurately. It was felt that the problem can be solved if the supernatant of digested tissue 
samples could be lyophilized and then re-dissolved using a known amount of liquid. 
Hence, this lyophilization step was included in the design of the following experiments. 
 
3.3.5.2. Ilomastat tablets in ex vivo rabbit eyes 
Previous studies have confirmed that 1) ocular tissues can be well digested without 
interfering with ilomastat 2) accumulation of ilomastat in dissected ocular tissues can 
occur, and 3) accumulated ilomastat is detectable by HPLC. However, the dissected 
ocular tissues are different from an intact eye. It is unknown how much ilomastat can 
accumulate in different parts of ocular tissue due to the presence of the tissue barriers 
and the aqueous/blood circulation. In order to simulate the in vivo condition, excised 
rabbit eyes were used to model a functioning bleb. A 5-10cm cut was made at the 
conjunctival/limbo edge of the eye and a pocket created posteriorly using forceps. A 
tablet was placed under the conjunctiva, and a tube connected to a peristaltic pump placed 
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at the front of the pocket. To seal the bleb, glue was used to attach the conjunctiva to the 
sclera below. This created a water tight bleb. To ensure that a water tight pocket can be 
created in an excised eye, a separate eye was subjected to the same procedure (minus the 
tablet) and a contrast agent (Rhodamine) injected through a tube (Figure 3.26.). The 
distribution of the dye showed both the formation and size of the bleb. PBS (pH 7.4) was 
pumped through the bleb at a flow rate of 2 µL/min. The eyes were kept moist through 
the use of a drip containing 0.9% NaCl (approximately one drop every 30 seconds onto 
the eye surface). Three eyes with ilomastat tablets were dissected after 4 hours, and a 
further 3 dissected after 24 hours along with 2 control eyes (no tablet). The bleb tissue 
(conjunctiva and sclera within the bleb) was dissected away, along with the cornea, 
muscle, iris, lens and vitreous body. Excluding the vitreous body all samples were briefly 
washed in PBS, weighed and placed into an eppendorf tube and stored at -20 °C. 
 
Figure 3.26.  Demonstration of the formation of a “bleb” in an excised rabbit eye. Rhodamine 
was pumped into the pocket to prove the formation of a sealed pocket. 
 
The tissue samples were next cut into small pieces and placed into a 15 mL round 
bottom falcon tube with 0.9 mL of the collagenase solution (2 mg/mL) along with 0.1 
mL of the Leu-Trp solution (500 μM, dissolved in DMSO). The tubes were placed in a 
37 °C shaking incubator for 48 hours (300 RPM). Following incubation samples were 
again passed through 29 gauge needles 5 times to ensure any remaining fragments were 
broken up. The sample solutions were centrifuged for 5 minutes (13,000 RPM). To 
ensure the samples were dissolved in the minimum amount of liquid possible the 
supernatants were lyophilized for 48 hours using a freeze-dryer set to -20 °C. 
Meanwhile, an ilomastat aqueous solution was lyophilized in order to ensure 
Bleb 
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lyophilization does not cause any degradation of ilomastat (Figure 3.27). 
 
Figure 3.27. HPLC chromatograms of original ilomastat (red) and lyophilized ilomastat (blue). 
Data suggest that lyophilization did not cause any decomposition of ilomastat. 
 
Following lyophilization, it was felt that DMSO would be a suitable agent for dissolving 
both the Leu-Trp and ilomastat. Hence, we decide to use DMSO to dissolve the samples. 
This way it was hoped that the amount of ilomastat contained in the samples would be 
as concentrated as possible because highly concentrated ilomastat is easier to detect by 
HPLC. However, the supernatant of the tissue samples did not dissolve well in DMSO; 
but it was found to dissolve well in water. The well dissolved samples were further 
subjected to filtration using a 0.22 µM filter and injected into the HPLC. Compounds 
were eluted using the isocratic method mentioned in 3.2.7.2. The HPLC chromatograms 
are similar to the tissues soaked in the 100 μM ilomastat solution. 
 
Ilomastat was detected in the conjunctiva, sclera and muscle near the bleb site (Figure 
3.28.). There was no significant difference in ilomastat concentrations for any individual 
tissue between 4 and 24 hours. The ilomastat concentration in the conjunctiva was 
approximately 0.5 µM per mg whilst in the sclera and muscle the concentration was 
10-20 times less (Figure 3.29.). However, it should be noted that these concentration 
were not exact because the real concentration could not be recovered using the internal 
standard. As the samples were finally dissolved in water, Leu-Trp did not dissolve 
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completely. Therefore, the peaks of Leu-Trp on the chromatogram were not reliable. 
Consequently, the loss of ilomastat during the tissue preparation could not be calculated. 
 
Figure 3.28. Chromatogram showing that there was no overlap between the different tissues 
and ilomastat. Tissues displayed on the graph are: conjunctiva (red), sclera (green) and muscle 
(pink). The ilomastat control (blue) is also displayed. 
 
 
  
Figure 3.29. Concentrations of ilomastat (ILO) in different part of the eye. ■tissue dissected 
from rabbit eyes with ex vivo GFS after 4 hours (n=3, error bars indicates standard deviation) 
■tissue dissected from rabbit eyes with ex vivo GFS after24 hours (n=3, error bars indicates 
standard deviation) ■tissue soaked in 100 μM ilomastat solution for 24 hours (n=1). Data 
suggest that in the ex vivo eye ilomastat was only detected in the conjunctiva, sclera and muscle 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Conjunctiva 
above Bleb
Rectus 
Muscle
Sclera 
below Bleb
Vitreous Iris Cornea
IL
O
 C
o
n
ce
n
tr
at
io
n
 (
μ
M
/m
g)
Chapter III Prolonged release of ilomastat 
127 
 50
 
near the bleb site.  
 
From Figure 3.29 it can be seen that the ilomastat concentrations in the sclera, iris, 
cornea and vitreous body were much higher in the tissue which was cut and soaked in the 
ilomastat solution, rather than in the ex vivo model. This suggests that in the ex vivo eye, 
probably due to the absence of blood and aqueous circulation, it was difficult for 
ilomastat to pass through the sclera and cornea. Accordingly, ilomastat could hardly be 
detected in the iris and vitreous body of the ex vivo eye. Ilomastat could only 
accumulate in the spongy conjunctival and the sclera below the bleb.  
 
An interesting discovery was made when looking at the ilomastat concentration in the 
conjunctiva. Figure 3.29. shows that the ilomastat seemed to be more concentrated in 
the conjunctiva from the ex vivo eye rather than from the dissected tissue which was 
soaked in ilomastat solution. This is not because the ilomastat particles remaining on the 
conjunctiva were not washed off properly before tissue digestion. From the release 
profiles of ilomastat in the 200 μl chamber at room temperature (Figure 3.1.), we know 
that the 1) the ilomastat concentration reached approximately 90-100 μM after about 4 
hours and 2) this concentration could be maintained in the flow chamber for days. 
However, it is estimated that the ilomastat concentration in the ex vivo bleb is higher 
than 100 μM. This is because the bleb created on the ex vivo eye had a volume which 
was less than 200 μl (50-100 μl). From the 5-FU release profiles from Chapter II, we 
know that, when the tablet is placed in a small chamber (50 μl), the tablet release rate 
and the drug concentration in the flow chamber were both increased significantly 
(Figure 2.13). Although the ilomastat tablet release profiles in a 50 μl chamber are not 
available, it is believed that the ilomastat concentration was also increased in the ex vivo 
bleb in comparison to the one in the 200 μl chamber. As the conjunctival is the main 
destination of the drug solution, the ilomastat concentration in the conjunctival from the 
ex vivo eye was higher than the one from the soaked conjunctiva. 
 
Although the ilomastat concentration in the tissue was not thought to be accurate due to 
the precipitation of Leu-Trp, it was confirmed that a) collagenase was able to digest tough 
Chapter III Prolonged release of ilomastat 
128 
 50
 
ocular tissue without interference to ilomastat and b) ilomastat accumulated in the ex vivo 
eyes could be detected using our HPLC method with a minimum sensitivity of 100 nM. 
 
3.3.5.3. Freeze dried ocular tissue digested using collagenase 
As Leu-Trp had been shown to be a poor internal standard, we had to consider whether we 
could detect ilomastat without using an internal standard. This is new because drug 
extraction from tissue without using internal standard is hardly reported in the literature. 
If tissue samples could be freeze dried before being digested in a known volume of 
collagenase, the water initially contained in the tissue could be removed. We then will 
be able to determine the concentration of ilomastat by injecting the supernatant of 
digested tissue into HPLC. However, we also understand that there is a possibility that 
ilomastat is bound to tissue/protein. Examining whether there is any binding between 
the drug and tissue will be part of the future studies. 
 
To test the possibility of freeze drying tissue in advance of digestion, we repeated the 
earlier experiment of soaking tissue in a 100 µM ilomastat solution. Following 24 hours 
of soaking, the tissues were washed using 1ml of PBS and placed in the freeze dryer. 
After lyophilization, the samples were transferred to a 15 mL round bottom falcon tube 
with 1 mL of collagenase solution (2 mg/mL) and then shaken at 37 °C at 300 RPM for 
48 hours. As with the previous studies, the 1 mL ilomastat solution was also freeze dried, 
re-dissolved in 1 mL collagenase D solution, and then shaken in the incubator for the 
same period of time (48 hours). The ilomastat concentration in the tissue is shown in 
Figure 3.29. The HPLC chromatograms are similar to the ones shown in Figure 3.28. A 
10% loss of ilomastat was observed using this method, which is probably because of the 
degradation of ilomastat in the 37 °C collagenase solution.  
 
The aim of this experiment was to determine the concentrations of ilomastat in ocular 
tissues using a non-radioactive/non-fluorescent method. The whole development process 
is summarized in Table 3.7. The most challenging obstacle was the development of a 
universal method for tissue homogenization. Previous studies have used a number of 
different methods. For example, iris and retina/choroid were homogenized with using 
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hydrochloric acid (pH 1.0) and centrifuged before subjecting the supernatant to solid 
phase extraction (Hu et al. 2007). The cornea/sclera were homogenized by an ultrasound 
bar and then in Sörensen phosphate buffer pH 7.4 mixed with dimethyl sulfoxide (3:7) 
(Knapp et al. 2003). The vitreous was homogenized with methyl-tert-butyl-ether (Knapp 
et al. 2003). However, if we were to digest the different part of ocular tissues using the 
different methods mentioned in the literature, it had to be ensured that all these methods 
do not led to the decomposition of ilomastat and the internal standard. In addition, 
depending on the types of tissue, different HPLC methods might need to be developed. 
This could be very complicated and time consuming. Furthermore, due to the limited 
availability of ilomastat, it was more convenient to develop a unique method to digest all 
the ocular tissues in a single protocol. As documented in Table 3.6 several methods were 
investigated, but for the reasons listed in the table, none could be brought forward mainly 
due to their effects on ilomastat. 
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Table 3.7 Summary of the method development for detecting ilomastat in ocular tissues.  
Experiments Progress  Problems Problem solving 
Increase HPLC 
sensitivity of 
ilomastat 
5 μM to 100 nM   
Look for commercial 
available internal 
standard 
Leu-Trp was purchased   
Develop HPLC 
method for both 
ilomastat and Leu-Trp 
Peaks were well 
separated 
  
Look for a universal 
method to digest all 
ocular tissue without 
interfering with 
ilomastat 
Tissue were well digested 
using Collagenase D  
  
Dissect different parts 
of the ocular tissue in 
a 100 μM ilomastat 
solution with Leu-Trp 
Tissues were well 
digested; ilomastat could 
be detected by HPLC 
without showing overlay 
peaks with the tissue 
samples. 
The ilomastat 
concentration was not 
accurate as the 
amount of water in the 
tissue could not be 
quantified. 
Lyophilize the 
supernatant of the 
digest tissue 
samples, then 
re-dissolved them 
in known amount 
of liquid. 
Ilomastat tablets were 
placed in artificial 
blebs created on 
excised rabbit eyes 
Tissues were well 
digested and a known 
amount of Leu-Trp added 
in. Samples were then 
lyophilized. 
Lyophilized samples 
could be re-dissolved 
not in DMSO but in 
water. Leu-Trp 
precipitated in water. 
Not to use Leu-Trp 
Repeat experiments 
by soaking tissue in 
100 μM ilomastat 
solution 
Tissue samples were first 
lyophilized and then 
digested by collagenase 
D. Ilomastat was detected 
by HPLC with 10% lost 
during the sample 
preparation process.  
The accumulation of 
ilomastat in a live eye 
could be lower than 
an ex vivo eye. The 
sensitivity of the 
HPLC method needs 
to be further 
improved. 
A HPLC-MS 
method is being 
developed. 
 
Using our extraction protocol, Leu-Trp was not an appropriate internal standard due to its 
poor aqueous solubility and also showed peaks that overlay with the tissue samples on 
the HPLC chromatograms. As no organic phase was used in our final extraction process, 
it was unclear whether the ilomastat extraction was complete during tissue breakdown or 
how much was lost during the preparation for HPLC. Since binding of MMPis to 
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extracellular matrix has been observed in literature (Zhang et al. 2008), it is possible that 
some ilomastat was bound to protein and consequently removed during the centrifugation 
step. Further interaction studies of ilomastat with proteins as well as extracellular matrix 
are needed. If ilomastat does indeed bind to tissue/proteins that we are unable to break 
apart, organic solvents will be needed to precipitate the tissue/protein. Furthermore, the 
sensitivity of our HPLC method, whilst good at 100 nM, may not be sufficient to detect 
very small amounts of ilomastat in tissue. Ideally we would prefer the sensitivity to be at 
least 100 times lower. Currently an HPLC-MS method with a higher sensitivity (2.57 nM) 
is being developed by our group (led by Dr. Hala. Fadda). 
 
Our ex vivo model of the bleb does not fully represent the in vivo conditions. It has a few 
limitations. Firstly, there is no blood supply through the tissue. Due to the absence of 
blood circulation, it would be difficult from this data to draw conclusions about how 
much drug may be in tissue in a living eye. Specifically it is not possible to predict the 
presence of the drug at the posterior segment of the eye brought by the ocular blood 
circulation. Secondly, the temperature was not body temperature. Finally, PBS was used, 
whereas it would be aqueous humor in a living eye. Since our colleagues have found that 
ilomastat solubility can be as high as 574 μM in 37 °C PBS (pH 7.4), we believe the 
ilomastat will be more soluble in an in vivo bleb than in an ex vivo bleb because the in 
vivo bleb has the temperature of 35 °C. Have considering these limitations, our findings 
are still encouraging. We have developed a simple method that can digest all of the 
ocular tissues with the exception of the lens. The detection of ilomastat in the ocular 
tissues can be accomplished without radiolabelling the drug or marking it with a 
fluorophore. Our experiments on the ex vivo eye suggests that the dispersal of a drug 
from an implanted tablet may be limited to the tissues surrounding it. Determination of 
ilomastat accumulation from the in vivo studies is currently underway. 
To summarize all our studies on the method development of ilomastat determination in 
ocular tissue, our best method so far is summarized below. More experiments will be 
conducted in the group to determine if further refinement of the method is required. 
1. Dissect, weigh and cut the tissue into small segments. 
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2. Lyophilize the tissue for 48 hours at -20 °C. 
3. Place the tissue in 1ml of the collagenase solution (2 mg/mL) for 48 hours (or until all 
tissue is digested) in a shaking incubator at 37 °C at 300 RPM in a 15 mL falcon tube. 
4. Pass the digested tissue through a 29 gauge or smaller needle in order to ensure that full 
tissue disruption has occurred. 
5. Centrifuge samples for 5 minutes at > 10,000 RPM. 
6. Filter the supernatant using a 0.45 µM filter. 
7. Inject the samples into the HPLC with a UV detector (λ=280 nm). The mobile phase is 
ammonium acetate buffer (pH 5.0) with 15% acetonitrile. The flow rate is 1.2mL/min. 
The injection volume is 100 µL. The ilomastat retention time is 25.6 minutes.  
 
3.4. Conclusions 
In conclusion, we have successfully made excipient-free ilomastat tablets. The release 
of ilomastat lasted more than one month in our flow chamber. In the in vivo studies, 
these tablets proved to be more effective and less toxic than 5-FU and MMC with 100% 
bleb survival for 30 days after surgery. This suggests that the ilomastat tablets could 
potentially be a better anti-scarring medicine for GFS compared to 5-FU and MMC. It 
was also found that ilomastat significantly reduced intraocular pressure compared to 
negative and positive group. To evaluate tissue accumulation of ilomastat in the eye, we 
have successfully developed a simple method of ocular tissue digestion that does not 
interfere with ilomastat detection. Using this method, the ilomastat accumulated in the 
ocular tissue can be detected by HPLC with a sensitivity of 100 nM. In addition, 
thermal and surface analyses of the ilomastat tablets were conducted. It was also found 
that ilomastat exists in different crystal forms, but this finding did not seem to affect the 
release of ilomastat in our in vitro model. The analysis results from AFM and nanoLTA 
indicate that incubation of the tablets led to changes (stiffness, adhesion, and thermal 
conductivity) in the tablet surface. The surface analysis by XPS and Tof-SIMS suggests 
that, even with presence of constant aqueous flow, deposition of salts and proteins on 
the tablet surface can be observed.  
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4. Chapter IV Molecular dynamics simulation 
of the dissolution of the excipient-free 5-FU 
and ilomastat tablets  
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4.1. Introduction 
In the previous studies, we developed two types of excipient-free tablets that can 
potentially be used for scar inhibition in the bleb. They were made from two different 
compounds. 5-FU is a hydrophilic water soluble compound; whilst ilomastat is more 
hydrophobic and less water soluble than 5-FU. As mentioned above, our tissue tablets 
will dissolve in the subconjunctival space which results in non-sink conditions due to its 
fairly small volume (approximately 50-100 μl). Since the drug release profile is 
associated with the efficacy and toxicity of the tablets, understanding the drug release 
behavior in the bleb becomes important. From the previous in vitro studies, we found 
that 1) saturation of the drug was not observed in the flow chamber due to the turnover 
liquid 2) the dissolution rate of the tablet was the rate-limiting step of the drug release 
process, and 3) tablet dissolution was related to the bleb volume and the aqueous flow 
rate. Therefore, the dissolution of the tablets cannot be simply calculated using the drug 
solubility. There are a number of methods other than in vitro models that can be used to 
investigate tablet dissolution. Since the tablets are excipient-free, their dissolution can 
be considered as the dissolution of a big drug particle. Since the dissolution of a 
compound in a solvent is related to its chemical structure, the dissolution of an 
excipient-free tablet may also be associated with the chemical structure of the 
compounds. Hence, we are interested in investigating the influence of the chemical 
structural features of the two molecules on the tablet dissolution. We also seek to 
investigate the dissolution of the tablet in non-sink conditions on a molecular level.  
 
Molecular dynamics (MD) is a computational method that calculates the behavior of a 
molecular system with regards to time (Adcock & McCammon 2006;Morra, Meli, & 
Colombo 2008). It has been widely used in investigating the structure, dynamics, and 
thermal dynamics of proteins and biomolecules (Adcock & McCammon 2006;Dodson, 
Lane, & Verma 2008;Grigera 2002;Gumbart et al. 2005;Haran, Haas, & Rapaport 
1994;Morra, Meli, & Colombo 2008). It is able to run “virtual experiments” with high 
temporal and spatial resolution in which cannot possibly be seen with lab experiments. 
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MD simulations help us to understand the dynamics and mechanical functions of 
biological molecules at the atomic and molecular level and therefore provides promising 
insights into the genetic, thermodynamic and functional/mechanistic behavior of 
biological processes (Dodson, Lane, & Verma 2008). A successful simulation that 
agrees with experimental observation might be able to suggest new experiments in the 
lab.  
 
The dissolution of sodium chloride crystals have been examined using MD simulations 
(H.Ohtaki et al. 1988;Siu et al. 2006;Yong Yang, Sheng Meng, & E G Wang 2006). 
However, no studies have been conducted on tablet dissolution using MD simulations. 
Here we intend to use MD simulations to understand the dissolution of a tablet in 
non-sink conditions at the molecular level. It is hoped that this simulation will be able to 
help us to understand the dissolution of the tablets and provide us useful indications for 
future in vitro and in vivo experiments. To model the dissolution times of the tablets in 
these conditions, we conducted computational simulations using MD on both the 5-FU 
and ilomastat tablets.  
4.2. Computational methods 
All the MD simulations were performed using Desmond v2.2 with Maestro 8.5 as a 
molecular modeling graphical interface. Conformational searches were conducted using 
a Macromodel (Schrodinger) to generate initial systems of drug molecules inside a 
constrained volume. 
4.2.1. Building a tablet 
The 3D structures of 5-FU and ilomastat molecules were generated using 3D builder in 
Maestro 8.5. Resulting structures were optimized using Macromodel 9.11 (Mohamadi et 
al. 1990), MMFFs force field (Cramer & Truhlar 1995) and the Generalized Borhn/ 
Surface Area (GB/SA) implicit solvation model (Still et al. 1990). An exhaustive search 
was carried out on a small number of molecules (25 5-FU with 2 water molecules, 10 
ilomastat respectively) by generating 1000 configurations for each system using the 
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Monte Carlo multiple minimum (MCMM) approach. The lowest energy configurations 
were chosen as a starting point for tablet modeling. The final structures of the exhaustive 
searches were multiplied into a rectangular shaped tablet (containing 690 and 110 
molecules of 5-FU and ilomastat tablets, respectively). Tablets were then optimized and 
the final conformations used to examine the intermolecular packing of drug molecules 
without the presence of extra water molecules. It is understood that ideally the tablets 
should compose not amorphous drug molecules but drug crystals. But we conducted the 
preliminary studies using amorphous drug molecules to form a tablet because 1) our 
current aim is to develop a MD simulation method to investigate the dissolution of a 
tablet in non-sink condition, and 2) creating drug crystals of 5-FU and ilomastat using 
MD simulation will include quite large amount of work which may take a few years.  
4.2.2. Tablet compression 
Molecular dynamics was performed using Desmond v2.2 with Maestro 8.5 as a molecular 
modeling graphical interface. The initial systems generated by conformational searches 
were truncated by deleting molecules and forming rectangular shapes. Simulation boxes 
of each tablet (672 5-FU and 110 ilomastat molecules, respectively) were prepared by 
Desmond setup and sizes coinciding with the size of the truncated sets (Figure 4.1). The 
temperature of the simulation during tablet compression was set at 300 K, corresponding 
to the room temperature and MMFFs force field. To imitate the process of tablet 
compression under increased pressures, the systems were subjected to initial relaxation 
minimization followed by simulation at an initial pressure of 1 bar for 0.06 ns (5-FU) or 
4.8 ns (ilomastat). The final structures were further simulated using constant pressures of 
2, 4, 8, and 12 bars without relaxation for 0.48 ns at each pressure. Finally, a production 
simulation was conducted at 14 bars for 4.8 ns. An additional simulation was conducted 
at higher pressure of 100 bars for 4.8 ns. 
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Figure 4.1. Simulation of tablet compression. 
4.2.3. Tablet dissolution 
The simulation of the tablet dissolution was performed using the final structures of 
rectangular shaped tablets after being compressed at 14 bars. The size of the tablets was 
reduced (164 5-FU and 90 ilomastat) to reduce the real CPU time of the simulations 
without losing the properties of tablets. By doing so, a 4.8 ns simulation usually takes 
about one month if everything goes smoothly. Assuming that the amorphous drug 
molecules will not crystallize during the tablet dissolution process, the initial simulation 
box systems were formed by solvating the tablets and forming all atom systems that 
consisted of a 5-FU or an ilomastat tablet surrounded by water molecules (12761 water 
molecules for 5-FU tablet and 6724 water molecules for ilomastat tablet) (Figure 4.2.). 
The final volume of both simulation boxes was 266966 ± 493.7 Å. In order to compare 
the drug dissolution from a tablet without or with the turnover of the aqueous humor, two 
types of simulations were performed. The first type of simulation was conducted to 
compare the dissolution rates of the two drugs (5-FU and ilomastat) and consisted of a 
production run of 4.8 ns. The simulation was conducted twice at two temperatures (300 K 
and 310 K, to represent ambient temperature and body temperature respectively) for 
both drugs. The second type was designed to examine the dissolution of the two drugs in 
the presence and turnover of the aqueous humor. The liquid turnover in the bleb was 
mimicked by eight simulating circulations. Each circulation lasted for 0.6 ns, where the 
released drug molecules were manually removed at the end of each step. A molecule was 
considered released when the contact with the tablet surfaces was lost. The manual 
removal of molecules at the end of each cycle was approximated to reflect the loss of 
molecules from the bleb by permeation. After each circulation, a new simulation box 
consisting of an increased number of water molecules was built, but the size of the box 
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was kept constant to continue the next circulation since it was assumed that the bleb 
volume would not change after drug release (Figure 4.3.).   
 
Figure 4.2. Demonstration of tablet dissolution in a box without liquid turnover. 
 
 
Figure 4.3. Simulation of dissolution of tablet with liquid turnover. 
4.2.4. Tablet interaction with a biological membrane 
The effect of membrane presence on dissolution rate was also investigated using the 
initial tablets which were used in the dissolution simulation described in the previous 
section. The tablet was placed on the top of a dipalmitoylphosphatidylcholine (DPPC) 
bilayer membrane in a simulation box that consisted of 12568 (for 5-FU) and 33578 (for 
ilomastat) water molecules respectively (Figure 4.4.). As we did not fix the lipid bilayer 
membrane, there was no static layer in the simulation. We aim to investigate whether 
tablet dissolution could be affected by tissue. The tissue was represented in a simplistic 
manner by a model of DPPC to consider the complex interactions of the polar interface 
and hydrocarbon chains with tablets. The volume of the simulation box was 701250 Å 
and 1766400 Å for 5-FU and ilomastat respectively. A 4.8 ns simulation was performed 
at 310 K which represents body temperature. The dissolution was monitored by 
calculating the change in the total molecular SA. 
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Figure 4.4. Demonstration of tablet permeation through a biological membrane. 
4.2.5. Analysis of the results 
Molecular dynamics trajectories were visualized and analyzed using Maestro and VMD 
(Humphrey, Dalke, & Schulten 1996). The explicit water molecules were removed 
within VMD to simplify the analysis. The configurations generated during the 
simulation were converted into pdb file format and sequentially saved for further 
analysis. The macromolecular properties of exported systems (surface area, molecular 
lipophilicity potentials (MLP), lipole) were analyzed using Vega ZZ (Pedretti, Villa, & 
Vistoli 2004). The estimated lipole value is calculated by projecting lipophilicity onto the 
surface but it depends on the conformation of the system. Molecular properties of single 
molecules (log P) were also calculated by Vega ZZ. 
4.3. Results and discussion 
All molecular dynamics simulations on limited size tablets were conducted to examine 
the dissolution of the two drug molecules with different molecular properties and 
solubility. It can be seen from Figure 4.5. that 5-FU has 3 hydrogen bond acceptors 
(HBAs) and 2 hydrogen bond donors (HBDs); whereas ilomastat has 5 HBDs and more 
than 3 HBAs. From literature it is known that the macroscopic aqueous solubility of 
5-FU and ilomastat is 11.1 mg/mL (pH 4.0) and 0.03885 mg/mL respectively (Millipore 
2010;Yalkowsky & He 2003). To understand the experimentally observed data, the 
dissolution simulations were correlated with the molecular properties (HBDs, HBAs, 
and log P) and macromolecular properties of the systems. Here the system represents an 
entirety that includes all the drug molecules.  
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Figure 4.5. Hydrogen bond donors (HBDs, **) and hydrogen bond acceptors (HDAs, *) of 5-FU 
(A) and ilomastat (B). 
 
The experimental log P of 5-FU is -0.83 (pH 4.0) (Buur & Bundgaard 1984), while the 
experimental log P of ilomastat was not reported. The experimental log P of ilomastat 
was not determined currently due to its limit availability. But to predict and compare the 
changes of the lipophilicity of the tablet system, we used Vega ZZ (Pedretti, Villa, & 
Vistoli 2004) to predict log P values of the two drugs. The predicted log P value of 5-FU 
and ilomastat was -1.362 and 0.652 respectively. Macroscopic values such as the lipole, a 
lipophilicity measure projected onto a molecular surface, can also be predicted using the 
same software. Lipole can be calculated for a single molecule as well as for the 
complexes, including the tablets. The lipole value was predicted as 0.5621 and 1.2751 for 
a single 5-FU and ilomastat molecule respectively. Assuming that the predicted log P 
value of 5-FU is similar to the experimental value, we aim to investigate the change of 
the tablet lipophilicity by comparing the difference of lipole values before and after 
dissolution.  
4.3.1. Conformational search 
The initial of 5-FU and ilomastat systems were generated by the MCMM method taking 
into account the solvent effects using an implicit model (GB/SA). Initial analysis of 
interactions between 5-FU molecules in the tablet suggests the presence of 
aromatic-aromatic interactions and hydrogen bonding (to a lesser extent) (Figure 4.6). 
Similarly, aromatic-aromatic interactions between ilomastat molecules were observed, 
predominantly in a face to edge orientation (Figure 4.7).  
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Figure 4.6. Interactions between the 5-FU molecules after conformational searches. The green 
broken lines represent the hydrogen bonds between the molecules. Interactions between 5-FU 
molecules in the tablet suggest the presence of aromatic-aromatic interactions and hydrogen 
bonding. 
 
Figure 4.7. Interaction between the ilomastat molecules after conformational searches. 
Aromatic-aromatic interactions between ilomastat molecules were observed, predominantly in 
a face to edge orientation A typical face to edge orientation is shown in the circle. The green 
broken lines represent the hydrogen bonds between the molecules. 
4.3.2. Simulation of tablet compression 
During tablet compression, change in the tablet/material volume reflects the extent of 
packing. As Maestro calculates the volume of the system by adding the number of atoms 
without including the space between molecules, the volume of the system remains 
constant before and after the tablet compression. Hence, calculation of the system 
volume was not able to reflect tablet packing properties. Therefore, we used the 
accessible surface area (ASA, the surface area of a biomolecule that is accessible to a 
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solvent) of the system to evaluate tablet packing. It was expected that ASA will decrease 
after compression because the molecules packed inside the tablet will not be exposed to 
the solvent.  
 
Although the 5-FU and ilomastat tablets were compressed using different pressures, no 
significant change in the ASA was observed between the beginning and the end of the 
compression (Figure 4.8.). As ilomastat is a larger molecule than 5-FU, its movement 
was more difficult during the conformational rearrangement. Consequently, the 
simulation of the ilomastat tablet compression needed more time. During the 
compression of the ilomastat tablet, the ASA of the ilomastat tablets increased for a short 
period at around 5 ns. But this does not contribute to our conclusion as it is simply the 
result of some ilomastat molecules moving out of the simulation box. On average, each 
ilomastat molecule has more H-bonds (2.3 per molecule) than 5-FU (1.6 per molecule) 
because ilomastat has more HBDs and HBAs. In the simulations of 14 bar or lower than 
14 bar, the number of H-bonds in both tablets did not change significantly (data not 
shown). However, in the 4.8 ns simulation at 100 bar, the number of H-bonds slightly 
increased in the 5-FU tablet but not in the ilomastat tablet (Figure 4.9.). Although 
ilomastat does not appear to be too hydrophobic (predicted log P = 0.652), it might be that 
the combination of hydrophobic interactions with the hydrogen bond formation leads to 
its observed lower aqueous solubility.  
 
Figure 4.8. Change in the accessible surface area (ASA) after tablet compression. Data suggest 
that there was no significant change in the 5-FU and ilomastat tablets after tablet compression. 
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Figure 4.9. Change in H-bonds in 5-FU (A) and ilomastat (B) tablets at a pressure of 100 bar. 
Data suggest that the number of H-bonds slightly increased in the 5-FU tablet but not in the 
ilomastat tablet. 
 
It is understood that the morphology of the drug is related to the tablet fabrication and 
dissolution. From the thermal analysis of the two tablets we know that both 5-FU and 
ilomastat exist in crystal forms. Therefore, ideally this simulation should be conducted 
on the drug crystals. The polymorph and thermal stability of 5-FU has been studied and 
predicted using computer (Hamad et al. 2006;Hulme, Price, & Tocher 
2005;Karamertzanis et al. 2008); whilst the polymorph and crystal habit of ilomastat has 
not been well studied. As this is only a preliminary study which aims to examine the 
possibility of simulating tablet dissolution in non-sink conditions, we did not involve 
the crystal structures of the drug. Future simulations involving in the future with the 
drug crystals will be able to provide us with more useful information.  
 
1.5
1.53
1.56
1.59
1.62
1.65
1.68
0 2 4 6
H
-B
o
n
d
s 
p
e
r 
m
o
le
cu
le
ns
2
2.1
2.2
2.3
2.4
2.5
2.6
0 2 4 6
H
-b
o
n
d
s 
p
e
r 
m
o
le
cu
le
ns
A 
A 
B 
Chapter IV Molecular dynamics simulation of the dissolution of the excipient-free 5-FU and ilomastat tablets 
144 
 50
 
The compaction of pharmaceutical powder has been numerically simulated using a 
number of different models in recent years (Han et al. 2008;Sanchez-Castillo, Anwar, & 
Heyes 2003a;Sanchez-Castillo, Anwar, & Heyes 2003b). The effects of compression 
speeds on the deformation behavior of the powder column, the microstructure, and the 
integrity of the formed tablet have been investigated (Sanchez-Castillo, Anwar, & Heyes 
2003b). In particular Han et al simulated the stress and density distributions during the 
tabletting process (Han et al. 2008). However, the compaction of drug crystals without 
excipients has never been simulated. As the drug crystals were not included, our 
simulation was conducted using amorphous drugs. Nevertheless, it was expected that 
the ASA of the particles or powders would be decreased after the compaction because 
this usually happens in real tablet compression. However, when the simulating system 
was built up before running the simulation, the molecules had to be very well packed in 
order to avoid adding any extra water molecules. Therefore, no significant ASA change 
was observed in our simulation since the initial tablet was built without allowing for 
empty space between molecules. Due to this fact, conformational rearrangement of the 
molecules became nearly impossible. Hence, no changes in packing during the 
compression were observed. Changes in the number of H-bonds during simulation were 
not significant, either.  
 
Although a pressure of 14 bar was applied when we compress the real ocular tissue tablets, 
using this number in the simulation system may not represent the same compression force 
as in the real conditions. In fact in some MD simulations of compression, the pressure 
was set as hundreds or thousands of bars (Knapp et al. 2003;Suihko et al. 2000;Tilleul et 
al. 1997;Zahn 2004). Hence, a 4.8 ns continuous simulation of tablets compressed at 100 
bars was conducted, but there was still no change to the tablet ASA. Although this might 
indicate that the monitoring of the molecular rearrangement during tablet formation 
might be variable, this approach can also be used to generate a tablet to further study its 
dissolution. 
4.3.3. Simulation of tablet dissolution 
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4.3.3.1. Simulation without the mimicking of liquid turnover  
Before simulating the tablet dissolution with a liquid turnover, a 4.8 ns continual 
simulation was conducted in a closed box at two different temperatures (300 K and 310 K, 
to represent room temperature and body temperature respectively). It was found that the 
number of released molecules from the 5-FU tablet was considerably higher than the one 
from the ilomastat tablet. During this process, only one ilomastat molecule came into the 
solution (figure not shown). Both 5-FU and ilomastat tablets dissolved faster at body 
temperature (310 K) due to the higher kinetic energy of the tablet dissolution at 310 K 
than at 300 K (Figure 4.10.). As a result, the ASA of the tablets increased more rapidly at 
310 K than 300 K (Figure 4.11.). The 5-FU tablet ASA did not increase significantly 
after 4 ns (Figure 4.11. A). This suggests that, without the presence of liquid flow, the 
solubility of 5-FU was high enough to achieve a saturated solution at around 4 ns. 
 
 
Figure 4.10. The kinetic energy of the 5-FU (A) and ilomastat (B) tablet dissolution without 
liquid turnover. Data suggest that both 5-FU and ilomastat tablets dissolved faster at body 
temperature (310 K) due to the higher kinetic energy of the tablet dissolution at 310 K than at 
300 K. 
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Figure 4.11. Change of ASA of 5-FU (A) and ilomastat (B) tablets in water box without liquid 
turnover. ■ represents 310K, ◇ represents 300K. Data suggest that the ASA of the tablets 
increased more rapidly at 310 K than 300 K. 
 
In addition to the change in the ASA of the molecules, we also examined the molecular 
lipophilicity potentials (MLP) of the tablets. The MLP describes the hydrophobic and 
hydrophilic surface properties of the molecules. In our case, it represents the 
hydrophobicity of the tablet surface, which can be correlated with the tablet dissolution 
rate. The MLP of the single molecules and tablets is shown in Table 4.1. The log P values 
were constant during the tablet compression and dissolution. It was observed that the 
lipole values of the both tablets decreased after the 4.8 ns simulation. The 5-FU tablet 
lipole value decreased since the molecules were rearranging to decrease exposure of the 
hydrophobic moieties to the surrounding water. The ilomastat tablet lipole value did not 
reduce as significantly as 5-FU due to the lack of molecular rearrangement (caused by 
their large volume and complicated structure) during the simulation. When comparing 
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the change in the ilomastat tablet lipole value before and after the 4.8 simulation, the 
reduction of the ilomastat lipole value indicates that ilomastat molecules tend to expose 
their hydrophilic parts to the water, but the change was not as large as that seen for the 
5-FU tablet.  
 
Table 4.1 MLP of 5-FU and ilomastat molecules and tablets. Data suggest that that the lipole 
values of the both tablets decreased after the 4.8 ns simulation 
Drug  Simulation time (ns) lipole Log P 
5-FU 
Single molecule - 0.5621 -1.362 
Tablet at 300 K 
0 0.1658 
 
4.8 0.0357 
Tablet at 310 K 
0 0.1437 
4.8 0.0594 
Ilomastat 
Single molecule - 1.2751 0.6520 
Tablet at 300 K 
0 0.9179 
 
4.8 0.8960 
Tablet at 310 K 
0 0.9983 
4.8 0.7335 
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4.3.3.2. Simulation with the mimicking of liquid turnover  
Since the drug was eliminated due to the flow of aqueous in the bleb, the computational 
experiment was designed to simulate the loss of drug molecules which in reality leave 
the bleb. The dissolution media (water) with already dissolved molecules (molecules 
that have detached from a tablet) was removed and replaced manually with dissolution 
media at the end of each 0.06 ns circulation. In each cycle, about 10 5-FU molecules 
that dissolved into water were removed manually (Figure 4.12, row b). It was observed 
that at the beginning of each circulation, the ASA of 5-FU was increasing due to 
relaxation of the tablet surface (tablet swelling) and consequently the detachment of 
molecules from the surface. After removing the detached 5-FU molecules at the end of 
each circulation, the ASA initially decreased due to the smaller number of molecules left 
in the solution. Then the ASA of the remaining tablet increased slowly due to the further 
dissolution with more 5-FU molecules being released into the solution. As a result, the 
volume (monitored through the ASA) of the 5-FU tablets reduces gradually during each 
step of circulation (Figure 4.14.). However, in the simulation of the computation 
experiment with ilomastat tablets, only one or two ilomastat molecules were released at 
the end of the 8
th
 circulation (Figure 4.12., row a). This indicates that 5-FU tablet 
dissolves much faster than ilomastat tablet.  
 
 
Figure 4.14. Change in the ASA of the 5-FU tablet in the presence of liquid turnover at 300 K. 
Data suggest that the ASA of the 5-FU tablet decreased significantly in the presence of liquid 
turnover. 
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Table 4.2 Increase of 5-FU ASA at each circulation with liquid turnover. 
No. of circulation  Increase of ASA  
1 14.3% 
2 15.0% 
3 4.3% 
4 9.9% 
5 9.9% 
6 7.9% 
7 38.1% 
8 8.7% 
 
When simulating the dissolution of the tablets, the molecule proportions of 5-FU and 
water were calculated to correspond to the experimental condition (5 mg 5-FU in 50 μl 
water, molecular ratio 1:72). To conduct a parallel study, the same size water box was set 
up for the ilomastat tablet. To keep the volume of water box constant, the number of the 
ilomastat molecules (90) was reduced compared to 5-FU (164) because the ilomastat 
molecules have a larger volume than the 5-FU molecules. A sudden significant increase 
in ilomastat tablet ASA was observed at the end of the simulation (Figure 4.11. B) as a 
result of some ilomastat molecules moving out of the simulation box. In order to prove 
that there was no mistake in the experiment setup, when the simulation was repeated, the 
same problem occurred. This suggests that a larger volume is needed for the dissolution 
of ilomastat in the future. However, this has not compromised the quality of results 
because we tend to evaluate the dissolution of the ilomastat molecules by observing the 
detachment of the molecules from the tablet. From the results we understand that the 
dissolution of the ilomastat tablet is much slower than the 5-FU tablets. 
 
It was encouraging that our simulation results, which have shown that the tablets 
dissolved faster when the temperature was increased, corresponding to the results of in 
vitro experiments. This higher rate of dissolution at 310 K is due to the increase in kinetic 
energy at higher temperatures. The total number of released 5-FU molecules compared to 
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the number of ilomastat molecules qualitatively correlates to the ratio of their 
experimental solubilities. Our results indicate that the solubility of the drug is not the 
sole measurement of the dissolution of an excipient-free tablet. The simulation with 
liquid turnover suggests that the liquid flow does affect the tablet release. This effect 
appears more significant on hydrophilic compounds. For example, in the absence of the 
liquid flow, the total molecular ASA of 5-FU increased 62.5% (from 8000 Å
2 
to 13000 Å
2
) 
after 4 ns; while the total molecular ASA of ilomastat increased approximately 1% (from 
14000 Å
2
 to 15000 Å
2
). With the presence of the liquid turnover, saturation of 5-FU 
could never be accomplished. Table 4.2 shows the increase of 5-FU ASA in each 
circulation with liquid flow. It can be seen that the increasing level of ASA (in 
percentage terms) decreased with time (with the exception of circulation 7). For 
example, the 5-FU ASA increased approximately 14-15% at the beginning; whereas this 
number decreased to around 8% in the 8
th
 circulation. This indicates that the tablet 
release rate decreases with the reduction of molecular ASA. These findings suggest that 
tablet dissolution is related to its surface area, which corresponds with the later findings 
in our in vitro model. It was also found (by Dr. Hala Fadda) that tablets containing the 
same amount of ilomastat but with different surface areas demonstrated significantly 
different release rates. Tablets with a larger surface area had a higher release rate. 
Therefore, in addition to the flow rate, surface area is another factor that affects the 
tablet release rate. 
 
It is understood that the reported aqueous solubility of 5-FU (11.1 mg/mL) is more than 
280 times higher than that of ilomastat (0.03885 mg/mL). This ratio can be changed 
when a different dissolution media is used. For example, in pH 7.4 PBS, the solubility 
of 5-FU was found to increase slightly (13.6 mg/mL), but the solubility of ilomastat 
increases to nearly 6 times higher (0.2230 mg/mL, by Dr. Hala Fadda). Hence, it is 
believed that the dissolution media dose have a significant effect on tablet dissolution. 
However, this was not included in our simulations since water was the only dissolution 
media. Hence, we seek to more closely mimic the dissolution media as a biological fluid 
in terms of ionic strength and proteins content.   
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Notwithstanding the physical and chemical properties of the tablets, our previous studies 
from the in vitro model have shown that the release profiles can be affected by 
temperature, chamber volume, aqueous flow rate, tablet surface area, and the dissolution 
media. When programming the experiments, the temperature could be adjusted for 
different types of simulations. The dissolution media volume could also be modulated 
manually by altering the size of the water box. In addition, the simulation flow rate 
could be adjusted by changing the frequency of the circulation. The change in total 
molecular ASA reflects the dissolution rate of the tablet. Hence, tablet dissolution can be 
further predicted and evaluated using molecular dynamics simulations. In the future, it is 
hoped that the simulation results can be correlated with the in vitro release data. 
4.3.4. Simulation of the tablet interaction with a membrane 
Considering that the tablets implanted in the eye are in contact not only with the 
aqueous humor but also with the tissue, including fibroblasts and collagens, the 
simulation was conducted in the presence of a DPPC membrane as a simplified model 
of a cell wall. It was observed that, in the presence of the membrane, many 5-FU 
molecules were released into water but only one or two ilomastat molecules were found 
to be released into the water. At the end of the simulation the total molecular SA of 
5-FU increased by about 75%, but the total molecular SA of ilomastat did not increase 
significantly (Figure 4.15.). These results are consistent with the previous dissolutions 
findings in water without the presence of the membrane. At the end of the simulation, it 
appeared that in both simulations two molecules had entered the membrane (Figure 
4.13.). Ilomastat molecules “diffused” into the membrane at around 0.6 ns, while 5-FU 
molecules did not do so until 3 ns. As 5-FU dissolved much faster than ilomastat due to 
its higher aqueous solubility, a larger number of isolated molecules have more chance to 
interact with the membrane. However, the trends of “diffusion” or “permeation” 
observed in the pictures are probably all artefacts. It might be very difficult for both 
molecules to pass through the membrane due to non-covalent intermolecular 
interactions between the drug molecules and the fatty acyl chains in the membrane. The 
results suggest that, compared with 5-FU, ilomastat molecules are more likely to 
interact with the biological membrane.  
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Figure 4.15. Change in the ASA of the tablets in the simulation of membrane permeation 
simulation. 5-FU ilomastat. Data suggest that the ASA of the 5-FU tablet increased 
significantly during the membrane permeation simulation, but the ASA of the ilomastat tablet 
did not. 
 
In addition to the total molecular ASA, changes in the lipophilicity of the ilomastat 
tablet surface were also evaluated. It was found that after the 4.8 ns simulation without 
the presence of the membrane, the average lipophilicity of the ilomastat tablet surface 
decreased by about 50% in the water box. But in the presence of the membrane, the total 
lipophilicity of the ilomastat tablet surface decreased by only 14% because part of the 
tablet surface was in contact with the DPPC membrane (Figure 4.16.). This suggests that 
the ilomastat molecules tend to expose their polar surface when they are surrounded by 
water, and that the ilomastat molecules tend to expose their hydrophobic parts when in 
contact with the DPPC membrane. 
 
Figure 4.16. Change in the molecular lipophilicity of the ilomastat tablet with (+) or without (-) 
the presence of DPPC membrane before and after the simulation at 310 K. Data suggest that 
that the ilomastat molecules tend to expose their polar surface when they are surrounded by 
water, and that the ilomastat molecules tend to expose their hydrophobic parts when in contact 
with the DPPC membrane. 
 
Although further simulations were not conducted due to time constraints, these 
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preliminary experiments give a very good indication about the effect of contacted 
membrane on tablet dissolution. Investigation of the interaction of ilomastat on the 
tissue, which is represented by DPPC membrane currently, is considered a fairly 
preliminary study using MD simulations. It is hoped that these studies can be further 
conducted in the future. 
 
Our simulations were only conducted on two types of tablets (5-FU and ilomastat). But it 
has shown a new way of evaluating a tablets release profile. The advantage of this 
simulation is that these “virtual experiments” can run as frequently as required and 
without the need for any laboratory facilities. In addition to the results we have above, 
lots of further studies, such as tablets with various excipients and coatings, can be 
conducted using similar methods.  
4.4. Conclusions 
Our computational efforts indicate that the dissolution process of a tablet in non-sink 
conditions can be modeled using MD simulations. The fabrication and dissolution of 
5-FU and ilomastat tablets were simulated. Both 5-FU and ilomastat tablets were found 
to dissolve faster when the temperature was increased; the release rate of 5-FU was 
found to be much faster than that of ilomastat. These results agree with our 
experimental observations. From these studies we found that 1) solubility is not the sole 
measurement of the dissolution of excipient-free tablet in non-sink conditions, 2) the 
dissolution rate is related to the chemical structural features of the drug, the temperature 
and the flow rate of the liquid turnover, and 3) the combination of non-covalent 
interactions and hydrogen bonds between the drug molecules may lead to the varied 
solubility of the compounds as well as the different dissolution rate of the tablet. Other 
factors that may affect the tablet dissolution rate, including the volume and composition 
of the dissolution media as well as the initial shape/surface area of the tablets may 
possibly be simulated by the use of computer modeling in the future.  
 
In addition to the tablet dissolution process, the interaction between the drug molecules 
and a biological membrane was also investigated using MD simulations. It was found 
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that ilomastat is more likely to interact with a biological membrane than 5-FU. 
Although much work on this subject is needed in the future, we have explored a new 
way to examine the behavior of excipient-free tissue tablets in non-sink conditions. 
Hopefully the simulation results will correlate with subsequent lab experiments and will 
give valuable indications for future studies.  
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5.1. Introduction 
5.1.1. Extension of excipient-free tablets for combined treatment 
From previous studies we know that an excipient-free ilomastat tablet placed in the 
subconjunctival space could potentially provide long term scar inhibition with low 
toxicity. The 5-FU tablets also have shown the potential in inhibiting proliferation of 
fibroblasts in vitro. Despite the use of these two excipient-free tablets, making tablets 
with different compounds may provide valuable information for the future development 
of tablets with combined treatments. It has been established that topical, postoperative 
applications of anti-inflammatory agents, such as corticosteroids, are effective in 
suppressing the local inflammatory response of GFS and hence improving the reduction 
of IOP (Araujo et al. 1995;Miller et al. 1990;Roth et al. 1991;Starita, Fellman, & Spaeth 
1985). Hence, it is thought that a combination of anti-inflammatory and 
anti-proliferative agents in our tissue tablets will be effective in long term scar 
inhibition after GFS. Combination of 5-FU and dexamethasone sodium phosphate 
(DEX-P) was attempted 10 years ago (Zignani et al. 2000a). It was found that the drug 
carrier (POE) alone led to a hyperemia and chemosis, but the addition of DEX-P 
improved the surgical prognoses and polymer tolerance due to its anti-inflammatory 
properties. In addition, DEX-P decreased the POE degradation rate and prolonged 5-FU 
release. Recently, How et al found that a combination of 5-FU and bevacizumab 
demonstrated a superior anti-fibrotic effect after GFS (How et al. 2010). These reports 
suggest that a combination of anti-inflammatory agents in our tablet has great potential 
in controlling the drug release, improving the biocompatibility of the tablet, and 
preventing the formation of capsules. The potential advantages of making combined 
tablets include not only combine treatment (e.g. anti-inflammatory and anti-fibrosis) but 
also the improvement of tablet fabrication and dissolution. Since our initial studies on 
5-FU and ilomastat were mainly focused on the excipient-free tablets, our subsequent 
studies continued with excipient-free tablets and we decided to make some 
excipient-free tablets from clinically used anti-inflammatory compounds.  
 
As the previous in vitro studies showed that tablets made of hydrophobic compounds 
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such as ilomastat have a long residential time in the bleb, it is important to determine 
the termination time of the tablets. However, although in the in vivo studies the 
ilomastat tablets have shown remarkable results in scar inhibition, the duration of the 
ilomastat release remains unclear. Hence, there is a need to understand the tablet 
dissolution and predict their termination time. Before manufacturing tablets with 
combined drugs, we need to obtain more general information on tablet dissolution in 
non-sink condition using tablets made from only one compound. We also tried to 
develop a computational mathematical model to mimic the tablet dissolution process. 
We firstly aim to correlate the current experimental data with the mathematical. If a 
good correlation is obtained, it was hoped that this model will be able to predict the 
tablet release and consequently reduce the time and cost of the laboratory experiments.  
5.1.2. Understanding tablet dissolution 
Release of the drug from a tablet is related to the manufacture and dissolution process of 
the tablet. 
 
 Manufacturing process 
The manufacturing process of the tablets affects the tablet dissolution. Our tablets were 
fabricated by direct compaction, which is associated with many technical issues 
including the flowability, bulk density, and compatibility of the material. Since there is 
no filler or binder in the excipient-free tablets, a few issues need to be considered. 
Firstly, the flowability of the drug directly affects the accuracy of the tablet weight. For 
example, as 5-FU has a better flowability than ilomastat, weighing a few milligrams of 
5-FU is easier and less time consuming than with ilomastat. Second, when the same 
amount of drug is weighed, the proportion of 5-FU that is lost during the compression 
process is less than that with ilomastat. Third, the compatibility of the drug directly 
affects the integrity and strength of the tablets. It is known that a highly compatible 
powder is able to form a tablet with a resistance to fracturing and without tendencies to 
cap or laminate. It was observed that ilomastat has better compatibility than 5-FU 
because the lowest pressure required for making a robust tablet (without any capping or 
laminate) is 5 and 14 bars for ilomastat and 5-FU respectively. The relationship between 
Chapter V Tablets derived from other compounds and development of a mathematical model to correlate drug release  
160 
 50
 
compaction pressure and tablet tensile strength were not studied in detail due to the 
limited availability of ilomastat. To avoid differences in the release of the tablet caused 
by compression pressure, all the other tablets in the later studies were compressed using 
14 bars. 
 
 Dissolution process 
In addition to the manufacturing process, tablet dissolution is also highly related to the 
properties of the tablets as well as the dissolution medium. From a pharmaceutical point 
of view, dissolution of an excipient-free tablet is considered as the dissolution of a large 
drug particle. As most drugs exist as crystalline solids, here we restrict our discussion to 
the dissolution of crystalline solids. The dissolution of a solid into a liquid is usually 
composed of two consecutive stages: 1) an interfacial reaction which lead to the 
liberation of solute molecules from the solid phase to the liquid phase and 2) the 
migration of solute molecules from the boundary layers to the bulk of the solution 
(Aulton 1998). The first stage of dissolution (interfacial reaction) is dependent on the 
relative affinity between the molecules of the solid substances and those of the solvent. 
In other words, a drug molecule dissolves when the attraction of a solvent overcomes 
the cohesive forces of attraction between the molecules of the solid. The second stage 
involves the transportation of the solute from the solid/liquid interface into the bulk of 
the liquid phase, through either diffusion or convection. Factors that affect the 
dissolution of a solid include 1) the surface area of undissolved solid, 2) the solubility of 
solid in dissolution medium, 3) the concentration of solute in solution at time, and 4) the 
dissolution rate constant (summarized in Table 5.1). Similarly, when an excipient-free 
tablet is placed in the bleb, its dissolution will be affected by many factors including the 
volume and temperature of the bleb, the surface area of the tablet, the chemical structure 
and wettability of the drug, etc. These factors are summarized in the last column of 
Table 5.1. We have known that a small tablet placed in the bleb forms a non-sink 
condition. It is commonly believed that drug saturation cannot be easily observed in 
non-sink conditions. In the bleb this becomes true only if the aqueous flow is absent or 
negligible. However, our previous studies using the flow chamber have shown that the 
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drug solution never becomes saturated; this suggests that the influence of the aqueous 
flow is not negligible. As drug accumulation occurred in the flow chamber (reflected by 
the increasing drug concentration at the early stages of dissolution), the drug molecules 
must have dissolved into the media at a higher rate than they left the bleb. Therefore, the 
drug dissolution rate becomes the rate-limiting step of the tablet dissolution in the bleb. 
 
Table 5.1. Factors affecting the rate of dissolution(Aulton 1998).      
Factors Explanation of the factors Factors that relate to the 
dissolution of excipient-free 
tablets in the bleb 
Surface area of 
undissolved solid 
(A)  
 Size of solid particles 
 Dispersibility/wettability of powdered 
solid in dissolution medium 
 Porosity of solid particles 
 Size/shape/surface area of 
the tablets 
 Wettability of the drug 
 Porosity of the tablets 
Solubility of solid 
in dissolution 
medium (Cs) 
 Temperature 
 Nature of dissolution medium (e.g. pH) 
 Molecular structure of solute 
 Crystal characteristics (polymorphism 
and solvation) of solid 
 Presence of other compounds 
 Temperature of the bleb 
 The composition of 
aqueous humor/dissolution 
media 
 Molecular structure of the 
drug 
 Crystalline of the drug 
Concentration of 
solute in solution 
at time (c) 
 Volume of dissolution medium 
 Any process that removes dissolved 
solute from the dissolution medium 
 Volume of the bleb 
 The flow rate of aqueous 
humor 
Dissolution rate 
constant (k) 
 Thickness of boundary layer (affected by 
speed of stirring/shaking, size/position 
of stirrer, volume of dissolution medium, 
shape and size of the container, and 
viscosity of dissolution medium) 
 Diffusion coefficient of solute in the 
dissolution medium 
 The shape and size of the 
bleb 
 The viscosity of the 
aqueous humor/dissolution 
media 
5.1.3. The potential of developing of a mathematical model for mimicking tablet 
dissolution 
The establishment of a mathematical model requires experimental data. To develop a 
good mathematical model, the experimental data should be representative for a wide 
range of drugs. Since it is known that drug dissolution rate is the rate-limiting step of 
the tablet dissolution in the bleb, any additional studies on excipient-free tablets should 
be conducted on tablets made from drugs with range of different solubilities. For the 
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potential development of combined treatments in the future, it is preferred that these 
drugs are clinically used anti-inflammatory compounds. Steroids such as 
dexamethasone (DEX, Figure 5.1 A) and triamcinolone (TRI, Figure 5.1 B) are 
commonly used anti inflammatory drugs with a fairly low aqueous solubility (Table 5.2). 
Naproxen (Mw 230.3, Figure 5.2.) is a non-steroidal anti-inflammatory drug (NSAID) 
which is commonly used to control the ocular inflammation response. Since it is 
practically insoluble in water, the eye drops usually contains its salt (sodium naproxen) 
which is more soluble than naproxen. However, the solubility of naproxen is pH 
dependent as it is a weak acid. Its equilibrium solubility in pH 7.4 PBS can be as high as 
6 mg/mL at 37 °C (Amaral, Lobo, & Ferreira 2001). Here we choose naproxen for the 
investigation of excipient-free tablets since its solubility at pH 7.4 is lower than 5-FU 
but higher than ilomastat.  
A     B 
Figure 5.1. Chemical structures of triamcinolone (A) and dexamethasone (B). 
 
 
Figure 5.2. Chemical structure of naproxen. 
  
Table 5.2. Solubility of some anti-proliferative and anti-inflammatory agents. 
Compound  Solubility in 
water 
(mg/mL) 
Solubility at 
pH 7.4 
(mg/mL) 
References 
5-FU 11.1 > 15.4  (Monnot et al. 1990;Singh, Singh, & Singh 
2005;Yalkowsky & He 2003) 
NAP 0.0263 2.92 (25 °C) 
6 (37 °C) 
(Amaral, Lobo, & Ferreira 2001;Mora & 
Martinez 2006;Yalkowsky & He 2003) 
Ilomastat 0.0389 0.223 (at 37 °C) (Millipore 2010) 
TRI 0.08 NA (Yalkowsky & He 2003) 
DEX 0.116 0.14  (Yalkowsky & He 2003) 
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After recruiting the potential drug candidates, we then considered the factors that affect 
tablet dissolution (listed in the last column of Table 5.1) before establishing the 
mathematical model. Some of these factors are almost constant, such as the bleb 
temperature and the composition/viscosity of aqueous humor. Others such as the 
aqueous flow rate, the shape and size of the bleb, are difficult to predict as they vary 
with individual patients. Although it is understood that some of these factors may vary, 
there is still a need to determine the therapeutic dose of the drug for further in vivo 
studies. This can be accomplished by in vitro experiments. Using our flow chamber 
model, most of the factors mentioned above (temperature, the nature of the dissolution 
media, the amount of the drug and the surface area/shape of the tablet) can be manually 
set up. Hence, it is hoped that the in vitro studies using the flow chamber can help us to 
find some general patterns of the tablet release profiles in non-sink conditions for the 
future development of the mathematical model.  
5.2. Materials and methods 
5.2.1. Materials and instrumentation 
Naproxen (NAP), triamcinolone (TRI), dexamethasone (DEX), trifluoroacetic acid 
(TFA), were purchased from Sigma-Aldrich (UK). The Discovery® HS C18 HPLC 
column (15 cm×4.6 mm, 5 μm) was purchased from Sigma-Aldrich (UK). The  
Synergi Hydro-RP 80A column (150×3 mm, 4μm) was purchased from Phenomenex 
(UK).  
5.2.2. Preparation of the tablets 
The NAP, TRI and DEX tablets were made by direct compression according to the 
method described in 2.2.4.3 using a pressure of 14 bars. The diameter of the tablets was 
3 mm. The weight of the excipient-free tablets was around 5.1 ± 0.4 mg (n=42). Their 
thickness was around 0.55 ± 0.06 mm (n=42). 
5.2.3. Evaluation of the release profiles of the tablets 
The dissolution profile of the tablets was evaluated using the method described in 2.2.5. 
The flow rate of PBS solution was set to 2 µL/min, which is the average flow rate of the 
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human aqueous humor.  
5.2.4. HPLC methods for the release of the tablets 
The HPLC methods were developed with the guide and discussion with Dr. Hardyal 
Gill at London School of Pharmacy. HPLC analysis was performed on an Agilent 
Technology 1200 series system consisting of a separation module for solvent and 
sample delivery, a UV detector and chemstation software for data acquisition and 
analysis. The UV wavelength was set to 254 nm, which is a universal wave length for 
aromatic rings. This wave length was chosen because in the future we might need to 
evaluate more than one compound simultaneously. To obtain the best retention and 
separation, a few HPLC columns, including C8, C18, and Synergi Hydro-RP 80A were 
tested. The best columns and mobile phase for each compounds are shown in Table 5.3. 
Chromatography was performed at 40°C. Samples were eluted at a flow rate of 1.0 
mL/min.  
Table 5.3 HPLC methods for the NAP, DEX, and TRI tablets. 
Compounds Column Mobile phase Retention time (min) 
NAP Synergi Hydro-RP 80A ACN: 0.1% TFA (35:65, v/v) 6.6 
DEX Discovery®HS C18 ACN: 0.1% TFA (35:65, v/v) 6.3 
TRI Discovery®HS C18 ACN: 0.1% TFA (25:75, v/v) 5.6 
5.2.5. DSC measurements of the tablets 
Preparation of the tablets 
The tablets were taken out from the flow chamber after 1 day (NAP) or 6 days (DEX, 
TRI) and rinsed three times with 200 μl de-ionized water. They were then dried in a 
37°C oven over night and crushed gently by motor and pestle before DSC measurement. 
The samples were weighed using METLER TOLERDO balance (XS105, d=0.01 mg).  
DSC measurements 
The DSC samples were all weighed using a METLER TOLEDO XS105 balance (d = 
0.01 mg). DSC measurements of NAP and DEX tablets were made with a Pyris 1 DSC 
(PerkinElmer Ltd.). Samples (2–5 mg) were sealed in non-hermetic aluminium pans and 
heated from 25 to 300 °C at 100 °C min
−1
 with a nitrogen purge gas (flow rate 20 
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mL/min).  
 
DSC measurements of TRI tablets were made with a Q2000 DSC and a RHC DSC (TA 
instruments). Samples (2–5 mg for Q2000 and 0.1 mg for RHC DSC) were sealed in 
non-hermetic aluminium pans and heated from 25 to 300 °C at 100 (Q2000) and 500 °C 
(RHC) min
−1
 with a nitrogen purge gas. In all the DSC experiments, an empty pan was 
used as a reference and the temperature and enthalpy of the instruments was calibrated 
with indium. 
5.3. Results and discussion 
5.3.1. In vitro release profiles of excipient-free NAP, DEX, and TRI tablets 
5.3.1.1. Release profiles of the excipient-free NAP tablets 
The excipient-free NAP tablets were evaluated in different flow chambers (50 and 200 
μl). All the tablets will be dissolved at the body temperature and not at room 
temperature but from a modeling perspective, the effect of temperature needs to be 
factored in. Hence, all the studies were conducted at two different temperatures 
(ambient and body temperature). It was found that NAP was completely released after 
approximately one week in ambient temperature (Figure 5.3). As with the 5-FU tablets, 
the NAP tablet was released faster when placed in the 50 μl flow chamber, compared to 
the 200 μl flow chamber. Six days after starting the evaluation, 84% of NAP was 
released in the 50 μl flow chamber; while 68% of the NAP was released in the 200 μl 
flow chamber. Nearly 100% of NAP was released at 37 °C within 5 days (Figure 5.4.). 
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Figure 5.3 Release profiles of the excipient-free NAP tablets at ambient temperature (n=4, 
error bars indicates standard deviation). □ 50 µL chamber ◇ 200 µL chamber. Data suggest 
that the release rate of NAP as well as the NAP concentration are enhanced with the decreasing 
of the chamber volume.  
   
Figure 5.4. Comparison of NAP release profiles at different temperature in the 200 μl chamber 
(n=4, error bars indicates standard deviation). ◇  Ambient temperature ○37 °C. Data 
suggest that the release rate of NAP as well as the NAP concentration are enhanced with the 
increasing of temperature. 
 
5.3.1.2. Release profiles of excipient-free DEX and TRI tablets 
As with the previous studies, the release studies of DEX and TRI tablets were 
conducted in parallel. In comparison to NAP, the release of DEX and TRI was much 
slower. After 5 days in ambient temperature, approximately 3.5% of DEX was released 
in the 200 μl chamber; whilst in the 50 μl chamber the release rate was double (Figure 
5.5.). In the release study at 37 °C, the DEX release rate raised to 7.5% in the 200 μl 
chamber (Figure 5.6.).  
 
Since DEX and TRI have very similar chemical structures, their release profiles are very 
similar. The release of TRI was slightly faster than DEX as it is more soluble than DEX. 
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In the experiments at ambient temperature (Figure 5.5.), the release rate of TRI in the 
two chambers reached 6.1% and 9.3% respectively on day 5, which is slightly higher 
than that of DEX (3.5% and 5.7%). At 37 °C the accumulate release of TRI in the 200 
μl chamber is approximately 1.6 times higher (12%, Figure 5.8) with respect to that of 
DEX (7.5%, Figure 5.6.).  
 
 
Figure 5.5. Release profiles of DEX excipient-free tablets at ambient temperature (n=4, error 
bars indicates standard deviation). □ 50 µL chamber ◇ 200 µL chamber. Data suggest that 
the release rate of DEX as well as the DEX concentration are enhanced with the decreasing of 
the chamber volume. 
 
Figure 5.6. Comparison of DEX release profiles at different temperature in 200 μl chamber (n=4, 
error bars indicates standard deviation). ◇ Ambient temperature ○37 °C. Data suggest that 
the release rate of DEX as well as the DEX concentration are enhanced with the decreasing of 
the chamber volume. 
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Figure 5.7. Release profiles of TRI excipient-free tablets at ambient temperature (n=4, error 
bars indicates standard deviation). □ 50 µL chamber ◇ 200 µL chamber. Data suggest that 
the release rate of TRI as well as the TRI concentration are enhanced with the decreasing of the 
chamber volume. 
 
     
Figure 5.8. Comparison of TRI release profiles at different temperature in the 200 μl chamber 
(n=4, error bars indicates standard deviation). ◇  Ambient temperature ○37 °C. Data 
suggest that the release rate of TRI as well as the TRI concentration are enhanced with the 
decreasing of the chamber volume. 
5.3.2. Development of the mathematical model to mimic the release profile 
After the evaluation of the excipient-free tablets using the flow chamber, we compared 
all the release profiles to see if there were any regular patterns. As mentioned before, 
saturation of the drug was expected to be observed for the tablets placed in non-sink 
conditions. However, dissolution of NAP, DEX, and TRI tablets again confirmed that 
the dissolution rate was the rate-limiting step in the tablet dissolution since saturation of 
drug in the flow chamber was never observed. It was found that these release profiles 
shared some common points. With no exception, the tablets dissolved faster when in the 
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small chamber (50 μl). This might be because, when the tablet is placed in a small 
chamber, the diffusion of drug from the boundary layer to bulk solution was accelerated 
due to the relatively high refreshment rate of PBS (2 μL/min ÷ 50 μl = 4% /min, 2 
μL/min ÷ 200 μl = 1% /min). The release rate of the tablets and collected drug 
concentrations in the 200 μl chamber were nearly double at 37 °C compared to at 
ambient temperature, but it is unknown how this doubled concentration is 
mathematically related to the change in chamber volume. If we sum up all the 
accumulate release of the tablets, we found that the shape of the curve looks similar to a 
logarithm curve (Figure 5.9.). The accumulate release of ilomastat, DEX, and TRI 
appears to be linear over a 6 day period but this may not reflect the true picture because 
so little drug was released during this period. They may also look similar to a logarithm 
curve if the accumulate release is measured in a sufficient long time. Additionally, the 
drug concentration reached a peak and then decreased following a curve which is 
similar to an exponential curve. Due to the differences among the collected drug 
concentrations, we did not sum up them in one figure. Most importantly the release rate 
of the drugs seems to be directly proportional to drug solubility. While there appeared to 
be dissolution rate anomalies, we still sought a mathematical model that could describe 
the release behavior of the tablets by using the drug solubility. 
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Figure 5.9. Comparison of the release fraction of all the excipient-free tablets in ambient 
temperature. The number 50 and 200 represent the chamber volume (μl). ILO equals to 
ilomastat. Data suggest that the shape of the curve looks similar to a curve of logarithm. 
 
5.3.2.1. Washington’s dialysis model 
When a tablet is placed in the bleb, the drug starts to dissolve in the aqueous humor. 
After a while the drug begins accumulate in the bleb; while simultaneously escaping 
slowly with the turnover of aqueous humor. Hence, during the dissolution process, the 
drug is distributed in three departments: the tablet, the bleb and the blood/lymphatic 
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circulation. As the volume of the blood in the whole body is much larger than the 
volume of the bleb, the whole body blood circulation is considered as a sink condition. 
Therefore, the tablet is placed in non-sink conditions (bleb), which is connected to a 
sink condition (blood circulation). 
 
Before developing the mathematical model, a literature search was conducted on 
mathematical models that describe non-sink conditions. It appears that the mathematical 
determination of drug release profiles in non-sink conditions are less studied than those 
in sink conditions. The models for non-sink conditions with connection of sink 
conditions have not been well developed. A dialysis model (Figure 5.10.) for evaluating 
drug release from colloids described some concepts which are very similar to the bleb 
(Washington 1989). It provided us with a good starting point. Based on this model, 
compartment A and B can be assumed as the tablet and bleb respectively, and 
compartment C represents the whole body blood circulation. However, all Washington‟s 
calculations were based on the assumption that the drug accumulation in compartment B 
was almost zero; but in our case the released drug does accumulate in compartment B 
(which for us is the bleb). Therefore, we wish to explore some ways to extend its use for 
our ocular drug release. 
 
Figure 5.10. Kinetic scheme for non-sink dialysis from Washington (Washington 1989). 
 
Ideally this model should be able to describe the tablet release in vivo, but currently our 
model is being developed based on the in vitro data only because the in vivo 
pharmacokinetics of the tablets have not been well established. It is hoped that, if the 
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correlation of the experimental data and mathematical model can be accomplished in the 
future, this mathematical model can be modified and used to predict the release of a 
tablet in the non-sink condition which is similar to the bleb. When observing the tablet 
release profiles, the drug distribution is similar to a typical two-step consecutive 
chemical reaction A→B→C (Coker & Kayode 2001)(illustrated in Figure 5.11.). 
 
Figure 5.11. Illustration of the mass change of the reactant and product in a first order 
consecutive chemical reaction A→B→C.  
 
Based on the dialysis model and the kinetics of a consecutive 2-step bidirectional 
first-order chemical reaction (Coker & Kayode 2001), we assume that compartment A 
and B represent the tablet and bleb respectively, and compartment C represents the 
whole body blood circulation (Figure 5.12). The tablet dissolution rate, the volume of 
the flow chamber, and the drug elimination rate from the bleb to the body are named as 
k1, Vb, and λ respectively. Since the saturation of the drug solution in the chamber has 
never been observed, it is assumed that the drug will not precipitate in the bleb. In 
addition, as the drug eliminated through the blood/lymphatic capillaries will be diluted 
immediately, after which it is assumed that the excreted drug will not come back to the 
bleb. Therefore, the backward reaction rate k -1 and λ -1 are assumed to be negligible 
(Figure 5.12). 
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Figure 5.12  Illustration of improved dialysis model. Department (A) represents the tablet, the 
dialysis bag (B) represents the bleb, and the sink (C) represents the blood circulation of the 
body.  
 
It is assumed that initially the amount of the drug in the tablet is A0. When the drug is 
distributed in compartment A (tablet), B (bleb), and C (systemic circulation), the total 
amount of drug is then expressed by applying stoichiometric principle to the dissolution 
system (Equation 5.1): 
             5.1  
Where At, Bt, and Ct are time dependent functions of the drug mass of A, B, and C 
respectively. As Equation 5.1 is based on the law of mass conservation, when t = 0 
(before the tablet starts releasing drug), B0 = C0 = 0. 
 
The drug concentration in the bleb is not uniform due to the existence of the aqueous 
flow. Therefore concentrations obtained from the exit of the flow chamber were close to 
but not equal to the real average concentration inside the flow chamber. It is very 
difficult to determine the real drug concentration in the chamber because at least 20-50 
μl liquid need to be taken out from the flow chamber for the HPLC injections. Taking 
this amount of liquid from the chamber frequently can alter the concentration gradient 
and consequently accelerate the tablet release. Hence, we collected liquid from the out 
flow of the chamber. The concentrations that we determined should be lower than the 
average concentration in the flow chamber as the liquid collecting point was far from 
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the dissolution boundary layer. Hence, to simplify the conditions, we assume that drug 
concentration in the bleb compartment is uniform, which means there is no 
concentration gradient in the bleb. We also assume that the drug molecules released 
from the tablet will not be degraded, metabolized or bound by the tissue/proteins in the 
bleb. The increase of drug mass in the compartment C (systemic circulation) is then 
governed by  
 B
dt
dC
  5.2  
Where   
         
  
. In other words, λ represents the refreshment rate of the liquid in 
the bleb (the flow chamber in the in vitro model).  
 
Since the use of excipients can alter the tablet release mechanism, our current 
mathematical model is only based on the excipient-free tablets. As the tablet release 
profiles appear similar to a first order consecutive reaction, we used the simplest first 
order model to describe the dissolution of a tablet (Coker & Kayode 2001): 
 
Ak
dt
dA
1
 
For a standard first order consecutive reaction, the mass accumulation of the drug in 
department B and C at each time point t is calculated as follows (Helfferich 2004): 
    
      
    
             5.3  
           
 
    
    
             5.4  
 
  
    
   
 
    
    
            5.5  
Therefore, the drug accumulate release (%) that we obtained from the experiment can be 
calculated using Equation 5.5. According to Equation 5.5, the accumulate release of the 
drug is independent of the total amount of the drug. To investigate the real local drug 
concentration, we can firstly use Equation 5.3 to calculate the amount of drug released 
in the flow chamber (Bt). The local concentration of the drug is then equal to Bt divided 
by the bleb volume (Vb). In this equation we need the values of A0, k1, and λ. A0 and λ 
are known as the original mass of the drug and the refreshment rate of the aqueous flow 
repectively; but k1 is unknown. By correlating our in vitro experimental data 
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(accumulate release) with the curve generated by computer using Equation 5.5 (Figure 
5.13., Figure 5.14.), the value of k1 can be determined (Table 5.4).  
 
Figure 5.13. Correlation between the experimental data (scattered plots at ambient 
temperature) and the calculated data using Equation 5.5. ILO equals to ilomastat.  
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Figure 5.14. Correlation between the experimental data (scattered plots at 37 °C) and the 
calculated data using Equation 5.4. ILO equals to ilomastat. 
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Table 5.4 The value of k1 determined using the correlation between the experimental results 
and computational curve shown in Figure 5.13. and Figure 5.14. 
Tablet 
k1 in 50 μl chamber  
(Ambient T) 
k1 in 200 μl chamber 
Ambient T 37 °C 
5-FU 3.59E-3 1.42E-3 5.00E-03 
NAP 2.03E-3 1.21E-4 3.50E-04 
Ilomastat NA 1.69E-5 6.50E-05 
TRI 1.00E-5 6.46E-6 1.60E-05 
DEX 9.16E-6 4.89E-6 1.00E-05 
 
Using the values in Table 5.4, the amount of drug released in the flow chamber 
(compartment B) can be calculated using Equation 5.3 (shown in Figure 5.15.). It can be 
seen that the 5-FU tablets had very high peak concentrations (2 or 7 mg/mL) but 
decreased to zero rapidly within 1-2 days (Figure 5.15 A); while the hydrophobic drugs 
(ilomastat, TRI and DEX) were released much slower. From this curve we can see that 
the concentrations of DEX and TRI could be maintained above 0.05 mg/mL for nearly 
100 days (Figure 5.15 B).  
 
Using Equation 5.5 and the k1 values shown in Table 5.4, we can calculate not only the 
drug concentration in the flow chamber but also the long term accumulate release of the 
drug. The calculated drug accumulation release at ambient temperature is shown in 
Figure 5.16. It suggests that the excipient-free NAP tablets will remain in the bleb for 
approximately 15 days; but tablets made from very hydrophobic compounds such as 
DEX or TRI will slowly release the drug for months even more than a year. It is 
unknown whether the prediction of DEX and TRI tablets is true because our in vitro 
experiments were only conducted for about a week. However, it was found that the 
prediction for the ilomastat tablet did not match very well with the experimental data. In 
our in vitro experiments, the ilomastat tablet disappeared in the flow chamber after 
about 45 days at ambient temperature; but the mathematical model suggests that the 
ilomastat tablet will stay in the 200 μl chamber for more than 3 months. This difference 
was also seen on the data at 37 °C. This indicates that the mathematical model may have 
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some limitations. Therefore, this model needs to be further improved.  
 
Figure 5.15. Calculated drug concentrations released for the excipient-free tablets (5 mg) in the 
flow chamber. 1. 5-FU in the 50 μl chamber; 2. 5-FU in 200 μl chamber; 3. NAP in the 50 μl 
chamber; 4. NAP in the 200 μl chamber; 5. ilomastat in the 200 μl chamber; 6. TRI in the 50 μl 
chamber; 7. DEX in the 50 μl chamber; 8. TRI in the 200 μl chamber; 9. DEX in the 200 μl 
chamber. The predicted results from the mathematical model suggest that the drug 
concentrations will be significantly different.  
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Figure 5.16. Calculated long term accumulation of drug release in the 50 and 200 μl chamber at 
ambient temperature using Equation 5.5. ILO equals to ilomastat. The predicted results from 
the mathematical model suggest that the drug release rate at ambient temperature will be 
significantly different. 
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Figure 5.17. Predicted long term accumulation of drug release in the 200 μl chamber at 37 °C 
using Equation 5.5. ILO equals to ilomastat. The predicted results from the mathematical 
model suggest that the drug release rate at 37 °C will be significantly different. 
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 0))...()(( 21  Ak
dt
d
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dt
d
k
dt
d
n
 5.6  
where niki ,,2,1,0   
If we take n=1, Equation 5.3 is then recovered. The general solution of Equation 5.6 can 
be written as 
 
tk
n
tktk neaeaeaA
  ...21 21  5.7  
in which  
 021 ... Aaaa n   5.8  
because 0)0( AA  . From equation 5.1, we have 
 0
dt
dC
dt
dB
dt
dA
 5.9  
Substituting Equation 5.2 into 5.9, we obtain 
 
dt
dA
B
dt
dB
   5.10  
The general solution of this equation can be written as 
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This leads to  
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which can also be written as 
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Substituting equation 5.7 into 5.12, we have 
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We replace a1in the above equation using equation 5.8. This leads to 
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5.14  
 
As mentioned above, λ in Equation 5.14 can be obtained directly from the experimental 
set up. It will be constant once the flow rate and Vb are fixed. The other parameters k1, 
k2, …, kn are all the factors that affect the tablet release rate. At the moment our 
experimental data is not sufficient to define these factors corresponding to k1, k2, …, kn 
one by one. But we can investigate whether the adoption of a higher order model can 
improve the correlation between the experimental data and mathematical model. 
 
As with the first order model, the coefficients a2, a3,…, an and k1, k2,…, kn in Equation 
5.14 were determined using the experimental data. To obtain these coefficients 
accurately, we would prefer the errors between the experimental data and the 
mathematical curve (generated by Equation 5.14 ) to be as small as possible. In other 
words, the experimental data and the computational curve from the mathematical model 
are expected to be as close as possible. This can usually be achieved through the least 
square method, which is applied to calculate the best fit between the modelled data and 
the observed data.  
 
It is assumed that in the experiment the amount of drug collected in compartment C at 
time t = tj is E (tj). We define an error function Er (a2, a3, …, an; k1, k2,… , kn) 
as 
Equation 5.15. 
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From a mathematical point of view, it is likely that the results will be considered more 
accurate when more factors are involved. In a preliminary study, we started evaluating 
the factors using the least square method with only one or two factors (n=1 or 2) 
included. Accordingly, we define that the errors (between experiment and mathematical 
model) as Er1 and Er2 respectively. The values of the coefficients (a1, a2, k1, k2) 
obtained with minimum errors using the best square method are shown inTable 5.8. It 
can be seen that when n=2, the value of Er2 is equal or less than Er1. The difference 
between Er1 and Er2 is shown in the last column ofTable 5.8. The higher the value is, the 
more significant the difference is. All these values are positive, which indicates that the 
accuracy can be improved when more than one coefficient is involved. This 
improvement has also been presented in an intuitional way (Figure 5.19 to Figure 5.23). 
In these figures it can be seen that, the predicted curve is able to stick more closely to 
the experimental data points when n=2 comparing to n=1. 
 
Although the accuracy of the mathematical model was improved when using a higher 
order equation, it is unclear how these parameters can be correlated with the properties 
of the drug or the tablets. We could not figure out any regularity from the parameters 
shown inTable 5.8. Therefore, we aim to look for another way to improve the model.  
 
We changed the unit of the drug solubility and then try to correlate them with the k1 
values obtained from Table 5.4. The values are listed again in Table 5.5. It was found 
that the solubility of the compounds appears linear to k1 (Figure 5.18 and Figure 5.19.). 
This indicates that the solubility of the drug is probably proportional to k1. Based on this 
assumption, we assume        , in which b, c, and s represent the slope, intercept 
(in Figure 5.18 and Figure 5.19.) and the drug solubility respectively. In this case, b 
changes along with λ; whilst c is a constant. Therefore, we developed the model using 
the drug solubility. Based on Equation 5.5, we write: 
 
  
    
   
 
        
                        5.18  
According to our assumption in Figure 5.18 and Figure 5.19., the value of b should be 
0.012 and 0.0303 for the 200 and 50 μl chambers respectively. However, it is unknown 
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whether the model is accurate when using Equation 5.18 with these values. Therefore, 
we used the solver function in excel to find the best correlation between the 
experimental data and mathematical model.  
 
Table 5.5 The relationship between the drug solubility and predicted k1. Data suggest that the 
values of k1 decreases with the decreasing of the drug solubility but increases with the 
decreasing of the chamber volume. 
Compound 
Solubility in the literature 
(mol/L) pH 7.4   
K1 in 50 μl 
chamber 
K1 in 200μl 
chamber 
5-FU > 0.118395783 3.59E-03 1.42E-03 
NAP 
Ambient T 0.01272479 2.03E-03 1.21E-04 
37 °C 0.026146829 NA 3.50E-04 
Ilomastat 
Ambient T NA 
NA 
1.69E-05 
37 °C 0.0005471* 6.50E-05 
TRI > 0.000202819 1.00E-05 6.46E-06 
DEX 0.000356723 9.16E-06 4.89E-06 
 * Determined by Dr. Hala Fadda  
 
Figure 5.18. Correlation between the drug solubility (5-FU, NAP, ilomastat, DEX, TRI) and k1 in 
the 200 μl chamber. Data suggest that the drug solubilities correlate well with k1.  
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Figure 5.19. Correlation between the drug solubility (5-FU, DEX, and TRI) and k1 in the 50 μl 
chamber. Note NAP was excluded to obtain a good correlation. Data suggest that the drug 
solubilities correlate well with k1.  
 
Solver is a mathematical software that solves a mathematical problem. In excel, it finds 
the values of certain cells in a spread sheet which optimize a certain objective. In our 
model, the solver function in excel will find the values of b and c that minimize the 
difference between the experimental data and calculated data. An example of 
calculation is demonstrated in Table 5.6. By running the solver, the best values of b and 
c were found to be 1.12 (200 μl chamber), 0.52 (50 μl chamber), and 0.0009 (Table 5.7). 
The correlation coefficient between the experimental data and predicted data was 
0.9392 (Figure 5.20). 
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Table 5.6 A demonstration of calculating b and c using solver function. 
    Solver calculates the values of b and c which 
make “total sum of difference” minimum. 
        
Type 
of 
tablet 
Experimental 
values  
Calculated 
values 
using 
Equation 
5.18 
Square 
difference 
between the 
experimental 
and calculated 
data 
Total sum 
of 
difference 
λ Solubility 
of the 
drug 
(mol/L) 
b 
(200 
μl)  
b 
(50 
μl) 
c 
5-FU 
200 
a1% a1‟% b1% m 
 
 
 
 
 
0.01 0.0118 ? ? ? 
 a2% a2‟% b2% 0.01 0.0118 
 … … … 0.01 0.0118 
5-FU 
50 
c1% c1‟% d1% 0.04 0.0118 
 c2% c2‟% d2% 0.04 0.0118 
 … … … 0.04 0.0118 
 
Table 5.7 The values of b and c calculated by excel using solver function. 
Chamber volume (μl) Flow rate (μL/min) λ b C 
200 2 0.01 1.12 
0.000898502 
50 2 0.04 0.52 
 
Figure 5.20. The correlation between the experimental and calculated data using Equation 5.18. 
Data suggest that the mathematical model correlates well with the experimental data.  
y = 0.9732x - 0.0057
R² = 0.9392
0%
20%
40%
60%
80%
100%
120%
0% 20% 40% 60% 80% 100% 120%
C
al
cu
la
te
d
 d
at
a
Experiemental data
Chapter V Tablets derived from other compounds and development of a mathematical model to correlate drug release  
187 
 50
 
The above findings suggest that the improved mathematical model is able to describe 
tablet dissolution in a non-sink condition with liquid turnover at a 94% confidence level. 
It is likely that the correlation coefficient (R
2
) can be improved if more experimental 
data are available. Although it is felt that b is correlated with λ, the data we have at the 
moment is not sufficient to define the relationship between b and λ as we have 
conducted experiments with only two different values of λ (0.01 and 0.04). To further 
investigate the accuracy of the mathematical model and to find out the relationship 
between b and λ, more experimental data with different chamber volumes and different 
temperatures is needed. 
 
As mentioned before, the mathematical model is also expected to be able to calculate 
the drug concentration. Since it has been confirmed from part of the ilomastat studies 
(Chapter III) that the drug concentration in the flow chamber is related to the surface 
area of the tablet, more experimental data with different tablet surface area are required 
to evaluate the accuracy of the mathematical model. However, most of our experimental 
data was based on tablets with nearly the same surface area (3 mm in diameter, 
approximately 0.5 mm thickness). Although the dissolution of the ilomastat tablets with 
different surface areas could provide us with some additional information, it is still not 
sufficient to develop a mathematical model because this data was generated from only 
one type of tablet. Therefore, more experimental data generated from different type of 
tablets with different surface areas is required in the future for the further development 
of the mathematical model. 
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5.3.3. Preliminary characterizations of naproxen, dexamethasone, and 
triamcinolone tablets 
We developed a mathematical model to describe the release profiles of the tablets. It 
should be noted that the mathematical model assumes that there is no change in the 
physical properties of the tablet. But the aqueous environment at body temperature may 
lead to changes in the physical properties and consequently cause a change in the tablet 
dissolution rate. Hence, as with the 5-FU and the ilomastat tablets, the physical 
properties of the NAP, DEX, and TRI tablets needs to be investigated. The incubated 
tablets were analyzed using differential scanning calorimetry (DSC).  
 
5.3.3.1. Naproxen tablets 
DSC measurements were performed with NAP powder (before compression) and NAP 
tablets which have been in the flow chamber for 24 hours. The DSC thermogram is 
shown in Figure 5.26. The NAP powder showed a sharp peak with a flat baseline with 
the onset temperature of 157 °C, which is slightly higher than the NAP melting point 
recorded in the Merck Index (152-154 °C). This could be led by the high heating rate 
used in the DSC experiments. The single sharp peak shown in this figure might indicate 
that the NAP powder was in crystal form before compression. However, the initial 
temperature cycling and annealing at 120 °C could have lead to conversion of less 
stable polymorphs back into the most stable polymorph. Therefore, to confirm the 
polymorph of NAP powder, further analysis will be conducted when needed.  
 
In comparison with the NAP powder, the NAP tablet has the same onset of melting 
temperature (157 °C) but a hump was observed on the melting peak. Since NAP is an 
ionizable compound, originally it was thought that this hump could be caused by the salt 
of NAP. However, the melting temperature of NAP salts, such as sodium NAP, is higher 
than 250 °C (Kim & Rousseau 2004). Hence, the hump is not caused by NAP salts. This 
might indicate a polymorphic transition of NAP crystals during the tablet soaking in 
37 °C PBS. But the crystal polymorphism of NAP is not well reported in literature as 
most studies focused on its sodium salt. To interpret whether this hump is caused by the 
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crystal polymorphism of NAP, further investigations are needed when necessary. The 
thermal analysis of the NAP tablets was not further investigated in detail because the 
aim of our research at the moment is focused on looking for the trend of dissolution in 
the non-sink condition mimicked by the flow chamber.  
 
Figure 5.26 DSC curves of NAP (solid line) and the NAP excipient-free tablets after being 
incubated in 37 °C PBS (broken line) in a nitrogen atmosphere, flow rate 20 mL/min, heating 
rate 100℃/min, non-hermetic aluminium pans. This might indicate a polymorphic transition 
of NAP crystals during the tablet incubation. 
 
5.3.3.2. Dexamethasone tablets 
On the DSC thermograph of the DEX samples, the DEX powder has an earlier onset 
temperature (276 °C) than the DEX tablet (283 °C, Figure 5.27). These melting points 
are higher than the DEX melting point that recorded in the Merck Index (268-271 °C) 
probably because of the high heating rate used in the experiments. It also can be seen 
that the melting peak of the tablet appears sharp with a flat base line, whilst a hump was 
observed on the melting peak of the DEX powder. In one of the recent DSC studies of 
pure DEX, a similar thermogram was observed (Rodrigues et al. 2009). However, the 
crystal polymorphism of DEX cannot be determined from the melting peaks shown in 
this figure as DEX melts with decomposition (British Pharmacopoeia). It is unknown 
yet whether there is any polymorphism of DEX since all the studies in the literature 
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were conducted on DEX salts (DEX sodium phosphate or DEX palmitate). In addition, 
the initial temperature cycling and annealing at 120 °C could have lead to conversion of 
less stable polymorphs back into the most stable polymorph. Therefore, our current 
DSC studies cannot yet predict any formation of DEX polymorphism. The thermal 
analysis of the DEX tablets was not further investigated in detail at the moment because 
the current aim of our research is focused on looking for the trend of dissolution in the 
non-sink condition mimicked by the flow chamber. 
 
Figure 5.27 DSC curves of DEX (solid line) and the excipient-free DEX tablets after being 
incubated in 37 °C PBS (broken line) in a nitrogen atmosphere, flow rate 20 mL/min, heating 
rate 100℃/min. This indicates DEX melts with decomposition. 
 
5.3.3.3. Triamcinolone tablets 
The DSC thermograms of the TRI samples are shown in Figure 5.28 and Figure 5.29. It 
can be seen that at the heating rate of 100 °C min
-1
,
 
neither TRI powder nor the TRI 
tablets showed a sharp melting peak. Different heating rates were used, but the peaks 
could not be separated (data not shown). Hence, the TRI tablets were analyzed using 
high performance DSC with a heating rate of 500 °C min
-1
. Figure 5.29 shows a single 
melting peak of TRI powder at 279 °C, and two separate peaks of the TRI tablet at 262, 
293 °C respectively. The onset temperatures of TRI shown in Figure 5.28 (at around 
260 °C) are consistent with the TRI melting point recorded in the Merck Index (269-271 
or 260-262.5 °C). But it also indicates the decomposition of TRI after 260 °C, which 
has been reported in the literature (Dozorova et al. 1987).  
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The polymorphism of TRI cannot be interpreted from these experiments. But it has been 
studied before (Suitchmezian, Jess, & Nather 2007). Suitchmezian et al has found that 
triamcinolone can have two solvent free forms and a pseudopolymorphic form from 
monohydrate. In their studies, the monohydrate TRI demonstrated endothermic events 
at peak temperatures of 101, 248 and 266 °C when using a heating rate of 3 °C min-1. 
As the initial temperature cycling and annealing at 120 °C could have possibly led to the 
lost of water in the monohydrate or the transformation of any other unstable polymorphs, 
our DSC results cannot prove the existence of monohydrate. Again further interpretation 
of the polymorph in the tablets was not conducted because we aim to look for the 
dissolution trends of the tablets in non-sink conditions using the flow chamber.  
 
Figure 5.28. DSC curves of the TRI (solid line) and TRI excipient-free tablets after being 
incubated in 37 °C PBS (broken line) in a nitrogen atmosphere , flow rate 20 mL/min, heating 
rate 100℃/min. This indicates that TRI melts with degradation. 
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Figure 5.29 DSC curves of the TRI (solid line) and TRI excipient-free tablets (broken line) in a 
nitrogen atmosphere, flow rate 25 mL/min, heating rate 500℃/min. This indicates that TRI 
melts with degradation. 
 
The investigation of the physical properties of the tablets was not done in depth since 
our current studies are mainly focused on investigating the general pattern of tablet 
dissolution. But our DSC studies cannot yet interpret any change of crystal forms of the 
drugs after the tablets are exposed to aqueous environment at different temperatures. It 
is understood that DSC analysis alone is not sufficient for investigating their physical 
properties. Further investigations using more techniques, such as X-ray crystallography, 
need to be conducted when necessary because 1) compounds from different suppliers 
can have different physical properties and 2) the change in physical properties could 
alter the tablet release profile. For tablets made from very hydrophobic compounds such 
as DEX or TRI, their physical properties need to be studied at more than one time point 
during the whole dissolution test.  
 
5.4. Conclusions 
Our dissolution studies using the flow chamber suggest that the dissolution of an 
excipient-free tablet is related to the solubility of the drug in the dissolution medium, 
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the flow rate of the aqueous media, and the volume/temperature of the flow chamber. 
When all these parameters are known, the tablet dissolution could be predicted using a 
mathematical model. The accuracy of the mathematical model needs to be improved in 
the future with more experimental data.  
 
The mathematical model does not include the change of the physical properties of the 
tablet. Our preliminary characterizations of the tablets using DSC suggest the possible 
transformation of the different crystal forms during the tablet dissolution process. 
Further investigations are needed to confirm these findings. If the transformation of the 
crystal forms significantly affects the tablet dissolution profiles, it needs to be included 
in the development of the mathematical model. 
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6. Chapter VI Conclusions and future 
perspectives 
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6.1. Fabricating the tablets and understanding drug release in vitro 
We successfully fabricated some implantable ocular tissue tablets with a 3 mm diameter 
to modulate the wound healing process after GFS. These tablets were made from some 
anti-proliferative and anti-inflammatory compounds including 5-FU, ilomastat, 
naproxen, dexamethasone, and triamcinolone. To ensure the reproducibility of tablet 
fabrication process, we have successfully designed a punch and die set for tablet 
compression. However, fabrication of these tablets is associated with the 
compressibility of the drug and/or excipients. A 3 mm diameter tablet may not be the 
most appropriated size and shape for all the compounds. The size and shape of the tablet 
could be changed accordingly to adjust the need of drug delivery in the future. For 
example, an injectable mini rod might be preferred in dose top up post surgery. It can 
also be injected into the vitreous body for treatment of the diseases at the back of the 
eye. In addition to the shape and size, controlled release of the hydrophilic drugs might 
be achieved by coating the tablet in the future. 
 
To understand the dissolution profiles of these tablets in the bleb, an in vitro model with 
a flow chamber which mimics non-sink condition in the bleb with small volume and 
constant aqueous flow has been developed. This model is more similar to the bleb and is 
able to predict the release of the drug more accurately compared to the ones reported in 
literature. Using the flow chambers, the 5-FU tablets were found to be dissolved 
completely within 10 hours; whilst the dissolution process of the other tablets was found 
to last for weeks or months. It was also found that 1) the solubility is not the sole 
measurement of the tablet dissolution in non-sink conditions and 2) the tablet release 
rate appears proportional to the solubility of the drug. Drug releasing from the 
excipient-free tablets were found dependent on many factors including the 
physical/chemical properties of the drug, surface area of the tablet, the volume of the 
bleb, the temperature, composition and flow rate of the aqueous medium. To obtain 
more precise and accurate results from the in vitro model, some issues need to be 
addressed in the future work: 1) a sponge or membrane need to be placed in the flow 
chamber to prevent small drug particles being flushed out of the chamber before they 
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dissolve, and 2) a better buffer system which is similar to aqueous humor need to be 
developed to replace PBS.  
 
Since the tablets will be exposed to the aqueous humor at body temperature for a certain 
period, the release behavior of the tablets might also be altered due to the possibility of 
capsule formation and physical transformation of the drugs. Since degradations were 
observed at melting point, preliminary characterizations using DSC could not fully 
indicate the transformation of the drug crystal forms after the tablets being exposed to 
the aqueous environment. This needs to be confirmed in the future studies.  
 
6.2. Potential in vivo application of the tissue tablets 
The 5-FU tablets have shown the potential of long term inhibition of fibroblasts 
proliferation. Their long term inhibitory effect on collagen contraction is currently being 
examined by our group. The ilomastat tablets have shown remarkable efficacy of scar 
inhibition in a clinical validated rabbit model. The bleb survival curve was found to be 
significantly superior to the negative (sterile water) control group and the positive 
control group (MMC) with 100% bleb survival 30 days after the surgery. It was also 
found that ilomastat significantly reduced intraocular pressure compared to the negative 
and positive control groups. In addition, ilomastat in the aqueous humor and blood 
serum could not be detected using a HPLC method with a sensitivity of 5 μM. However, 
the accumulation of ilomastat in the ocular tissues is unclear. We therefore developed a 
simple method of ocular tissue digestion that does not interfere with ilomastat detection. 
Using this method, the ilomastat accumulated in the ocular tissue can be detected by 
HPLC with a sensitivity of 100 nM. In the future the sensitivity of the HPLC method 
can be further increased by HPLC-MS. It is hoped that the tissue accumulation of 
ilomastat in the eye will be evaluated accurately using HPLC.  
 
In addition, thermal and surface analyses of the ilomastat tablets were conducted. Data 
suggest the possible existence of different ilomastat crystal forms, but this finding did 
not seem to affect the release of ilomastat in our in vitro model. The analysis results 
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from AFM and nanoLTA indicate that incubation of the tablets led to changes (stiffness, 
adhesion, and thermal conductivity) in the tablet surface. The surface analysis by XPS 
and Tof-SIMS suggests that, even in the presence of constant aqueous flow, deposition 
of salts and proteins on the tablet surface can be observed. These findings may 
contribute to the possible encapsulation of the ocular tissue tablets.  
 
6.3. Mimicking tablet dissolution using molecular dynamics 
Using the flow chamber is not the only way of examining the tablet dissolution in 
non-sink conditions. We have explored a new way to examine the behavior of 
excipient-free tissue tablets in non-sink conditions using molecular dynamics 
simulations. The fabrication and dissolution of 5-FU and ilomastat tablets were 
simulated using molecular dynamics simulation. Both 5-FU and ilomastat tablets were 
found to dissolve faster when the temperature was increased; the release rate of 5-FU 
was found to be much faster than that of ilomastat. These results agree with our 
experimental observations in the laboratory. From these studies we found that 1) 
solubility is not the sole measurement of the dissolution of excipient-free tablet in 
non-sink conditions 2) the dissolution rate is related to the chemical structural features 
of the drug, the temperature and the flow rate of the liquid turnover. In addition to the 
tablet dissolution process, tablet dissolution was also conducted when in contact with a 
simulated biological membrane at 310 K without the liquid turnover. The results 
suggested that, compared with 5-FU, ilomastat molecules are more likely to interact 
with the biological membrane. The dissolution rate of the tablet tends to be affected by 
the presence of the biological membrane. 
 
In the future, the other factors that may affect the tablet dissolution rate, including the 
volume and composition of the dissolution media as well as the surface area of the 
tablets, are possibly simulated using molecular dynamics on the computer. The 
simulation results are hoped to correlate with more lab experiments and to give valuable 
indications for future studies. 
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6.4. Simulating and predicting tablet dissolution using a computational 
mathematical model  
Our release profiles of the 5-FU, ilomastat, naproxen, dexamethasone, and 
triamcinolone tablets obtained from the flow chamber suggest that the dissolution of an 
excipient-free tablet is related to the solubility of the drug in the dissolution medium, 
the flow rate of the aqueous media, and the volume/temperature of the flow chamber. 
Based on these dissolution profiles, a computational mathematical model was developed 
to mimic the excipient-free tablet dissolution in non-sink conditions using the solubility 
of the drug in the dissolution media (with 94% confidence). The accuracy of the 
mathematical model needs to be improved in the future with more experimental data. It 
is hoped that the tablet dissolution in vivo can be predicted using a mathematical model 
in the future. To accomplish that, the in vitro and in vivo data need to be correlated. 
Much work on both in vitro and in vivo studies is therefore needed in the future.  
 
The currently developed mathematical model assumes that there is no change of the 
physical properties in the tablets. But our preliminary physical characterizations of the 
tablets suggest the possible transformation of the different crystal forms during the 
tablet dissolution process. It is unknown whether the crystal transformations could alter 
drug release and tablet dissolution rate. This needs to be confirmed in further 
investigations. If the transformation of the crystal forms significantly affects the tablet 
dissolution profiles, the mathematical model needs to be further improved. 
 
In summary, we have fabricated some implantable excipient-free tissue tablets for 
modulation of wound healing after trabeculectomy. The excipient-free ilomastat tablet 
has shown a remarkable effect on wound healing modulation on a clinically validated 
rabbit model. The dissolution of the excipient-free tablets can be simulated using 
molecular dynamics simulations and a computational mathematical model. 
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Appendix I Prolonged release of anti-scarring agents after glaucoma filtration surgery 
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